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Atopic dermatitis (AD) is a common, often persistent skin disease that is characterised 
by severe itching and inflammation of the skin. Although it is most common in children, 
AD in adults is often a serious condition and poses a significant social issue, with a 
number of studies suggesting a significant negative impact of AD on quality of life (QoL) 
and mental health in adults.   This multi-method thesis aimed to explore QoL and mental 
well-being in adults living within the UK. After conducting a systematic review and meta-
analysis of studies investigating QoL in adults, the first empirical study (chapter 4) 
qualitatively explored the daily experiences and perceptions of adults with AD. 
Additionally, in order to measure quality of life and mental health, psychometric 
questionnaires were completed by a large UK sample (chapter 5). Finally, this research 
aimed to measure the temporal relationship between psychological stress and AD 
severity over time in a feasibility study (chapter 6).  The qualitative study found that 
participants with the condition experienced many challenges such as living with the 
visibility of AD, physical and psychological distress, and lack of support from others. The 
quantitative study built on these findings and established that AD patients reported lower 
health-related QoL and higher levels of anxiety compared to healthy adults. Several 
psychological, clinical and demographic variables also significantly predicted QoL in this 
study. Finally, the feasibility study found that psychological stress experienced one week 
significantly predicted disease severity the following week. The opposite was also found 
where AD severity measured one week significantly predicted stress the following week. 
The findings of this thesis will facilitate better understanding of living with the condition 
and enables recommendations for clinical practice which include support from health 
care professionals and increased public awareness of the condition. 
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Chapter 1: Introduction 
This chapter provides a background to atopic dermatitis (AD), its’ symptoms, aetiology, 
prognosis and treatment. The impact of AD on quality of life (QoL) as well as the 
association between AD and mental health determinants with a focus on anxiety, 
depression and psychological stress are then discussed. Gaps in current literature and 
rationale for this thesis are considered, and finally, the outline of the thesis is discussed.  
 1.1. Long-term conditions 
When diagnosed with a long-term condition/illness, an individual can change from being 
healthy to living with long-term illness in a world of health (Radley, 2004). Approximately 
half of the UK population reports having a long-term illness, with the most commonly 
occurring long-term illnesses being hypertension, asthma, and depression (ONS, 2015). 
A long-term condition (LTC) is any medical condition that cannot currently be cured but 
can be managed with the use of medication and/or other therapies (De Ridder, Fournier 
& Bensing, 2004).  
According to George and Martin (2016), approximately thirty percent of the UK 
population with LTCs account for seventy percent of the health spend.  Over fifteen 
million people in England are estimated to have at least one LTC (George & Martin, 
2016) and it is estimated to increase to approximately eighteen million in another five 
years.  Individuals with long-term conditions are frequent users of health care services 
and are estimated to account for 77% of all inpatients, 68% of A&E and hospital 
appointments and 55% of primary care appointments in the UK  (George & Martin, 2014). 
There are different types of LTCS, some may be life-threatening whereas others such 
as atopic dermatitis are not considered to be (Radley, 2004). The terms long-term 
condition and chronic condition have been used interchangeably in literature, however 
the UK Government (DOH, 2015), and the National Health Service (NHS, 2016) in the 
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UK use the terminology, long-term condition. Thus, in this thesis, the term long-term 
conditions will be used throughout. 
1.2 Atopic dermatitis 
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterised by intense 
and unrelenting pruritus (itch), lesions, dry skin and water loss through the skin.  The 
lifetime prevalence of AD is 10-20% in children and 1-3% in adults worldwide (Larsen & 
Hannifin, 2002), with almost 90% of AD patients being diagnosed with the condition 
younger than the age of five (Krakowski, Eichenfield, & Dohil, 2008). Although majority 
of AD patients grow out of it, the disease may persist into adulthood and may even 
present for the first time during adulthood (Novak, Leung, & Bieber, 2003). Indeed, AD 
in adults tends to be more severe and debilitating (Kapoor et al., 2008). There are two 
main forms of AD that have been identified: an ‘extrinsic’ form which is associated to 
Immunoglobin-E (IgE) -mediated sensitisation involving 70-80% of patients, and an 
‘intrinsic’ form of AD without IgE-mediated sensitisation which involves 20-30% of 
patients. IgE is an antibody found in the blood that is a marker for allergic diseases and 
people who have elevated IgE levels can have one or more allergies.  A number of 
clinical studies propose that AD is the cutaneous manifestation of a systemic condition 
that can give rise to allergic rhinitis, food allergy and asthmas, all of which are 
distinguished by high serum IgE levels. This is a phenomenon defined as ‘atopic march’ 
(Spergel & Paller, 2003).  
The concept of ‘atopy’ which originated form the Greek atopic meaning ‘different’ or ‘out 
of place’, was proposed by Coca and Cooke in 1923 (Coca & Cooke, 1923), and referred 
to abnormal levels of sensitiveness, the cause of which was uncertain. The original 
definition did not include AD in its’ definition, it included allergic rhinitis and asthma. Many 
years of research in dermatology have introduced considerable developments to the 
management and understanding of the condition (Ring, 2016). Nonetheless, the cause 
of AD remains somewhat elusive. AD is considered to be a complex association between 
15 
 
the environment, genetics, skin-barrier dysfunction, immunological defects and 
cutaneous infections (Otsuka, Rerknimitr, Seidel, Honda, & Kabashima, 2017). 
1.2.1 Clinical presentation 
There are several major features of the disease that help in its’ identification; a typical 
illustration of the condition is one that is characterised by dry, itchy skin with lesions of a 
typical appearance and distribution (Leung & Bieber, 2003). Pruritus (itch) is present in 
all patients with AD and is exacerbated by numerous factors such as changes in 
humidity, allergen presence and psychological stress (Leung & Bieber, 2003). Although 
it occurs throughout the day, it is often perceived more severe during the night (Leung & 
Bieber, 2003). Scratching the skin over prolonged periods of time results in lichenification 
(thickening) of the skin.  
The distribution of AD is mainly determined by a patient’s age and disease severity 
(Leung & Bieber, 2003). AD symptoms are largely present on exterior surfaces of the 
hands and legs. . The involvement of the face and neck is most prevalent in adult AD, 
also known as head-and-neck dermatitis, (Salvador, Romero-Pérez, & Encabo-Durán, 
2017). Chronic inflammation of the area surrounding the mouth is also common in young 
women (Hello, Aubert, Bernier, Néel, & Barbarot, 2016). Hyperpigmentation of the neck 
is present in severe cases of AD; this is a phenomenon called ‘dirty neck’ as a result of 
its’ unclean appearance.  Skin lesions in AD may be patchy and a large number of 
patients report suffering from complications such as bacterial and viral infections of their 
skin (Cho, Strickland, Boguniewicz, & Leung, 2001). To put in context, more than 80% 
of patients with AD have colonisation with staphylococcus aureus on their skin (Breuer, 






1.2.2 Diagnostic criteria 
The diagnosis of AD is based on the clinical presentation of the disease as opposed to 
laboratory tests. A clinician may look out for essential features of AD e.g. pruritus, and 
genetic factors such as family history of the condition (Leung et al., 2004). However, it 
is challenging to determine a defined set of criteria for a condition that is so variable in 
time, distribution, and morphology (Williams, 2000). Hanifin and Rajka (1980) defined a 
set of minor and major diagnostic criteria based on the most commonly occurring 
symptoms of AD in patients. These diagnostic criteria are highly suited for use in hospital 
settings, but unsuitable for use as a tool in primary care or population-based studies 
(Schultz & Hanifin, 1992). This is because the features in the criteria have been derived 
largely from hospital patients from a white ethnic group, and some of the features are 
relatively poorly defined themselves while some, such as food intolerance are prevalent 
in people with other types of condition. The Hanifin and Rajka criteria serves as a 
foundation for a more streamlined set of criteria defined as the UK Working Party’s 
Diagnostic criteria for Atopic Dermatitis (table 1) (Hanifin & Rajka, 1980). With sensitivity 
of 85% and 96% specificity, it is a reasonably good diagnostic tool for atopic dermatitis 
in both tertiary and primary care settings and is the criteria used in the UK for diagnosing 
AD (Kanwar & Handa, 2006). 
Table 1.1  UK Working Party Criteria for diagnosing AD 
An itchy skin condition plus three or more of the following: 
• Onset below the age of 2 years 
• History of skin crease involvement   
• History of a generally dry skin  
• Personal history of other atopic disease 
• Visual flexural dermatitis   
 
1.2.3 Epidemiology 
The prevalence of AD is estimated to have increased in the past forty years in Europe, 
despite there not being strong evidence to support this (Williams, Stewart, von Mutius, 
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Cookson, & Anderson, 2008).  This is due to the majority of data being comprised of 
patient-reported outcomes using questionnaires, which results in difficulty interpreting 
and comparing due to variations in the methodology used and data collected (e.g. socio-
demographic characteristics). Nonetheless, a number of conclusions can be ascertained 
from published literature. Trends in Europe and globally reflect one another and include 
the notion that AD is more prevalent in overcrowded urban areas and symptoms are 
worsened in cold or temperate climates (Nutten, 2015). Additionally, higher socio-
economic status, family education, family history, being female and a smaller family size 
are associated with development of AD (DaVeiga, 2012). 
With regards to AD in adults, there are little differences between Europe, Japan and 
America for the prevalence of the disease (2.1%-4.1%), although there are different rates 
of prevalence within and between countries. AD diagnosis using the UK Working Party 
criteria ranges from 4.3% (Japan) to 16.7% (Italy) and is higher than the proportion of 
patients who reported being diagnosed by a physician. AD prevalence among older age 
groups is found to be lower than younger ages, with the peak prevalence estimated in 
the 25 to 34 age groups. after the age of 45 (Barbaot et al., 2018). Southern Europe has 
higher proportions of mild AD relative to the UK and Germany, which have lower 
proportions of mild AD using various severity scales (Barbaot et al., 2018).  
1.2.4 Pathogenesis of AD  
Despite the number of people who suffer from AD, the pathogenesis of the condition 
remains unclear. There are two major hypotheses surrounding the pathogenesis of the 
condition: the ‘outside-inside hypothesis’ and the ‘inside-outside hypothesis’. The 
‘outside-inside’ (Elias, Wood, & Feingold, 1999) hypothesis suggests that a skin-barrier 
dysfunction Is the main cause of AD and as a result microbes can penetrate the skin and 
affect the immune system.. The skin inflammation that occurs as a result causes an 
increase in AD severity and compromised barrier function. In contrast, the ‘inside-
outside’ hypothesis (Hatano, Terashi, Arakawa, & Katagiri, 2005) suggests the opposite; 
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the abnormally sensitive immune system responds more than it should to a small amount 
of microbes and the resulting skin inflammation is unable to serve as an effective barrier, 
which as a result allows more microbes to penetrate the skin (Elias & Schmuth, 2009). 
Skin barrier defects were first proposed by Elias, Wood, and Feingold (1999) and Taieb 
(1999). 
The complicated immunopathology of AD comprises various types pathways and 
inflammatory cells (Fiset, Leung, & Hamid, 2006). Interestingly, when compared to other 
skin conditions such as psoriasis, it is only AD which results in  frequent skin infections 
due to the fact that those with AD present down regulation of the genes responsible for 
the immune defence system  (Nomura et al., 2003).  AD onset is also strongly influenced 
by genetic and environmental factors. A number of empirical findings suggest a stronger 
association of AD with maternal atopy compared to paternal (Cookson et al., 1992; 
Diepgen & Blettner,1996; Moffatt & Cookson, 1998). However, conflicting evidence for 
this exists with some studies (Purvis et al., 2005; Wadonda-Kabondo, Sterne, Golding, 
Kennedy, & Archer, 2004) showing no parent-of-origin effect in AD. Generally, compared 
to allergic asthma and rhinitis, parental AD causes a higher transmission risk to offspring 
(Leung & Bieber, 2003). A recently conducted systematic review of population-based 
twin studies of the concordance and heritability of AD reported concordance rates for AD 
ranged from 0.15 to 0.86 for monozygotic and from 0.05 to 0.41 for dizygotic twins, with 
an overall ratio of monozygotic: dizygotic twins of approximately three. The heritability of 
AD is estimated to be approximately 75% (Elmose &Thomson, 2015) suggesting the 
presence of AD specific genes.  
Many however, suggest that the increase in AD coupled with its’ strong association with 
socio-economic status and urbanisation indicates that AD develops as a result of 
environmental factors. The decrease in family size, improved personal hygiene and a 
reduction in infections have resulted in the development of the so-called hygiene 
hypothesis (Strachan, 1989) which helps explain the increased incidence of AD. A large 
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body of literature supports the hypothesis (El-Zein, Parent, Benedetti, & Rousseau, 
2010). Debarry et al. (2007) and Ege et al. (2011) found that children exposed to animals 
in farms during early childhood has lower incidence of atopic conditions  Nevertheless, 
a number of studies have shown that some infections can increase a person’s risk of 
atopic dermatitis (Cramer et al., 2012).  
1.2.5 Management of atopic dermatitis 
An approach that involves many steps or stages is required in the treatment and 
maintenance of AD.. An effective treatment regime should aim to alleviate AD symptoms 
and reduce the frequency of exacerbations and inflammation of the skin. Hoare, Po, and 
Williams (2000) proposed that an effective management strategy for AD should involve 
restoring the skin-barrier function, eliminate factors that trigger symptoms, reduce skin 
inflammation and the use of antibiotics in case of skin infection. A 2011 Scottish 
Intercollegiate Guidelines Network (SIGN) guideline proposes guidelines for the 
management of AD which are similar for children and adults with the condition AD 
(Scottish Intercollegiate Guidelines Network, 2011), although the current NICE 
guidelines only apply to children. In 2014, the American Academy of Dermatology 
proposed approaches for the management of AD in children and adults (Eichenfield et 
al., 2014; Sidbury et al., 2014). The Primary Care Dermatology Society (PCDS) stepwise 
approach updated in July 2016, characterizes updates guidance on managing AD in the 
UK (Table 1.2). According to these guidelines, patients with AD flares should be treated 
with copious amounts of emollients and the short-term use of  steroid to alleviate 







Table 1.2 Summary of the Primary Care Dermatology Society recommendations for the 






Patient education and signposting  
Develop a management plan  






presenting with a 
flare-up 
“Hit hard” for a few days with a 
moderate to potent topical steroid 
once daily until settled 
e.g. Betnovate (betamethasone valerate_ 
or Elocon (mometasone) 
Skin infection- widespread Add a systemic antibiotic i.e. flucloxacillin 
or erythromycin, for one week 
Skin infection- localised Consider Betnovate cream or Fucibet 
(fusidic acid/ betamethasone valerate) 
cream without a systemic antibiotic 
Marked sleep disturbance  Consider a sedating antihistamine 
(hydroxyzine, chlorpheniramine) 
take a skin swab if not settling; 







Emollients (mainstay of therapy)  
Allow 15-20 minutes to dry before 
application of topical steroid  
Moisturisers: use patient preference, 
prescribe generously 
Bath/shower preparations: those with 
antiseptic properties for frequent flares; 
antipruritic such as Balnuem-plus bath oil 
for itchy skin 
Soap substitutes: one of the prescribed 
moisturisers can be used 
Topical steroids  
Use lowest appropriate potency for 
age, site, and severity, and apply 
thinly  
Extra care needed o the face and 
around the yes 
Avoid use on lower legs of alder 
patients and others at risk of leg 
ulcers 
Adult face: mild or moderate potency e.g. 
Eumovate (clobestasone butyrate 0.05%)  
Adult trunk and limbs: potent e.g. 
Betnovate 0.1% or Elocon 
Palms and soles: potent or very potent 
e.g. Dermovate (clobestasol propionate 
0.05%)  
Bandages and dressings can be 
sued to top of emollients or topical 
corticosteroids (but not on wet, 
infected AD)  





Infrequent flare ups (every 4-8 
weeks) 
• Limited prophylaxis with topical steroid 
(Betnovate or Elocon): “weekend 
regimen” 
• Consider topical tacrolimus as steroid 
alternative 




• Check adherence 








Consider topical calcineurin 
inhibitors when: 
• Eczema involves the eyelids and 
periorbital skin 
• Regular topical steroid use on 
the face 
• Pimecrolimus for milder cases 
• Tacrolimus for more severe cases 
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• Regular topical steroids use on 
the lower legs 
(elderly patients) and others at risk 
of leg ulcers 




Scalp eczema • Mild tar-based shampoo 
• Water-based topical steroid scalp 
application 
once or twice daily until settled 
•Remove thick scale before 
applying a topical 
 
• e.g. Betacap (betamethasone valerate) 





Referral Refer in cases of: 
• Diagnostic uncertainty 
• Severe eczema 
• Moderate to severe eczema only 
partially 
responding to steps 1–5 
• Steroid atrophy or concerns 
regarding the 
amount of topical 
steroids/immunomodulators 
being used 




1.3 Atopic dermatitis in adults  
Although AD often starts in infancy and early childhood, it  can progress to adulthood. 
Approximately ten percent of patients diagnosed as children continue to suffer with AD 
in adulthood (Bruin Weller, Rockmann, Knulst, & Bruijnzeel-Koomen, 2013). According 
to research exploring the prevalence of AD, 3-17% of adults self-report having the 
condition (Harrop et al., 2007; Kim et al., 2010; Muto et al., 2003)  The reported 
prevalence of people reporting long-term or lifetime AD  ranges more widely, from 3% to 
40%. Most sufferers of AD have had it through childhood or had a family history of the 
condition (Harrop et al., 2007; Muto et al., 2003).   
AD in adults is often severe and in many cases involves chronic, red, thick, lichenified 
plaques (raised areas on skin), sometimes with isolated pruritic papules (itchy raised 
areas) (Bruin Weller, Rockmann, Knulst, & Bruijnzeel-Komeen, 2013) In adulthood, 
itching is often severe and has effects on patients’ daily lives, sleep and activity (e.g. 
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Kelsay, 2006; Kong, Han, Lee, & Son, 2016; Sherry, Attarian, Zee, & Silverberg, 2016). 
As discussed earlier, different parts of the body are affected in adults compared to 
children; visible areas of the body such as the neck and face are often more affected 
(Zeppa, Bellini, & Lisi, 2011). These often serious symptoms can give rise to infections 
and metabolic disorders and can result in hospitalization. Adult AD has significant social 
implications with approximately 30% of affected adults being unable to keep their jobs 
due to flare-up of the condition (Shum, Lawton, Williams, Docherty, & Jones, 2000).A 
reddened face is one of the most problematic but common symptom of AD in adults can 
gives rise to stigmatisation (Tada, Yasamati, Toi, Akiyama, & Tarata, 1999). 
Hyperpigmentation of the neck is also a frequently occurring symptom unique to adults 
AD. T It has been suggested that children with AD ‘grow out’ of the condition but, by 
young adulthood, 80% of those who have not grown out of it have persistent symptoms 
(Abuabara, Hoffstad, Troxel, Gelfand, & Margolis, 2015).  
Two large (n=833, n=955) studies which followed a cohort for over 24 years, recruited 
patients with AD who were dermatology clinic patients as children. AD was present in 
62% of participants who were admitted to hospital as children and in 40% of those who 
had not., AD symptoms were more prevalent on the hands (Rystedt, 1985) and neck 
(Sandstrom & Fergemann, 2004) These findings suggest that AD in adults may be the 
result of persistent AD through childhood through to adulthood, with a small group of 
patients presenting late-onset of the disease (Garmhausen et al., 2013; Tanei & 
Katsuoka, 2008). The above discussed factors taken together can have a significant 
impact on quality of life in adults 
1.4 Quality of life  
Quality of life (QoL) is a broad multidimensional concept that considers both positive and 
negative subjective evaluations of life (The WHOQoL Group, 1998). The World Health 
Organisation (WHO) defines quality of life as “an individual’s perception of their position 
in life in the context of the culture and value systems in which they live and in relation to 
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their goals, expectations, standards and concerns. It is a broad ranging concept affected 
in a complex way by the person’s physical health, psychological state, level of 
independence, social relationships, and their relationships to salient features of the 
environment” (p.5, WHOQoL Group, 1994). Early QoL measurements in relation to 
health relied on assessments of physical abilities, for example, the ability of a patient to 
walk a certain distance or walk without the need of a walking aid or assistance. However, 
in the last ten years, the concept of health related quality of life has encompassed how 
an individual’s actual situation is different to their expectations.  
Because many life domains are related to health, HRQoL is used to differentiate and 
specify health related issues from the general issues of quality of life. The term HRQoL 
was developed by psychological and sociological researchers primarily to help measure 
the health domains that influence an individual’s physical and mental health status (Cella 
et al., 2005). HRQoL as a concept, therefore, is more appropriate in that it can be 
measured within distinct components which can be interpreted separately (Kolotkin et 
al., 2003). Health-related quality of life is broadly defined as “quality of life relative to 
one’s health or disease status” (Bakas et al., 2012, p.1). It is associated with “optimal 
levels of mental, physical, role, and social functioning, including relationships, and 
perceptions of health, fitness, life satisfaction and well-being including  assessment of 
patients’ level of satisfaction with treatment, outcome, and health status with future 
prospects” (Bowling, 1995, p.6). According to Both, Essink-Bot, Busschbach & Nijsten 
(2007), incorporating HRQoL in AD patient assessments has become significant due to 
the increased prevalence of skin conditions. Whilst there is a large pool of instruments 
and psychometric techniques to measure HRQoL, there is often uncertainty over which 
HRQoL instruments should be used in dermatology. Both QoL and HRQoL concepts 
represent patients’ own satisfaction with life and can be influenced by how they perceive 
the physical, mental, and social effects of long-term conditions such as AD on their daily 
living (Fivenson, 2002). This suggests that QoL and HRQoL are individualised concepts 
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and AD may be considered as an irritation for one patient but may be severely frustrating 
for others (Mozaffari et al., 2007).  
Studies that have examined QoL and HRQoL in patients with AD of different ethnicities 
and religious beliefs have found significant differences in their perceptions about factors 
that make up their overall QoL (Jobanputra & Bachmann, 2008). Assessing QoL and 
HRQoL therefore, using measures that can capture patients’ individualised experiences 
of health becomes a vital and often required part of health outcomes appraisal (Anderson 
& Burckhardt, 2003).  
1.4.1 Measuring QoL in Dermatology 
There are numerous reasons why quality of life should be measured in those with skin 
diseases. In places that have a lack of dermatology services, it is imperative that health 
care professionals emphasise the effect of skin disease on their patients and this effect 
is in place equivalent, or even greater than the effect of some systemic diseases. This 
evidence may be used to inform the development of dermatology services (APPG, 
2009). Clinical trials and research do not typically consider the view of patients with skin 
disease, rather they focus on traditional outcomes such as measuring skin lesions. When 
developing new therapies, QoL measurement in addition to clinical measurements 
provides added perspective, and these is increased interest in such outcome measures. 
Many health care professionals consider QoL of their patients when making critical 
decisions about their care and treatment, for example starting azathioprine in AD 
patients (Hermansen, Helland & Finlay, 2002). Similarly, in places where clinical audit 
activities are required, QoL measures may be used. Some of the components of generic 
health questionnaires may be redundant in assessing quality of life in skin disease. For 
example, in AD, an instrument that does not contain a question about the effect of itching 
may underestimate the impact of the condition on a patient’s life. Many generic 
measures of QoL also do not include many of the salient factors known to be associated 
with skin diseases, which may respond to treatment. Therefore, several questionnaires 
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have been the outcome of the growing interest in QoL e.g. the Dermatology Life Quality 
Index (DLQI) (Finlay & Khan, 1994), Skindex (Chren et al., 1996) and the Dermatitis 
Family Impact (DFI) questionnaire (Lawson, Lewis-Jones, Finlay, Reid, & Owens, 1998).  
1.5 Quality of life and atopic dermatitis in adults 
Health professionals commonly discount atopic dermatitis and tend to perceive it as a 
trivial condition of the skin that resolves itself in time (Noerreslet, Jemec, & Traulsen, 
2009). Those who do comprehend the seriousness and chronic nature of AD are often 
not aware of the implications the disease has, despite patients with AD being impacted 
by the visibility attached to AD and living with the condition itself (Finlay, 2001). 
Furthermore, with an increasing incidence in developing countries, and it being regarded 
as one of the most common long-term conditions in Western countries, AD is a global 
public health concern. Although it is not life-threatening, AD has an impact on patients’ 
QoL due to the disfiguring and irritating characteristics of the condition . Indeed, skin 
diseases were recently found to be the one of the most troublesome non-life threatening 
disease according to a global survey (Hay et al., 2014). This burden includes the 
significant social and economic costs related not only to the direct cost of treatment, but 
also additional indirect costs such as impact on employment and productivity, and the 
substantially reduced HRQoL of patients with AD (Dalgard et al., 2015).  
Emotional impact and symptoms surrounding the condition are regarded to be aspects 
of QoL most affected compared to factors such as social functioning which has less of 
an impact on patients (Holm, Wulf, Stegmann, & Jemec, 2006). Nonetheless, Roosta, 
Black, Peng and Riley (2010) found that more than a quarter of college students 
perceived a significant impact of AD on their social lives. Daily activities have also been 
found to be affected in more than 35% of participants in a community-based survey and 
approximately the same amount of participants were limited in self-care such as wearing 
makeup and shaving (Anderson & Rajagopalan, 2001). Decreased QoL in AD is 
correlated with disease severity and increased itch and sleep disturbances, as reported 
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in numerous studies (Beikert et al., 2014; Chrostowska‐Plak, Reich, & Szepietowski, 
2013; Holm et al., 2006; Misery et al., 2007; Sanchez-Perez, Dauden-Tello, More, & 
Lara, 2013; Wittkowski, Richards, Griffiths, & Main, 2004). Notably however the 
correlation of QoL with objective measures of disease severity such as Scoring Atopic 
Dermatitis (SCORAD) is often not strong (Chrostowka-Plak et al., 2013; Haeck et al., 
2012; Wittkowski et al., 2004). 
AD symptoms that are present on visible areas of the body and genital areas have been 
found to predict impaired QoL in adult patients with AD (Beikert et al., 2014; Holm et al., 
2004; Misery et al., 2007).Thus factors aside from objectively measured AD severity 
appear to impact quality of life. Kiebert et al. (2002) explored quality of life in 107 adult 
AD patients using generic quality of life questionnaire (SF-36) and compared these 
findings to SF-36 scores collected in the past on healthy people. The authors found that 
AD patients had worse mental QoL compared to those with other conditions such as 
type 2 diabetes.  
However, as with other studies mentioned above, recruitment was limited to outpatient 
dermatology clinics, which tends to see more severe patients (Basarab, Munn, & Jones, 
1996). Additionally, the authors did not consider socio-demographic characteristics such 
as gender and age when comparing the QoL scores of the AD group with the general 
population and people with other diseases. The impact of AD on QoL has been found to 
differ by age and gender (Chernyshov, 2012; Holm et al., 2004; Hon, Wong, Leung, 
Chow, & Ng, 2008).  Despite these limitations, AD does appear to be associated with 
quality of life and mental health issues. 
It is not surprising that AD has a great impact on HRQoL in patients partly due to the 
chronic clinical course of the condition. Further, since it has no definitive cure, patients 
with AD not only suffer with the symptoms caused by the disease but also from 
compromised and life-long psychosocial and economic burden (Dalgard et al., 2015; 
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Hay et al., 2014). Since HRQoL encompasses both QoL that is independent of, but 
possibly affected by the disease (Lifschitz, 2015), the burden of the illness, and 
functional impairments in completing daily tasks are common factors impacting HRQoL 
(Lifschitz, 2015). Although these studies demonstrate the extent to which AD impacts 
QoL in adults, they are not without their limitations such as small sample sizes.. This 
thesis will address some of the issues uncovered in the literature such as small sample 
sizes and methodological weaknesses  and inconsistencies in the measurement of QoL 
in adults with AD.  
1.6 Atopic dermatitis and mental health 
Atopic dermatitis is significantly related to mental health determinants such as anxiety, 
depression and psychological stress. This section provides evidence surrounding the 
relationship between AD and these mental health determinants, and gaps in current 
literature. 
1.6.1 Atopic dermatitis and psychological stress  
Complex psycho-neuro-immunological interactions are involved in AD (Arndt, Smith, & 
Tausk, 2008). Stress is found to alter the skin barrier, antimicrobial immunity and t-cell 
immune responses, which in turn gives rise to pruritus and increased skin damage from 
scratching (Arndt, Smith, & Tausk, 2008). Stress-related severity is one of the most 
significant triggers of AD symptoms (Morren et al., 1994). The resulting itch-scratch cycle 
causes high levels of stress and anxiety in patients, decreasing overall QoL (Arck & 
Paus, 2006).  
The central nervous system (CNS) can initiate and/or aggravate atopic inflammation 
through release of pro-inflammatory neuropeptides (Misery, 1997). On the other hand, 
these neuropeptides that are released in the skin when exacerbated impact the CNS, 
disturbing perception and recognition networks of patients with AD (Fitzpatrick, Eisen, 
Wolf, Freedberg, & Austen, 1993), suggestive of a bi-directional relationship between 
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stress and AD. Early clinical observations first proposed the notion that psychology 
stress related to a traumatic life event is associated to the development of  atopic 
dermatitis (Brown, 1972; Greenhill & Finesinger,1942; Wittkower & Russel, 1953). 
Psychological stress and AD severity in these studies were mainly explored using 
questionnaires or interviews with patients and these events included death in the family, 
problems during childhood and parental divorce. Notably however the accuracy of adults’ 
abilities to recall childhood events is questionable and unreliable. Nonetheless, the 
association between AD severity and stress in more recently published literature shows 
that interpersonal and daily stressors are also highly related to AD severity in adults (Oh 
et al., 2010; Arndt, Smith, & Tausk, 2008).  
The only known longitudinal study used daily diaries to assess stress in 40 adults over 
a period of two weeks. The authors found that stress on day X predicted AD severity on 
day X+1 and this prediction was reciprocal. Patients with AD may suffer from generally 
elevated stress levels due  to living with the condition. For example, Buske-Kirschbaum, 
Gierens,  Höllig, and Hellhammer, (2002) found that adults with AD report higher levels 
of distress due to their condition, and the amount of stress is positively related to the 
severity of the condition, medication taken and intensity of priorities. Social skill deficits 
have also been reported by others, whereby adults with AD when engaging in 
discussions with their parents and partners, showed less willingness to discuss their 
condition, showed less self-acceptance and displayed less self-disclosure compared to 
a nonatopic control group. Thus, AD patients appear to have more problematic 
relationships with their families and significant others which could result in increased 
interpersonal stress levels   (Carroll, Balkrishnan, Feldman, Fleischer & Manuel, 2005). 
A cross-sectional study (Benea,  Muresian, Manolache, Robu, & Diaconu, 2001) looking 
at the relationship between stress and severity of AD found that stress alone is not the 
most important trigger factor of AD exacerbation (only 5.83% of patients), but it is a very 
important factor in maintaining the AD (45.42%) and the disease itself could be a stressor 
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for the patient, resulting in a vicious circle (17 of 50 patients who were reviewed by a 
Psychologist reported that the duration of the disease induced stress; 34%). The causal 
relationship between stress and AD is poorly understood due to the lack of longitudinal 
studies, and many existing studies focus on self-reported perceptions of stress, not 
taking in to account objective measures such as salivary cortisol, which is a biological 
indicator of stress. 
Cortisol is secreted from the adrenal cortex in the Hypothalamic-Pituitary-Adrenal( HPA) 
axis, with elevated levels due to both acute and chronic stressors resulting from for 
example,  discrimination, social isolation and feelings of stigmatisation in relation to AD 
(Steptoe, Cropley, Griffith, & Kirschbaum, 2000) and situations giving rise to acute stress 
such as earthquakes (Kodama et al., 1999). Salivary cortisol levels are found to reflect 
psychological stress, thus are reliable and accurate indicators of chronic stress. . 
Mizawa, Yamaguchi, Ueda, Makino, & Shimizu, (2013) compared psychological stress 
in  AD patients to healthy participants through the measurement of cortisol levels in 
saliva. The SCORAD severity measure was also used to assess disease severity in 
adults with AD.  The findings illustrated significantly  higher salivary cortisol levels in AD 
patients compared to healthy participants  (p<0.001). Furthermore, cortisol levels in the 
saliva were also significantly correlated with objective disease severity (r=0.42, p<0.05). 
This leads to speculation that higher AD severity is related to increase in psychological 
stress compared to mild or moderate severity and also suggests that patients with AD 
might be suffering from chronic stress.  
Overall, findings of published literature suggest that AD is a cause of stress in patients 
and symptoms of AD may be exacerbated by stress. Hence, it should be viewed as a 
chronic inflammatory skin condition that has a strong psycho-dermatological component. 
As a result of the cross-sectional design used in the majority of the studies exploring 
stress and AD, a temporal relationship between AD and psychological stress cannot be 
determined. Additionally, most studies exploring stress and AD rely on self-reported 
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assessments of stress levels, which may not relate to physiological changes such as 
cortisol levels, which can result in an exacerbation of AD symptoms. However, it could 
be argued that self-reporting of perceived stress allows for an appropriate measure of 
the actual levels of stress experienced by patients (Nielsen et al., 2005). In an ideal 
world, it would be beneficial to measure stress using both objective measures and self-
report.   
1.6.2 Atopic Dermatitis, anxiety and depression  
Although there is acknowledgement of physical comorbidities such as asthma and food 
allergy alongside AD, there is a lack of appreciation for the psychological impact it may 
have on the patient, in particular anxiety and depression (Park et al., 2016; Radtke, 
Schafer, Glaeske, Jacobi, & Augustin, 2016).  Mental health comorbidities such as 
anxiety and depression are present in a number of skin conditions, however five decades 
ago, AD patients were noted to have a unique psychological profile, high in anxiety and 
depression, which is unlike the case for patients with other cutaneous conditions (Ahmar 
& Kurban, 1976). Adults with AD experience relentless pruritus, the main source of 
morbidity in this condition. Even mild disease negatively affects a patient’s life, and more 
generalised disease can affect a patient to a similar degree as having diabetes (Kiebert 
et al., 2002). Through the studies done so far, a strong association is found between 
dermatological conditions and psychological problems (Shenoi, Prabhu, Nirmal, & 
Petrolwala, 2013). 
The incidence of mental health comorbidities among dermatology patients has been 
found to be approximately between 30% and 40% (Ghosh, Behere, Sharma, & 
Sreejayan, 2013). The presence of a concomitant compromised mental well-being is 
predominantly observed in patients with various dermatological disorders like atopic 
dermatitis, acne, pruritus, urticaria, alopecia, psoriasis or vitiligo (Picardi, Abeni, Melchi, 
Puddu, & Pasquini, 2000) of which AD is the most common skin disease observed in 
general practice. Various mechanisms have been proposed to understand this 
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association, both forming a vicious cycle (Hashizume & Takigawa, 2006). Most frequent 
symptoms reported as a basis for distress are disfigurement and itching causing 
significant insomnia, and sleep deprivation leads to fatigue, mood lability, impaired 
functioning and suicide in a few cases (Gilchrest, 1982; Dieris-Hirche, Gieler, Kupfer, & 
Milch, 2009; Rønnstad et al., 2018). Furthermore, frequent bullying and embarrassment 
due to disfigurement leads to social stigma and social isolation.  Disfigurement caused 
by AD can lower patients’ self-esteem, in turn increasing the propensity to suffer from 
anxiety and depression (Koo & Lebwohl, 2001).  
Studies investigating the relationship between AD and depression or anxiety disorders 
in adults are very limited, and findings are equivocal across studies (e.g. Ginsburg, 
Prytowsky, Kornfeld, & Wollland, 1993; Dieris-Hirche, Gieler, Kupfer, & Milch ,2009; 
Slattery & Essex, 2011). It is not clear if a severity-dependent relationship is present 
between AD and anxiety or depression. A nationwide Danish cohort study found no 
relationship between the likelihood of using antidepressants and mild AD, however 
moderate-severe patients with AD had increased risk of antidepressant and anxiolytic 
medication use (Thyssen et al., 2018). In contrast, a US cross-sectional study found no 
difference between patients with moderate-to-severe AD and depression and anxiety 
compared with patients with mild AD (Whiteley, Emir, Seitzman, & Makinson, 2016), 
however, the AD cohort had a significantly higher prevalence of anxiety and depression 
compared to healthy controls. 
There are very few randomised controlled trials (RCT) exploring the impact of anxiety 
and depression treatment on AD but one methodologically sound study explored anxiety 
after treatment with either an antidepressant or placebo drug.  Thirty-seven adults with 
AD took part in a double-blind clinical trial and were randomised to either receive daily 
anxiolytic/antidepressants or placebos for a month. Significant improvements were 
noted in mood and disease severity in those who received antidepressants/anxiolytics 
but this improvement was not seen in the placebo group (Kawana, Kato, & Omi, 
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2010).Interestingly, significant positive correlated between anxiety and disease severity 
were also noted showing that as anxiety reduced so did reported severity. Adults with 
AD reported an association between emotional distress, itch, and scratching; 81% of 
patients reported that anxiety and stress exacerbated their itch (Wahlgren, 1992). In two 
randomized controlled trials and several case series, the selective serotonin reuptake 
inhibitors (SSRIs) paroxetine, sertraline, and fluoxetine which are antidepressants, 
improved pruritus (itch) which were the result of a number of medical conditions 
(Browning, Combes, & Mayo, 2003; Mayo et al., 2007; Zylicz, Smits, & Krajnik, 1998; 
Zylicz, Krajnik, & Sorge, 2003). Another RCT used treatment for AD as opposed to 
anxiety/depression as above. Trial results from a clinical trial of dupilumab, a medicine 
used in the treatment of AD, found that the number of adults with severe AD who also 
suffered with anxiety or depression showed significantly more improvement in their 
anxiety/depression in the active arm compared to those who received placebos 
(Simpson et al., 2016).  
Kim et al (2015) found a greater relationship with depressive symptoms in adults who 
had moderate or severe AD compared to mild AD, although this difference was not 
significant. The researchers used a sample of 1517 men with dermatologist-diagnosed 
AD for their study. A 2013 survey of 428 US adult patients showed higher rates of 
depressive symptoms in those with moderate or severe disease (40%) compared to mild 
AD (34.6%), although this difference was not statistically significant.  
Based on the above findings, there are contradictory findings surrounding the severity-
dependent relationship between AD and mental health comorbidities (Holm et al., 2016). 
Dieris-Hirche, Gieler, Kupfer, and Milch (2009) found significantly higher levels of 
anxiety, depression and suicidal thoughts in patients with atopic dermatitis, however 
increase in suicide risk and severity of depression were not significantly correlated with 
clinical severity of the condition. A further study found an association between AD 
severity and suicidal ideation, however after adjusting for depression and other factors, 
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this association was non-significant (Dalgard et al., 2015). The finding above supports 
the notion that suicidal ideation occurs as a result of mental health issues and not just 
due to AD (Hawton, Casanas, Haw, & Saunder, 2013). 
it is likely that the combination of anxiety, depression, psychological stress and disease 
severity form  a vicious cycle in patients with AD (Oh et al., 2010) and in severe cases, 
may result in suicidal ideation, attempts and actual suicide. The inconsistencies in the 
findings between AD and psychological variables may be as a result of various study 
methodologies, including varying anxiety/depression scales and limitations in previous 
studies including the use of non-validated symptom questionnaire instead of validated 
measures. Furthermore, not all studies have adjusted for atopic comorbidities and 
demographic characteristics in their analyses, therefore one cannot deduce the lone 
effect of AD in the development of depression and anxiety disorders.  
Unfortunately, there is a lack of psychological support available to patients. A report 
compiled by the officers of the All Party Parliamentary Group on Skin (APPGS) in 2011 
consisting of dermatologists, GPs, and patient groups reported there is a lack of 
appropriate psychological support for patients with AD amongst other skin conditions, 
with AD being trivialised and thought of as a minor skin ailment. A life-long AD patient 
reported how her condition played a part in her decision to stop practising as a 
commercial lawyer; issues such as dress code and frequent absences due to the 
condition or hospital appointments were poorly  appreciated by work colleagues. . 
Dermatologists, nurses, and patients acknowledged the lack of psychologists and other 
professionals specialising in mental health , and only three out of 127 hospitals had a 
dedicated psycho-dermatology service. Health care professionals also emphasised their 
concerns about patients not being referred to psychologists due to referrals falling on 
‘deaf ears’(p. 25). This emphasises the notion of mental health needs being viewed as 
largely separate to that of physical needs, despite the significant impact of these AD and 
other related skin conditions on patients’ quality of life and psychological well-being.  
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1.7 Chapter summary  
The fact that AD is not a fatal condition should not make it less attractive from research 
funding point of view. As discussed above, AD has a significant impact of QoL and is 
associated with anxiety, depression and in some severe cases, suicidal ideation and 
suicide.  It can also have an impact on family members and poses a huge burden to the 
healthcare system. As detailed above, QoL research looking at AD in adults is also 
relatively scarce; most research focuses on children with the condition. Inconsistencies 
in measurements used for QoL and disease severity may result in conflicted findings. 
Moreover, most current research is cross-sectional, has small sample sizes and does 
not differentiate between clinically diagnosed and self-diagnosed AD. There is also lack 
of research on AD in the United Kingdom, despite the UK having one of the highest 
prevalence rates of the condition in adults (5%) (Harrop et al., 2007). The majority of 
previous research on QoL and mental health in AD has been conducted in France, 
Germany, Spain, Sweden and the USA; prevalence rates in these countries are lower 
(2-3%) than the UK (Harrop et al., 2007). All research to date on the impact of AD on 
QoL in adults has been quantitative and much is cross-sectional rather than longitudinal. 
In-depth qualitative research could help explore issues which are not fully addressed in 
quantitative studies and allow a more detailed participant exploration of living with the 
condition. people’s lives. In order to address some of the limitations of the research to 
date, this thesis aims to explore in detail the impact AD has on quality of life and mental 
health of adults through a systematic review of published literature, a qualitative study 
using one-to-one interviews, a quantitative study to investigate QoL and mental health 
in adults with AD using a large sample of people living in the UK and a longitudinal study 
to investigate the causal impact of stress, anxiety and depression on AD. 
1.8 Brief overview of thesis main studies  
This thesis seeks to explore quality of life and mental well-being in adults with atopic 
dermatitis in the UK. Using both qualitative and quantitative methods, it is hoped that this 
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research will inform better health care provision and support for patients with AD, as well 
as a richer information base for health care professionals dealing with these patients.  
Chapter 2: General methodology 
This chapter discusses the researcher’s epistemological stance, methodological 
decisions made throughout the research process and justification for the choice of 
analyses for each study in thesis.  
Chapter 3: systematic review and meta-analysis  
This chapter provides the first systematic review exploring QoL in adults with AD. It 
includes a rigorous narrative synthesis and critical review of studies conducted in the 
area so far as well as methodological and general recommendations. Seven studies 
included in the review are included in a meta-analysis.  
Chapter 4: Qualitative exploration into adults’ experiences of living with AD 
This chapter explores participants’ accounts of living with AD and issues that have been 
uncovered through the systematic review are explored in further detail. Participant 
interviews are analysed using thematic analysis (Braun & Clarke, 2006) and novel issues 
not found in previous literature are uncovered in this chapter.  
Chapter 5: A quantitative exploration on the impact of AD on QoL and mental health in 
adults  
This chapter uses validated questionnaires to compare QoL, anxiety, depression, and 
psychological stress in adults with AD compared to healthy controls. Participants in this 
study include adults with clinically diagnosed AD living in the UK. Data in this study have 
been analysed to explore differences between groups as well as to explore predictors of 
QoL. 




The final empirical chapter makes use of daily diaries and validated questionnaires to 
explore the bidirectional relationship between psychological stress and AD severity. It is 
a 12 week-long feasibility study which required participants to record stressful events 
and flare-ups. Data for this study have been analysed using cross-lagged panel analysis 
and Pearson’s correlations. Implications and recommendations are discussed.  
Chapter 7: General discussion  
This chapter discusses the findings and contributions of each study detailed in the thesis. 
It employs a critical view of how the thesis has contributed to existing knowledge in the 
field of dermatology. It also provides recommendations for clinical practice and finally 
















Chapter 2: Methodology  
This chapter provides justification for methodological decisions and the researcher’s 
epistemological position. Additionally, decisions surrounding study designs, participant 
recruitment, data collection and data analyses are presented.  
Using a range of research methods collectively is referred to as ‘mixed methods’. Mixed 
methods designs have become increasingly popular in the health sciences (O’ Cathain, 
2009). There has been a view that both methods are incompatible with each other 
because they are underpinned by fundamentally different assumptions about reality 
(ontology) and understanding(epistemology). This incompatible paradigm debate exists 
due to the differences in theoretical perspectives of these methods, for example between 
quantitative and qualitative research. For this thesis a multiple-method approach has 
been used as opposed to a mixed-method. Multi-method research involves using more 
than one method of data collection in a study, whereas mixed-methods research 
includes the mixing of both quantitative and qualitative methods or paradigms in one 
study (Ivankova, Creswell, & Plano Clark, 2007). Mixed-methods research may indeed 
be perceived as a type of multi-method research. This thesis uses both quantitative and 
qualitative methods to explore quality of life and mental health in adults with atopic 
dermatitis, with the use of a cross-sectional survey, daily diaries over a period and semi-
structured interviews together.  
2.1 Epistemology  
The philosophical assumptions underpinned by quantitative and qualitative research are 
often perceived as holding opposing paradigms (Todd, Nerlich, McKeown, & Clarke, 
2004).  According to Hall (2013), the use of multiple methods in one study is often 
referred to being incompatible due to the opposing paradigms. Thus it is important for 
researchers to be aware of and discuss what assumptions they make about knowledge 
as it shapes the method of inquiry and overall research process (Creswell & Plano-Clark, 
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2011). The over-simplistic belief is that qualitative research is associated with 
‘interpretive’ or ‘constructivist’ paradigms and quantitative research focusses on 
‘scientific’ or ‘positivist’ paradigms despite significant overlap between these methods. It 
is important to be aware of these differences, although this chapter asserts that these 
differences are overstated and can be overcome. If the differences in aims and 
assumptions between the two approaches are not identified and acknowledged, 
research that incorporates both methods is likely to violate the assumptions of one or 
other of these approaches.  
Quantitative methods propose an objective reality and the notion that absolute 
knowledge can be obtained (Scotland, 2012); these approaches are based on 
positivism. Indeed, from the quantitative perspective, an investigator and the 
phenomena investigated are separate entities.  Thus, a phenomenon can be studied 
with being influenced or influencing it, “inquiry takes place as through a one-way mirror” 
(Guba & Lincoln, 1994, p. 110). Qualitative approaches on the other hand reject the 
notion of a single correct definition of knowledge or reality; these approaches are rooted 
in the interpretivist paradigm (Braun & Clarke, 2013; Mcevoy & Richards, 2006). They 
assume a number of realities and aim to explore in depth how individuals perceive the 
world and experience events (Braun & Clarke, 2013; Willig, 2013).  Thus, interpretive 
researchers argue that attaining ‘objective knowledge’ is not possible (Yardley & Bishop, 
2008) and acknowledge the role they play in knowledge construction and thus practise 
reflectivity.  
Some researchers argue that focussing on certain types of methods is in itself unhelpful. 
According to Hiles (2014), emphasizing on the differences between quantitative and 
qualitative approaches is problematic; placing this importance does not account for the 
importance of impact of the strategy on the research design. Hiles (2014) also argued 
that the terms ‘qualitative’ and ‘quantitative’ methods should be abandoned, and that all 
research makes paradigm assumptions and decisions about research design, data 
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collection, data analysis and critical evaluations. Instead, three logics on inquiry have 
been proposed by Hiles (2014): induction, abduction, and deduction. Induction is a data-
driven approach which aims to use data to generate new theories. Qualitative research 
tends to take an inductive approach. On the other hand, deductive approaches are 
concerned with testing data from theories, and quantitative research tends to be 
deductive. Finally, abduction begins with several observations from which the simplest 
and most likely conclusion is derived. Unlike deductive reasoning, this process results in 
a reasonable conclusion, but it does not positively verify it. According to Hiles (2014) 
abductive reasoning employs ‘mixed measures’ or what is commonly referred to as 
‘mixed methods’ research.  
2.2 Mixed methods research  
Both qualitative and quantitative methods uniquely contribute to research thus 
incorporating them both in research has the ability to explore and reveal different areas 
of a topic under study (Harper &Thompson, 2012). Qualitative approaches may identify 
experiences or concepts that are not easily captured using questionnaires or response 
categories whereas quantitative approaches are able to test pre-existing theories and 
provide comparisons and patterns.  (Creswell & Plano-Clark, 2011). It is however 
imperative for researchers to be aware of the differences in assumptions and aims 
between these two types of approaches, in order to avoid applying inappropriate or 
inaccurate criteria for validity assessments of, for example qualitative research (e.g. use 
of a large sample, objectivity) and as a result proposing irrelevant conclusions (e.g. 
causality between variables). Equally, lack of knowledge surrounding quantitative 
approaches could also result in inaccurate criteria (e.g. small, unrepresentative sample, 
inappropriate statistical tests). Sale, Lohfield, and Brazil (2002) argue that regardless of 
the debate surrounding incompatible paradigms, a mixed approach permits for greater 
insight of complicated issues than if either approach was used alone. Triangulation is 
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another advantage that is proposed to improve the integrity of results (Merterns & Hesse-
Biber, 2012).  
Both qualitative and quantitative approaches study different phenomena thus 
distinguishing between the two is vital (Sale, Lohfeld, & Brazil, 2002). Although the 
‘involvement’ may appear similar across the two approaches, the distinction is between 
the ‘lived experience’ and ‘measure’. Distinction between both methods encourages 
clarity and links the phenomenon to its corresponding paradigm and method. Positioning 
the study as multi-method helps to determine if any approach takes precedence within 
the research and minimises undermining one aspect. Within this thesis, the qualitative 
element is deemed equally as important as the quantitative element although 
quantitative approach encompasses a larger volume of the findings; both approaches 
are awarded equal weighting.    
When using different types of methods, a researcher needs to contemplate and focus 
on differences in paradigms (Harper & Thompson, 2012). For example, in this thesis 
daily diaries and online surveys were used and aligning with positivism, assumes that 
that data collected represents a factual truth which is autonomous from participant 
effects. Additionally the qualitative study in this thesis used semi-structured interviews 
which were analysed thematically; the focus here is on individual experiences and 
perceptions of living with AD and it was assumed these experiences may share common 
themes. The section below details the rationale for study design, sampling, recruitment 
methods, and data analysis for each empirical study in this thesis. 
2.3 Systematic review and meta-analysis 
2.3.1 Study design  
For many years, numerous studies focussing on the psychological and social impacts of 
skin conditions have been published (Al-ahmar & Kurban, 1976; Baughman & Sobel, 
1971;Coles, 1975; Gupta, Gupta, & Ellis, 1987; Ramsay & O'Reagan, 1988; Stankler, 
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1981; Susskind & McGuire, 1959; Wittkower, 1946; Wittkower & Hunt, 1958). 
Nonetheless, only recently have these studies have become increasingly consistent in 
their methodology (de Korte, Mombers, Bos, & Sprangers, 2004).This increase is partly 
due to the recent development and use of QoL questionnaires which allow for 
comparisons across AD patients as well as other patients groups and healthy controls.  
Research into the impact of AD on patients’ QoL is carried out worldwide and specialist 
journals are produced, informing readers about new developments. However, with over 
200 journals in dermatology alone (Delamere & Williams, 2001), it is near impossible for 
anyone to keep informed about this vast quantity of research. Reviews aim to address 
this problem by summarising studies that focus on similar/same questions. Cook, Mulrow 
and Haynes (1997) define a systematic review as a summary current literature that 
makes the use of reproducible methodology to critically evaluate, systematically search 
and effectively synthesize data on a specific area. A systematic review synthesizes 
findings of empirical studies that are related to one another by using bias and error 
reducing strategies (Cook, Mulrow, & Haynes, 1997).The systematic review conducted 
for this thesis included studies that explored QoL in relation to AD in adults.  
In healthcare settings where evidence is evolving frequently, systematic reviews have 
become increasingly valuable. Health care professionals use these reviews to keep 
informed of the evidence in their field and these reviews are frequently used as a starting 
point in developing clinical guidelines in practice (Moher, Liberati, Tetzlaff, & Altman, 
2009). The researcher carried out a systematic review to identify what is currently known, 
where knowledge is lacking, as well as guide future research. By developing a coding 
protocol in which all the categories of data extracted from empirical studies were listed 
and defined, the review revealed various gaps in current QoL literature in relation to AD. 
These will be discussed in detail within the next chapter. This is the first systematic 
review to explore QoL in adults with AD. A meta-analysis of homogenous studies was 
also conducted. The systematic review and meta-analysis within this thesis focuses on 
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quality of life specifically as opposed to quality of life and mental health. This was due to 
a number of reasons such as the presence of existing reviews focusing on mental health 
and atopic dermatitis in adults (Ronnstad et al., 2018) and the intention for a succinct 
and focused review which not have been possible when considering the wide-ranging 
definition of mental health. Mental health, although highly related to quality of life, is a 
factor that affects AD separately, with or without an impact to QoL.   
Systematic reviews provide a wide range of topics within a given subject; may be useful 
in understanding new concepts, but are rarely comprehensive; rarely give details about 
the methods; are likely to be written in line with the opinions of the author; quality 
differences between the studies are rarely considered; and as a result, can be 
misinterpreted and lead to inadvertent bias (Selcuk, 2019). To avoid these issues in 
systematic review writing, the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) group, which mainly consists of Cochrane authors, has 
developed the PRISMA guidelines in 2009 (Moher, Liberati, Tetzlaff, & Altman, 2009). 
The review in this thesis followed the PRISMA guidelines for several reasons.  A 
systematic review will extensively scan published literature on a certain subject and seek 
answers to a succinctly detailed research enquiry, whilst using a variety of inclusion and 
exclusion criteria to identify studies for the review and then synthesize the findings. The 
PRISMA statement which consists of a 27-item checklist and a four phase flow diagram, 
aims to improve the reporting of systematic reviews and meta-analyses. Full compliance 
with the checklist items facilitate clarity and transparency in reporting; thus ensuring a 
well-structed report that well-defines the study question, clearly states its’ title and 
objectives, clearly and justifiably indicates inclusion and exclusion criteria, critically and 
accurately prioritizes the reviewed study reports, and provides a clear analysis of the 





2.4 Qualitative study using semi-structured interviews  
In this section further information on rationale for study design, sampling, recruitment 
methods, and data analysis are discussed for the qualitative study.  
2.4.1 Study design  
The systematic review revealed that QoL in relation to AD was measured using only 
cross-sectional methods, and although the findings illustrated a profound effect of AD in 
QoL, the review highlighted areas that warranted further exploratory research, such as 
sleep disturbances and personal relationships. Thus, this study employed a qualitative 
inductive approach to explore lived experiences of adults with AD using semi-structured 
interviews. 
Interviewing is the most common method of data collection for qualitative research 
(Barriball & While,1994; DiCicco-Bloom & Crabtree, 2006, King, 2004). The purpose of 
a qualitative research interview is to gain an understanding of the interviewee’s 
perspective of the research topic (King, 2004). Several advantages of the semi-
structured approach to collecting data were considered for this study. First, a semi 
structured interview is a useful method for exploratory research topics that are complex 
or where little is known about the research area. Since this is the first study exploring 
adults’ experiences of living with AD, this method of data collection was considered most 
appropriate. Second, semi-structured interviews are considered a useful approach to 
answer questions from the perspective of subjective experience, enabling the individuals 
to be participants in meaning-generation and interpreters of their experiences as 
opposed to sources of information (DiCicco-Bloom & Crabtree, 2006; Saks & Allsop, 
2012). This was considered very useful for the present study as it sought to explore the 
experiences of AD patients. Third, by adopting a semi-structured approach, the 
interviews allow flexibility in collecting data by enabling the interviewer to probe the 
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participant for more information and clarification of answers and pursue emergent 
themes (Barriball & While, 1994, Saks & Allsop, 2012).  
Face-to-face interviewing is thought to be the most effective way of gathering data during 
interviews (Hold, 2010) and is assumed superior than other methods in ensuring high 
quality of data. However Norvick (2008) found that when interviews are conducted via 
telephone, there is little compromise on quality depth of findings. Moreover, Hold(2010) 
identified a number of advantages of conducting interviews via telephone, such as less 
cost of travel, practicality and increased articulation due to lack of non-verbal 
communication. These are benefits that also apply to video-conferencing software such 
as Zoom, with the added advantage of being able to visually communicate with 
participants (Hanna, 2012). In order to effectively manage the research budget and 
practically collect a range of responses, face-to-face, Zoom and telephone interviews 
were deemed feasible to collect data for this study. Participants in the study were offered 
these options prior to arranging interviews.  
2.4.2 Sampling and recruitment methods 
Recruitment of all participants was achieved through purposive sampling. This is a 
extensively used non-probability method which is utilised when aspects are chosen 
through the judgement of the researcher (Patton, 2002). Purposive sampling identifies 
people who have knowledge of or are experienced with a chosen phenomenon of 
interest (Creswell & Plano-Clark, 2011). According to Palinkas et al (2015), using 
purposive sampling for a multi-method study adheres to the similar principles that 
regulate other forms of sampling.  
Within qualitative research, the sample size is often determined when data saturation 
has occurred; this is a notion rooted in grounded theory analysis  (Bowen, 2008). 
Although there is no universally accepted approach for reaching data saturation, it is 
said to transpire when the collection of further data does not create new meaningful 
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information and the study can be replicated (Guest, Bunce, & Johnson, 2006; Morse, 
1995), deeming it ambiguous as there are currently no pragmatic guidelines (Fusch & 
Ness, 2015). As a result, in the vast majority of qualitative studies, the notion of 
saturation is introduced but how it is relevant in the context of the study is often not 
discussed (Bowen, 2008).  
Is beneficial to consider sample sizes with regards to data sufficiency i.e. “are the amount 
if interviews I have conducted enough to answer my research question?” Data 
sufficiency was sought through frequent research supervision and via a reflective diary. 
For example, a quote from the reflexive diary  following  the 16th interview reads: “I am 
satisfied with the interviews so far, and can see similar discussion topics cropping up in 
the interviews”. Further, although discussions during supervisory meetings confirmed a 
range of participants’ experiences and narrative,, there was a large sense of consistency 
between interviews, with the remaining interviews conducted with the confidence that 
data sufficiency had been attained.. Sample for this study falls within the ‘moderate’ 
criteria as recommended by Braun & Clarke (2013)- a small sample size would include 
six to ten participants with moderate samples ranging from 10-20 participants.  
Participants for the study were recruited using various platforms on social media and via 
Aston University using posters and e-mail circulations. One application of social media 
in research settings is the ability to facilitate recruitment in studies. Traditionally, 
snowball sampling is a process of recruiting participants who may be challenging to 
recruit using other means (Faugier & Sargeant, 1997).  In health and clinical research, 
this may comprise those who feel socially isolated, stigmatised or have specific 
demographic characteristics, such as areas where there is cultural diversity or where 
literacy or language barriers may exist (Sadler, Lee, Lim, & Fullerton, 2010). As social 
isolation has been found in adults with AD (Blome, Radtke, Eissing, & Augustin, 2016; 
Chamlin, 2006; Zuberbie et al., 2006), it is essential to apply data collection strategies 
that can be easily accessed, such as online data collection strategies (Lyons, 2015). 
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According to Slamons (2016), such data collection can occur through any means that 
are used as communication devices, for example, computers and mobile devices. The 
use of internet-mediated research methods can enable access to a diverse sample of 
the general population. Indeed Facebook use in the UK is one of the highest penetration 
rate in the EU (O’Dea, 2019). Additionally, this social networking site is used multiple 
times a day by approximately half the UK population and only 20% of UK adults that use 
the internet do not use Facebook (O’Dea, 2019).  
It is also important however to acknowledge a number of challenges with online data 
collection that apply to the studies in this PhD thesis, for example the issue of 
‘representativeness’ (Coulson, 2015, p.14) where  participants who are recruited using 
online methods may not be representative  of the AD population as the internet may not 
be equally available across the population. However this may change as the use of 
internet grows (Hewson, 2003). Hewson (2016) suggests that although ‘in the early days 
of internet mediated research, there were widespread concerns about biases inherent in 
the internet-user population’ (p.71), there is no evidence of bias regarding some groups 
of users (White, upper-class, well-educated males). Additionally, data collection using 
traditional methods such as pen and paper have been found to be consistent with online 
data collection (Gosling, Vazire, Srivastava, and John, 2004) thus the discrepancies 
between the two may be slight. According to Hewson (2003), participants recruited 
online may indeed be more representative than those recruited using traditional 
methods..   
2.4.3 Rationale for method of analysis  
The chosen method of analysis for this study is thematic analysis (TA). This widely used 
method is used to identify, analyse and interpret patterns or themes  in qualitative data 
(Braun & Clarke, 2006). It is a unique form of qualitative analysis as it can be applied  to 
numerous theoretical contexts whereby the researcher embraces a systematic approach  
and undertakes several steps  in order to generate initial codes and develop themes 
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which embody patterns of meaning.  According to Braun and Clarke (2013), TA was 
developed due to its’ flexibility and usability as a technique to recognize themes within 
and across data with regard to participants’ feelings, perspectives, views and 
experiences (Braun & Clarke, 2013).Although its’ flexibility is considered a strength, TA 
has also been criticised for this flexible approach due to lack of transparency and its 
undefined nature(Antaki, Billig, & Potter, 2003).  Willig (2013) states that using TA as a 
tool does not offer a clear theoretical base for research.  In order to overcome these 
limitations, a number of decisions are required by the research and these need to be 
explicit, including approach of data, generation of codes, interpretation of data beyond 
spoken word and the researcher’s epistemological stance. The researcher has identified 
critical realism epistemological stance, thus the two remaining issues will be discussed.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
A deductive or ‘bottom up’ approach is determined by the researcher’s theoretical 
interest and uses a pre-existing theory to understand the data. On the other hand, an 
inductive or ‘top down’ approach is data driven therefore not influenced by the 
researcher’s analytic preconceptions (Willig, 2013).  In order to explore participants’ 
experiences of living with AD, an inductive thematic analysis approach was employed. 
The findings are therefore grounded in participant’s accounts as opposed to pre-
conceptual framework. TA also has the ability to identify different kinds of meaning. 
These include the explicit content of participant discussions, or latent meanings which 
rely on the researcher’s interpretation of participant discussions (Willig, 2013), For this 
study, a latent approach was employed as the researcher was interested in ‘unspoken’ 
information during the interview. Participant quotes were included in the write-up of this 
chapter to enhance credibility of the researcher’s interpretation and demonstrate how 
conclusions were derived.  
It could be argued that Interpretative Phenomenological analysis (IPA) might be a better 
method of analysis to explore experiences of adults with AD. It is a qualitative approach 
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that takes an idiographic focus i.e. it aims to offer insight into how an individual, in a 
certain situation, makes sense of a given phenomenon (Smith & Shinebourne, 
2012).Both IPA and TA analyses involve coding and theme development, however both 
processed differ somewhat for each method. Coding within IPA involves initial notes or 
comments whereby the researcher writes their initial analytic observations about the 
data, whereby coding in TA occurs after data familiarisation where the researcher notes 
initial analytic observations surrounding the entire data set and each data item. This is 
followed by codes across all data items. IPA is recommended when working with a 
smaller sample and maintains a more idiographic focus, and thematic analysis is 
recommended when working with a larger sample with a focus more on patterned 
meaning across the dataset (Braun & Clarke, 2006). There is sometimes the assumption 
that if one is conducting phenomenological research, IPA must be used. Therefore, it is 
important to note that there is a long and diverse history of phenomenological research 
in the social and health sciences (Langdridge, 2007). Thematic analysis has a long 
history as a phenomenological method that predates the development of IPA. As a result 
of its theoretical freedom, TA offers a highly flexible approach which can be modified for 
the requirements of many studies, providing complex, rich and detailed account of data 
(Braun & Clarke, 2006; King, 2004). The usefulness of TA in exploring research 
participants’ perspective, generating unanticipated insights and highlighting differences 
and similarities are amongst the purposes proposed by Braun and Clarke (2006) and 
King (2004). Thematic analysis is also ideal for use in large data sets for summarising 
key features, as in this thesis, due to it forcing the researcher to implement a well-
structured approach to handling data and in turn generate a clear, organised report. 
Additionally, as there were no qualitative studies focusing on adults with AD at the time 
of writing, a large, diverse set of participants best allowed for initial qualitative exploration 




2.4.4 Reflexivity  
Coyle (2016) discusses the importance of reflexivity in qualitative research, defining it as 
an acknowledgement of the researcher’s personal understanding, experiences and 
theoretical commitments have in their analysis. Reflexivity allows the researcher to 
determine their influence on the research process and analysis (Willig, 2013). According 
to her, reflexivity involves ‘reflecting upon the ways in which our own values, 
experiences, interests, beliefs, political commitments, wider aims in life and social 
identities’ have shaped the research process (Willig, 2013, p.10). In order to be reflexive, 
the researcher needs to consider the ways that the ways that they may have/can 
influence the data. The remainder of this section-which will be written in first person- will 
discuss the researcher’s impact of the research process, the data and how personal 
experiences could influence the analytical process (Coyle, 2016).  
. As I was diagnosed with and have suffered from AD since childhood, this experience 
was the most important aspect for reflection. Living with the condition could impact my 
interpretation of the data through consideration of my personal experiences of having 
AD. I was however diagnosed at a very young age and have been able to manage my 
AD through pharmacological interventions and dietary changes; my condition is classed 
moderate to severe. My participants’ experiences, were largely different to my own and 
this allowed interpretation to be grounded in the participants’ experiences, as opposed 
to my own experiences or assumptions. I also had regular meetings with my supervision 
team to discuss the findings of the analysis and kept a reflective diary throughout this 
process in order to further ensure that my analyses were grounded in participants’ 
experiences and perceptions. . 
2.5 Quantitative study using questionnaires  
In this section further information on decisions made regarding study design, sampling, 
and recruitment methods are discussed for the cross-sectional survey study.  
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2.5.1 Study design 
 An online quantitative survey was used with the aim of collecting data from a large 
sample in order to maximise representativeness of adults with AD. The systematic 
review highlighted the paucity of large-scale quantitative studies in the UK, with most 
large-scale studies being conducted outside the country where the prevalence, 
management of AD and health-care system may be very different to the UK (Kowalska-
Olędzka, Czarnecka, & Baran, 2019). 
Survey methods use a systematic method to collect data directly from respondents using 
standardised questionnaires for the purpose of quantitatively analysing a target 
population (Callegaro, Manfreda, & Vehovar, 2015; Shi, 2007).  Surveys can be 
considered a useful approach to explore factors associated with phenomenon of interest 
and test hypotheses (Shi, 2007).  As a research method, surveys, particularly cross-
sectional surveys, are considered the most used method of data collection (Shi, 2007).  
Cross-sectional surveys capture response data from a sample of a target population at 
one point in time (Shi, 2007). Previous research has widely adopted cross-sectional 
survey methodology to explore quality of life in adults with AD (Lee et al., 2018; Misery 
et al., 2007; Misery et al., 2018; Silverberg et al., 2018).  
Online surveys fall within the broader category of survey methods. Whilst retaining the 
same principles of general survey methodology, online surveys can offer several 
additional advantages. In addition to being deemed efficient and cost-effective, online 
surveys reduce the demand placed on study subjects, as they have the flexibility of 
completing the questionnaires in their own time and can opt out without feeling obliged 
to continue (Murdoch et al., 2014). Hewson (2014) also suggests that online surveys can 
yield reliable and valid data, whilst also extending the geographical sampling area and 
maximising chances of recruiting a representative sample.  
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Using online survey panels to recruit participants also helps optimise recruitment of 
healthy people when they are used as a comparison group in health research. For the 
present study, conducting an online survey allowed all adults with AD in the UK take part 
in the survey if they wished to do so whilst giving respondents the flexibility to complete 
the survey at their convenience (Shi, 2007). An additional advantage that online surveys 
can offer is that data entry is not a separate process, therefore errors associated with 
data entry are reduced (Wright, 2005). 
However, disadvantages associated with online surveys were also considered. Self-
selection bias is a major limitation of online survey research (Bethlehem, 2010; 
Eysenbach, & Wyatt, 2002; Thompson, Surface, Martin, & Sanders, 2003). Undoubtedly, 
there would be some individuals  more likely than others to complete the online survey 
and a tendency for some individuals to respond to a study invitation whereas others 
might ignore it, resulting in a systematic bias.  However, for the quantitative study, 
participants were recruited both online and via an outpatients Dermatology clinic.  
2.5.2 Sampling and recruitment methods  
Recruitment of all participants was achieved through opportunity sampling. As this was 
an online survey, anyone who met the inclusion criteria was eligible to take part.  A 
number of recruitment methods were used to achieve this, including recruitment via an 
outpatients Dermatology clinic in Birmingham and recruitment using social media 
platforms such as Facebook and Twitter. The decision to use social media to 
complement the dermatology clinic was based upon findings of the systematic review. 
The majority of the studies in the review had recruited through clinics and typically 
patients referred to tertiary care tend to represent a more severe sub-set of cases and/or 
need hospital facilities that are not available at general practices (Basarab, Munn,  & 
Jones, 1996).  
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Inclusion criteria were adults aged 18 or above with clinically diagnosed atopic 
dermatitis. The exclusion criteria were participants living outside the UK. Within the 
control sample, participants had to be aged 18 and above with no long-term conditions 
as these could affect their QoL ratings and undermine differences between healthy 
groups and AD patients.   Further, adults with AD were excluded if they had any other 
skin condition or diagnosed long-term condition apart from asthma, hay fever or food 
allergy as these conditions are commonly experienced by patients with AD. This was 
due to studies reporting significantly poorer QoL in patients with long-term conditions 
such as arthritis and diabetes (e.g. Malm, 2017; Trikkalinou, Papazafiropoulou, & 
Melidonis, 2017). A long-term condition in this context was defined in accordance to the 
NHS definition “a health problem that requires ongoing management over a period of 
years or decades”. Participants were also required to read and understand English in 
order to complete the questionnaires as these questionnaires were only available in 
English.   
2.5.3 Rationale for method of analysis 
The data for this study were analysed using a range of statistical tests including t-tests, 
ANOVAs, multiple regression and Pearson’s correlation analyses. Multiple regression 
was used in order to assess the contribution of disease severity, mental health variables 
and socio-demographic characteristics towards the variance in quality of life. Multiple 
regression has the ability to control for other variables in the model, therefore allowing 
for the unique prediction of each variable towards the outcome variable. ANOVAs and t-
tests explore differences between variables and were used to assess mean differences 
in QoL and psychological variables between socio-demographic groups and variables 
surrounding the condition (medication, family history, diagnosis). These tests are the 





2.6 Longitudinal diary study 
This section details rationale surrounding study design, sampling, and recruitment 
methods for the longitudinal diary study.  
2.6.1 Study design  
Very few longitudinal studies have been conducted with adults with AD, in fact, there has 
only been one published study exploring AD and stress longitudinally (King & Wilson, 
1991). There are a number of reasons for using a prospective diary approach to explore 
the temporal relationship between psychological stress and AD severity. First, AD 
exacerbations and severity often change rapidly therefore daily reporting of the condition 
will reveals even minimal fluctuations. Furthermore, the research of Kalaki and Mizara 
(2018), Silverberg et al. (2018) and others suggest that psychological stress is related 
to the onset or severity of skin symptoms in AD  Daily diaries detailing levels of 
psychological stress and state of the skin can provide stronger evidence of this 
association. Finally, there are a number of conflicting findings regarding the association 
of skin with emotional distress such as frustration(Patrizi et al., 2011) and anger (Lewis-
Jones, 2006). Weekly and daily measurements  of these emotional reactions in relation 
to the fluctuating course of AD will allow for comparisons and the temporal relationship 
to be examined. 
This study was conducted as a feasibility study due to the novelty of the research and 
thus the researcher needed to explore whether the study would warrant and be 
appropriate for further testing. Feasibility studies enable an assessment of whether the 
findings, methodology, and ideas are ideal and can be sustainable. Feasibility studies 
allow the research to identify what needs to be modified in the research and how these 
changes may occur. The objectives of this type of study differ from those of a definitive 
future study and aims to address the issues of uncertainty in preparation for a large-
scale study to be conducted in the future. Additionally, feasibility and pilot studies are 
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not designed to answer or address a research question; this is instead an objective of 
the future definitive trial (Lancaster, 2015). In 2004, Lancaster, Dodd, & Williamson 
(2004) proposed a number of recommendations for good practice  relative to the design 
of feasibility and pilot studies.The authors published a number of evidence-based 
objectives including testing the integrity of the study protocol for the future trial, gaining 
initial estimates for sample size calculation, testing data collection forms or 
questionnaires, estimating rates of recruitment and consent, determining the 
acceptability of the study and selecting the most appropriate primary outcome measures. 
2.6.2 Sampling and recruitment methods 
For this study, recruitment of all participants was achieved through purposive sampling 
similar to the qualitative study. Participants were recruited using social media platforms 
including Facebook and Twitter. It was anticipated that for a longitudinal study, 
recruitment would be more problematic than for the other studies in this thesis, therefore 
prior to commencement, the researcher put up a poll on Facebook where AD patients 
could ‘vote’ for or against taking part in the three month long study which required daily 
stress diaries being completed for a month. Thirty-six respondents voted ‘for’ taking part 
in the study until the end, and three respondents voted ‘against’ taking part due to 
reasons such as tendency to forget and time-consuming, when completing the daily 
diaries. The suggested adequate sample size for a feasibility study varies greatly, 
however as rule of thumb, it is suggested that for single-group, the sample size for a 
feasibility study should be between 15 and 20 for a small to medium effect size (Julious, 
2005; Teare et al., 2014).  
2.6.3 Rationale for method of analysis  
This study aimed to explore the temporal relationship between psychological stress and 
AD severity. In order to achieve this, the study employed a cross-lagged panel analysis. 
This is an analysis used to explore and describe reciprocal relationships and directional 
influences between a number variables over a certain amount of time. Cross-lagged 
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panel models (CLPM) are also referred to as cross-lagged regression models and cross-
lagged path models- this thesis will refer to them as cross-lagged panel models. CLPM 
are estimated using longitudinal data where each participant or observation is recorded 
at multiple points in time (Byrne, 2013).  The term ‘crossed’ in CLPM is due to the fact 
that they estimate relationships from one variable to another, and vice-versa. They are 
‘lagged’ as they estimate relationships between variables at different time points. Put 
together, these models are able to estimate the directional influence variables have on 
each other over time (Byrne, 2013). This analysis was used in order to investigate 
whether psychological stress on day X would predict disease severity on day X + 1, and 
vice-versa. In CLPM, stability of the constructs is controlled for through the inclusion of 
autoregressive relationships, therefore often it is  thought that the cross-lagged 
regression parameters acquired in the model are the most suitable measures for 
examining causality in longitudinal correlational data (e.g., Deary, Allerhand, & Der, 
2009; Soenens, Luyckx, Vansteekiste, Duriez, & Goossens, 2008; Wood, Maltby, Gillett, 
Linley, & Joseph, 2008). Specifically, it is common practice to standardize the cross-
lagged regression coefficients and compare their relative strength to determine which 
variable has a stronger causal influence on the other (Bentler & Speckart, 1981). The 
analysis was carried out using IBM SPSS AMOS 25 and M Plus software. In addition to 
CLPM, correlations were sought between mental health variables and disease severity 









Chapter three: Quality of life in adults with atopic dermatitis: systematic review 
and meta-analysis 
This chapter presents a systematic review and meta-analysis of studies exploring QoL 
in adults with AD. This chapter was written as a journal article and accepted for 
publication in The International Journal of Dermatology in November 2019 (see appendix 
1 for the published paper). A review of the literature identified that no systematic reviews 
had been conducted on the impact of AD on quality of life in adults. This chapter 
therefore presents the first systematic review to explore this research question.   
3.1 Introduction  
Although there have been no previous systematic reviews investigating the impact of AD 
on HRQoL in adults, a literature review carried out by Lifshitz (2015) on the impact of AD 
on QoL focussing primarily on infants, children, and their families confirmed that AD has 
a significant and lasting effect on HRQoL, in particular on psychological wellbeing and 
social functioning. Patient-assessed severity of AD correlated with HRQoL decrements 
demonstrating a greater impact on HRQoL as disease severity increased. Additionally, 
a literature review carried out by Lewis-Jones (2006) on QoL and childhood AD 
confirmed that QoL in children was severely impaired with issues such as 
embarrassment and bullying affecting children psycho-socially and physically.  
The impairments of QoL caused by childhood AD have also been shown to be greater 
than other common childhood diseases such as asthma and diabetes, emphasising the 
importance of AD as a chronic disease (Lifshitz, 2015). If QoL in children with AD is 
affected to this extent, it is probable that it will have an impact on QoL as children 
progress to adolescents and adulthood, given the severity and persistent nature of AD 
in adults (Hoare, Po, & Williams, 2000). 
Research conducted on adults with AD suggests that all aspects of HRQoL are affected, 
and that HRQoL is more compromised in adults with AD when compared to adults with 
chronic urticaria and psoriasis (Grob, Revuz, Ortonne, Auquier, & Lorette, 2005).  Little 
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is known about how HRQoL of AD patients varies with disease severity; the literature 
that has investigated this issue has found that greater disease severity is related to 
poorer HRQoL (e.g. Fivenson, 2001; Haeck et al., 2012; Silverberg, 2018). To draw 
together what is currently known in this area and identify gaps in knowledge, the present 
study reports the results of the first systematic review and meta-analysis of the impact 
of atopic dermatitis on QoL in adult patients. 
3.1.1 Aims of this review 
This review aimed to synthesise and provide an overview of published empirical 
literature focussing on quality of life in adults with AD. A clearer understanding of the 
extent that quality of life is affected can improve awareness and reduce stigma whilst 
improving outcomes for adults with the condition. In this systematic review and meta-
analysis, relevant studies are discussed and critically appraised. A narrative synthesis 
across the literature is presented alongside a meta-analysis of seven studies. 
Recommendations for future research have also been considered. 
3.2 Methods  
3.2.1 Developing the search strategy  
Databased searched initially included the Cochrane Database of Systematic Reviews 
library and Prospero in order to identify any previously published and ongoing reviews 
exploring quality of life in adults with AD; no such reviews were identified. The researcher 
conducted initial scoping searches for relevant titles within, Scopus, MEDLINE and Web 
of Science Core Collection. Databases were searched up to 1st April 2020 with no limit 
to the start date. Databases were searched using the following terms: Atopic Dermatitis, 
Atopic Eczema, eczema, AD, atopy, quality of life, QoL, HRQoL, well-being, health 
status, and their spelling variations. The terms "Atopic Dermatitis" and "quality of life" 
were searched as keywords, and also searched as a Medical Subject Heading to help 




3.2.2 Inclusion/exclusion strategy and data extraction  
To be included in this review studies had to report data from adults. The legal age of 
adulthood differs according to country. Study search was limited to English-language 
articles on human populations. Case-reports and conference abstracts were excluded. 
All study types and designs were included if they reported on a QoL measure.  When 
devising a search strategy, the PICOS framework was used (Richardson, Wilson, 
Nishikawa, & Hayward, 1995).  The PICO tool focuses on the Population, Intervention, 
Comparison and Outcomes of a (usually quantitative) article. 
Table 3.1 PICOS Criteria 
 Inclusion  Exclusion 
Participants Adults with Atopic 
Dermatitis 
Infants and children 
Adults with non-atopic dermatitis  
Interventions - Comparison of surgical treatment, pain 
control, palliative medication, or 
psychological/homeopathic intervention as 
opposed to the direct impact of AD on QoL 
regardless of medical interventions. 
Comparators Studies with and without a 
comparison group will be 
included 
 
Outcomes  Primary outcome:  
Measurement of quality of 
life 




Any study design 
Any country 
Papers written in English 
Language 
No study design will be excluded 
Papers not written in English language 
 
3.2.3 Population  
This review included participants aged 18 and above or 16 and above if defined as an 
adult in a study. Studies that combined adult and children data into one analysis were 
excluded. Studies that collected data from both adults and children, but reported data 
separately for these sub-groups, were retained in the review. 
3.2.4 Interventions 






Studies measuring QoL on its’ own, in relation to disease severity, compared to healthy 
controls or compared to patients with other conditions were included in the review.  
3.2.6 Outcomes 
The primary outcome in this review was QoL in adult patients with AD.  
3.2.7 Study design  
The scoping reviews revealed a range of research designs therefore studies of mixed-
method, quantitative and qualitative research designs were considered for inclusion in 
the review. There was no exclusion based on study quality in this review and quality 
appraisal was carried out. 
 3.2.8 Language 
Due to a lack of resources to translate papers written in any language apart from English, 
if non-English papers were identified through study search, they were excluded from the 
review with language listed as the reason for this.  
3.2.9 Study selection 
The titles and abstracts of papers retrieved were screened by the researcher for 
potentially eligible studies based on inclusion and exclusion criteria. The researcher, in 
an attempt to avoid missing any potentially relevant articles, was inclusive at this initial 
stage of study searches. Any articles that the researcher was unsure about were 
discussed with the supervisory team to reach an agreement about the suitability of the 
study. Following this, full texts were retrieved and screened for inclusion/exclusion 
criteria by the researcher. Although the Cochrane Handbook for Systematic reviews 
recommends a second reviewer assessing these studies independently, this was not 
possible due to resource and time constraint. Instead, if there was any uncertainty 
regarding eligibility of papers for inclusion, the researcher reviewed these papers with 





3.2.10 Quality Appraisal  
The quality of the included studies was assessed using the Mixed Methods Assessment 
Tool (MMAT) (Pluye et al., 2011). The MMAT (appendix 2) is a quality appraisal tool for 
quantitative, qualitative and mixed methods studies included in systematic reviews. For 
quantitative studies, it addresses methodological issues such as selection bias in 
recruitment, validity and appropriateness of measures used in a study, whether the most 
important factors are considered in analyses, and acceptable response rates. For each 
study, an overall quality score can be calculated; this can be the number of criteria met 
divided by four (scores varying from 0% no criterion met- to 100% -all four criteria met. 
All members of the supervisory team reviewed and agreed on the quality ratings for each 
paper included in the review.  
3.2.11 Data synthesis   
Where studies reported QoL scores using the same instruments, results were pooled 
using meta-analysis. In cases where pooling was not considered appropriate, narrative 
synthesis was carried out. This is an approach which makes the use of text and words 
to summarise and decipher results of multiple studies (Pope, Mays & Popay, 2006). 
According to Popay et al (2006), narrative synthesis is suitable for use in reviews which 
include a range of evidence sources.  
3.3 Results 
3.3.1 Literature search 
Figure 3.1 outlines the search strategy following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) standards (Liberati et al., 2009).  A 
total of 35 papers met inclusion criteria and were included in this systematic review. No 
mixed methods or qualitative papers included a measure of QoL, therefore all included 
papers in this review are quantitative and reviewed using narrative synthesis. Seven 
papers reported a correlation between the Dermatology Life Quality Index (DLQI) and a 
validated measure of AD severity (SCORAD). Correlations from these papers were 
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pooled using random-effects meta-analysis in Comprehensive Meta-Analysis Version 3 
(2005, Biostat Inc.).  
3.3.2 Study characteristics  
Twenty-one studies explored the relationship between disease severity and QoL and 
twenty of these studies used DLQI as the QoL measure. A total of 16 studies compared 
QoL in adults with AD to that of healthy controls using both generic and disease-specific 
QoL measures. Five studies compared QoL in AD patients with other patients groups 
such as vitiligo and psoriasis. Twenty studies used DLQI to measure QoL, twelve studies 
used SF-36 either in addition to a disease-specific QoL measure or on its’ own. Less 
frequently used  QoL scales included the VQ Dermato and the Skindex-16.Twenty  
studies were conducted in Europe of which five included participants from the UK, five 
studies were conducted in the USA, and nine in Asia. Sample sizes for those with AD 
ranged from 32 to 1467 across the studies. All identified studies were quantitative and 
cross-sectional. Thirty studies recruited through dermatology clinics/hospitals, three 
studies recruited through eczema support organisations e.g. National Eczema Society 
and two studies recruited through universities. AD was defined using the Hanifin & 
Rajka(1980) AD diagnostic criteria in eighteen studies, the UK Working Party criteria 
was used in one study, AD criteria set by Adinoff and Clerk (1996) was used in one 
study, and fifteen studies did not specify which criteria dermatologists used to diagnose 










Table 3.2 Study Characteristics  
Authors Country N Participants Measures used  Outcomes 
measured 
Outcomes  










1232  1098 with moderate-to-
severe AD and 134 with 














AD severity and EQ-5D scores in patients with 
moderate-to severe AD showed a negative 
correlation (Spearman’s r = – 0.38; P < 0.001). 
AD severity was positively correlated 
(Spearman’s r = 0.61; P < 0.001) with DLQI 
scores. AD severity and the perception of the 
AD symptoms by the patient (POEM) showed 
a positive correlation (Spearman’s r = 0.51; P < 
0.00) 
       
Authors Country N Participants Measures used  Outcomes 
measured 
Outcomes  





Arima et al 
(2018) 
Japan 638 Mean age- 38.67 years, 
52.37% female. 45.45% 
rated severity as 
moderate/severe, 54.54% 
rated severity as mild. 
Comparisons with 1268 








AD patients reported significantly reduced 
HRQoL relative to matched non-AD controls 
(p<0.001) for mental and physical domains of 
the SF-36.  
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Baron et al 
(2006)  
UK 63 Mean age – 34 years, Mean 
duration of AD- 15.2 years, 
26 men and 37 women  
SCORAD DLQI Relationship 
between 
disease severity 
and QoL  
The mean DLQI reduced over three visits from 
9.5 to 8.8 at T2 to 7 at T3. The DLQI was 
significantly correlated with SCORAD at T1 (r= 
0.389, p <0.01) and at T2 (r=0.321, p < 0.01) 
but not at T3. Mean SCORAD reduced by 52% 
from T1 to T2 (F 2,62 =37.9, <0.001) but there 
was no significant change in SCORAD from T2 
to T3.  
Beikert et al 
(2014) 
Germany 384 384 AD patients (mean age 
42, range- 18-92, 69.8% 














The mean DLQI total score in AD was 8.5, 
compared to 7.0 in Vitiligo and 6.7 in psoriasis 
and 4.3 in rosacea. Impairment of QoL 
measured by DLQI correlated positively with 
the affected body surface area (r=0.46, 
p<0.001). Characteristic AD symptoms such as 
skin dryness, pruritus, and sleep disturbances 
also correlated significantly with the DLQI total 








1467 811 females; 547 with mild 
AD, 520 had moderate AD, 








DLQI score among participants with severe AD 
(16.2 ± 6.9) showed a large effect on quality of 
life that was higher than those with moderate 
(10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 
0.001). 




1132 The participants were 
categorized in to 3 groups: 
- SF-36 QoL 
comparisons 
QoL was significantly lower for patients with 
AD compared to controls in 5 out of 8 domains 
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1) AD (n=90), 2) non-atopic 
hand eczema (n=205), 3) 
control group with no 
aforementioned skin 
conditions (n=837), average 










including social functioning, bodily pain, vitality, 
mental health and general health (ps <0.05). 
No significant difference was found between 
the AD group and the non-atopic eczema 
group in all domains of QoL investigated. 
Chrostowska-
Plak et al 
(2013) 
Poland 89 59 females and 30 males. 
Mean age- 31.6 years.  
Mean disease duration- 
22.8 years.   




There was a significant correlation between 
pruritus and HRQoL (r= 0.5, p < 0.001) DLQI 
also correlated with periods without itching 
indicating that patients with longer itching-free 
periods had better HRQoL (r= 0.23, p<0.05) 
There was a significant correlation between the 
severity of the disease (using SCORAD) and 
HRQOL (r=0.65, p < 0.001) 
Coghi et al 
(2007) 
Brazil 75 Patients were diagnosed 
and treated as isolated AD 
by the attending clinician; 
65.33% were females, 
mean age -26.28 years, 
average years of duration of 







QoL and disease control were found to be 
related but with low scores both in DLQI (r = 
0.26) and in SF-36 (r = 0.2) but with greater 
correlation for SF-36 mental components. Both 
correlations were significant (p < 0.001).  
Eckert et al 
(2017) 
USA 349 Mean age- 46.1 years; 
68.3% women; 66.8% 
White. Matched with 698 













AD patients reported significantly reduced 
HRQoL relative to matched non-AD controls 
for both mental and physical domains of the 
SF-36 (P<0.001 & p=0.004 respectively). 
Compared with psoriasis, AD had a similar 
impact on HRQoL.  
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Finlay (1996) UK 92 43 males and 49 females; 
average age 33.2 years 








other conditions.  
The mean DLQI index was 18 with subsections 
relating to ‘symptoms and feelings’ and 
‘treatment effects’ scoring highest. Disease 
comparison utility questions demonstrated that 
patients consider diabetes and hypertension 
would be better than having eczema whereas 
bronchitis would be worse than having 
eczema. 
Fivenson et al 
(2002) 
USA 107  298 participants; 107 
adults; mean age of whole 



















46% of adults had mild disease, 11% adults 
had severe disease. In terms of provider 
assessed severity, 51% adults had mild 
disease. The mean DLQI score was 6.6 for 
adults with a range of 0 to 27. The mean score 
for DLQI increased with increasing disease 
severity for all but two questions. For the SF-
36, statistically significant differences were 
detected between the study group and the US 
population norms for vitality, social functioning, 
and mental health. Patient-assessed severity 
had a stronger association with DLQI (r = 0.57, 
p = 0.0001) than provider-assessed severity (r 
= 0.27, p = 0.0036).  




1356 An investigator had to 
recruit clusters of three 
patients, one with chronic 
urticarial (CU), one with 
psoriasis (PSO) and one 
with AD, matched by sex 
and age. Subjective 
impression of severity was 












other conditions.  
After adjustment for confounders, HRQoL 
dimensions were differently affected in the 
three diseases. The ‘physical discomfort’ 
dimension was more degraded in AD and CU 
than in PSO (p < 0.001) and ‘leisure activities 
more in PSO than in CU (p < 0.001). No aspect 
of HRQoL was spared in AD. The mean overall 
VQ-Dermato index was significantly lower in 
CU (M= 36.93) and in PSO (M= 38.88) than in 
AD (M= 44.62, p < 0.001). 
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Haeck et al 
(2012) 
Netherlands 54 Average age of the patients 
was 37.3. At inclusion, the 
average objective SCORAD 
was 43 indicating severe 
AD, average DLQI was 14.6 
indicating a large effect on 
QoL. 




At t=0, there was a small non-significant 
correlation between the DLQI and objective 
SCORAD, ‘rule of nine’ or serum TARC level. 
At t=6 the objective SCORAD, serum TARC 
and the ‘rule of nines’ scores showed 
moderate and significant correlations with the 
DLQI (r = 0.34, p = 0.02; r = 0.31, p = 0.03; r = 
0.49, p <0.001). An individual’s improvement in 
disease activity (SCORAD, SASSAD and ‘rule 
of nines’) with 10 points was associated with 
an improvement in DLQI.  
Higaki et al 
(2004) 
Japan 162 162 patients with AD 
ranged in age from 17-77 
years: the mean age was 
29 years; 55% were female. 
17 had mild, 107 had 
















Each of the three scale scores (symptoms, 
emotions and functioning) of the patients with 
AD were significantly higher than those of 
patients with isolated lesions. Patients with 
severe AD showed significantly higher scores 
in the three scales, as well as the Global Scale 
than those with moderate dermatitis. There 
was a significant positive correlation between 
the severity and each of the three scale scores 
(r’s= 0.32 to 0.45, p < 0.001).  
Holm et al 
(2004) 
Denmark 112 Mean duration of AD of 28.6 
years. Females (n=88) and 
males (n=24); mean age of 











women with AD 
For women, there was a significant positive 
correlation between disease severity ad DLQI 
score (KW test, 15.9; p < 0.001) and also 
between DLQI score and visible regions 
affected by disease (KW test, 14.2; p = 0.001); 
these correlations were not observed in men. 
No significant differences between men and 
women were noted for age, disease duration, 
overall disease severity or QoL as assessed 
using the DLQI. 
Holm et al 
(2006) 
Denmark 101 101 atopic eczema patients, 







Patients with AE had significantly lower QoL 
(p<0.05) than healthy controls (median DLQI 
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score 5 in AD patients vs. 0 in controls) and 
the general population. DLQI, pruritus and 
patents and investigator overall assessment of 
eczema severity were significantly (p < 0.0001) 
and positively correlated with SCORAD, while 
the generic questionnaire showed only poor 
correlation.  
Holm et al 
(2016) 
Denmark 191 Mean age- 31.32 years, 
59.2% females 




Significant relationship between disease 
severity and HRQoL ( r=0.42, P<0.001), with 
increase disease severity significantly 
associated with worsening HRQoL.  There was 
also a significant relationship between DLQI 
and self-rated health (r=-0.37, p<0.001).  
Kiebert et al 
(2002) 
USA 239 Mean age- 36 years, 79% 
female; 18.2 years mean 
duration of disease, 46% 
mild severity, 41% 















SF-36 scores showed a significant decrease 
with increasing disease severity.  DLQI scores 
correlated well with patients ratings of disease 
severity. The SF-36 scores correlated 
significantly with DLQI scores. The SF-36 
scores of patients with AD were significantly 
lower (indicative of more impairment) than 
those of the general population. The mental 
component score of the SF-36 was 
significantly correlated with patient severity 
rating (r=-0.41, p<0.001), the physical 
component was not. 
Kim et al 
(2012) 
Korea 415  Subjects were divided in to 
three groups; infants, 
children and adults ((75 
males and 72 females). 
Mean age of adults= 25.8 
years. 




The total mean DLQI score was 10.7. No 
significant differences in gender and age were 
observed. Adults with atopic disease including 
AD with concomitant asthma, allergic rhinitis or 
allergic conjunctivitis had higher total scores 
than those with AD alone. Both the Rajka & 
Langeland eczema severity score (r=0.261, 
p<0.05) and SCORAD index correlated 
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significantly with all the total QoL scores 
(r=0.432, p < 0.001). 
Kong et al 
(2016) 
Korea 50 22 men and 28 women, 
mean age 26.4 years. 




Significant relationship between disease 
severity and HRQoL ( r=0.237, P<0.001), with 
increase disease severity significantly 
associated with worsening HRQoL. There was 
also a significant association between sleep 
disturbance and QoL (r=0.388, p=0.04), with 
increase sleep disruption associated with 
worsening QoL.  
Kwak et al 
(2017) 
Korea 157 Mean age- 35.2 years; 
51.8% Males; 11,756 non-
AD controls (mean age- 
45.3 years; 49.3% male)  





Adults with AD had lower HRQoL (p=0.013) 
and more stress (p=0.002) than those with AD. 
Even when controlling for demographic 
characteristics, HRQoL of adults with AD was 
lower than adults without AD. 
Lee et al 
(2018)  
Korea 677 Mean age 36.1 years; 
47.8% females; 36,901 
controls- mean age 45.4 









EQ-VAS scores were significantly higher in 
patients with AD than in those without AD 
(p=0.004). A higher rate of pain/discomfort, 
and anxiety/depression was found on the EQ-
5D in AD patients compared to controls 
(p=0.003 and p<0.001, respectively).  
Linnet & 
Jemec (1999) 
Denmark 54 23 women (mean 
age=27.5), 9 men (mean 
age=30.3); average 
duration of condition=26.1 
years. Aged 18-60 years. 
SCORAD DLQI Relationship 
between 
disease severity 






AD patients- significantly lower dermatological 
life quality (Z= 5.1, p<0.001) and higher state 
(Z= 2.14, p<0.032) and trait (Z= 3.49, p<0.001) 
anxiety compared to the control group. 
Significant positive correlation between 
SCORAD and DLQI (r= 0.54, p<0.002). 
Lundberg et al 
(2000) 
Sweden  366 The average duration of AD 
was 25.83 years and the 









DLQI scores showed poorer HRQoL for 
patients with AD compared to psoriatic patients 
but this was not significant when controlling for 
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was 34.79 years old; 92% 
were male. The average 
duration of psoriasis was 
18.39 years and the mean 
age of psoriasis patients 
was 49.87 years old; 51% 
were male.  











confounding factors. No significant difference 
on the SF-36 between patients with AD and 
patients with psoriasis. There was a 
decreasing DLQI score for patients of higher 
ages; improved HRQoL. Spearman’s 
correlation coefficients showed that all SF-36 
dimensions were significantly correlated with 
all measures of disease activity (r= 0.182 to 
0.526), the DLQI correlations with VAS were 
also significant (r=0.005 to 0.595). 
Maksimovic et 
al (2012) 
Serbia 130 Adults- 56.1% female, 
mean age 34.18 years, 
mean age of onset of 
disease -13.95 years, mean 












The DLQI scores corresponded well with 
disease severity; increased disease severity 
was associated with greater impairment in 
HRQoL (r=0.14 to 0.47 for all domains of the 
DLQI). In adults, significant differences were 
only found between DLQI scores for mild and 
severe AD. The highest correlations were seen 
between symptoms and feelings and daily 
activities (r = 0.75, p < 0.01), symptoms and 
feelings and work/school (r = 0.53, p < 0.01) 
and leisure and work/school (r = 0.59, p < 
0.01). Patients with AD had inferior social 
functioning and mental health scores 
compared with the general population. 
Mikolajczyk et 
al (2017) 
Poland  59 36 women and 23 men with 
AD; aged 18 to 46 years; 
mean age- 26.9 years; 
mean disease duration- 
15.1 years 
- DLQI Gender 
differences in 
QoL; impact of 
illness duration 
on QoL 
No significant differences between women and 
men for DLQI scores (p>0.05); significant 
correlations between QoL and health 
evaluation and body areas satisfaction (r=-
0.48), appearance orientation (r=0.31).  




266 34.2% patients were males 
and 65.8% were females. 








The mean DLQI score was 8.8 and the 
physical and mental composite 12 scores were 
50.7 and 39.5 respectively. Analyses according 
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years and mean duration 
was 19.3 years. 1,6% had 
mild AD, 42.9% had 
moderate AD, and 55.6% 





to SCORAD showed DLQI scores 6.8 (SD=4.4) 
and 10.2 (SD=5.6) for moderate and severe 
AD groups (p<0.0001).  
Misery et al 
(2018) 
France 1024 58.3% female; 27.6% mild 
AD, 40.4% moderate AD, 






QoL by visible 
area 
involvement  
Patients with visible area involvement were 
found to have lower QoL than those without 
(p<0.0001), EQ-5D (p<0.05), and the mental 
score of the SF-12 (p<0.0001). No differences 
in physical score of SF-12.  
Mozaffari et al 
(2007)  
Iran 184 75% AD adults were 
female, 57.2% control group 
adults were female. Mean 
age of AD adults was 38.25 
and mean duration of 
disease was 20.6 years, 
9.5% had mild AD, 12% had 
moderate AD, and 18% had 












Significant differences between DLQI mean 
scores in AD group (M=20.5 SD=4.7) and 
control group (M=1.15, SD=0.85) mean score 
(p < 0.001). Scores of each question were 
significantly higher in the AD group than in the 
control group (p<0.001). Correlation between 
DLQI and AD severity was significantly positive 
(r=0.88, p < 0.001).  
Noh et al 
(2013) 
Korea 180 27 males (45%), 33 females 
(55%) with AD, mean age 
32.4 years. Mean age of 
Vitiligo patients was 35.1 
(31 males and 29 females), 
mean age of normal 
controls was 31.9 (25 males 
and 35 females). 









other conditions.  
AD patients- significantly higher scores for all 5 
questionnaire items compared with normal 
controls (p<0.001). In the comparison between 
the AD and Vitiligo groups, AD patients 
reported lower QoL (β= 0.752, t=11.522, p < 
0.001) 
Sanchez-
Perez et al 
(2012) 
Spain 323 Adults mean age was 32.3 
years and 58.7% were 
women; over half of adults 









Significant differences in QoL observed 
according to investigator assessed severity 
(mild disease – M=5.5, SD=5.3; Moderate 
disease- M=7.5, SD=4.8; severe disease- 
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18 and 30 years. 
Concomitant disease was 
observed in 40% of adults. 
M=12, SD=5; p < 0.05). Pruritus caused 
everyday problems related to sleep and sexual 
function. The presence and intensity of pruritus 
was very closely related to HRQoL, with a high 
correlation coefficient between overall itch 
severity scale (ISS) score and overall DLQI 
score (0.72).  
Silverberg et al 
(2018)  
USA 602 53.6% female and 71.9% 
White, with mean age of 52 
years. AD severity was 
measured using self-
reported global severity- 
53.1% mild, 38.8% 















SF-12 mental health sub-scores for moderate 
AD were lower than all other disorders (e.g. 
diabetes, asthma, anxiety/depression, heart 
disease) and for severe AD, dramatically lower 
than all other disorders. Little difference 
between physical health scores across 
disorders. Moderate and severe AD (using PO-
SCORAD, PEOM and global severity) were 
significantly associated with DLQI (ps<0.0001).  
Torrelo et al 
(2013) 
Spain 282  48.2% were male and 
mean age of the adults was 
33.06 years. 79.4% had 
moderate AD and 19.9% 
had severe AD. Mean 
duration of AD for adults 








Statistically significant impact on the daily lives 
of patients receiving maintenance therapy. 
However, patients with moderate AD had 
higher levels of emotional, physical and social 
well-being compared to those with severe AD 
(p < 0.05). 
Treudler et al 
(2019) 
Germany  372 57% female; median age- 
52 years; 9109 participants 
were healthy controls; 
51.9% female; median age- 
58 years 





Physical Component Score (PCS) and Mental 
Component Scores (MCS) were significantly 
lower in subjects with AD compared with 
controls (mean 46.9 vs. 48.0 and 50.6 vs. 52.5, 
P < 0.001, respectively). Linear regression 
showed regression coefficients of -1.7 (PCS; P 
< 0.001) and -1.5 (MCS; P < 0.001); reduced 
QoL with regard to physical and mental 






UK 125 23 males, 102 females; 
aged 18 to 66 (mean age of 
37.2 years).  The mean 
duration of AD was 30.7 








Disease severity was significantly correlated 
with QoL (r = 0.49, p < 0.01), perceptions of 
stigma (r = -0.28, p < 0.01) and depression (r = 
0.18, p < 0.05). 46.7% of the variance in DLQI 
scores (p<0.001) was explained by depression 
and disease severity. Disease severity 
accounted for 23% of the variance in DLQI 








Figure 3.1: Diagram of article flow during literature search and article screening 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) standards. 
Papers identified by searching 
bibliographic databases 
n= 8114 
Papers excluded after removing 
duplicates 
n = 1163 
  
Papers retained for screening by title 
n = 6951 
  Papers excluded after screening titles 
n = 6821 
  
Papers retained for abstract screening 
n = 130 
  
Papers excluded after screening 
abstracts (with reasons) 
 
Non-Atopic Dermatitis- 26 
Children and adults grouped into one analysis -
19 
Non-English- 1 
Not looking at quality of life -27 
Not assessing patient directly- 11 
  n= 84 
Full text papers accessed for detailed 
evaluation 
n = 46 
  
Conference abstracts and non-English   
n = 6 
  
Studies included in qualitative 
synthesis  
n = 35 
  
Papers excluded after reading full text 
(with reasons) 
Children and adults grouped together = 2 
Not measuring QoL directly = 1 
Grouping AD with other skin conditions = 2 
 
 
n = 5 
  
Full text papers read 
n = 40 
  
Studies included in quantitative 
synthesis (meta-analysis) 




3.3.3 Quality of included studies 
Methodology of included studies during the data extraction process was appraised using 
the MMAT version 2011 tool (Pluye et al., 2011). Quality appraisal using the MMAT 
demonstrated that that 27 of 35 (78%)  met 75% of the quality criteria used, symbolic of 
high-quality studies (table 3.3). The remaining eight studies met 50% or less of the 
quality criteria. The reasons for the drop in ratings included lack of information about the 
missing data or the dropout rate of the participants (n=5), invalid tools used to measure 
QoL in AD participants (n=1) or low response rates (n=2). The majority of the included 
studies in this review were of high quality, meeting between 75-100% of the criteria 
detailed in the MMAT.  
3.3.4 Quality of Life 
The Dermatology Life Quality Index (DLQI) was used to measure QoL in 27 out of 35 
studies included in this review. The DLQI was established by Finlay and Khan in 1994 
to measure QoL in adults for use in clinical practice. It is a 10-item questionnaire which 
explores the impact skin disease has on day-to-day activities, social and working life of 
patients. It is scored from 0 to 3 for each item with a maximum score of 30; a higher 
score reflects worsening QoL. The DLQI is not a disease-specific instrument but is rather 
a speciality-specific one and is suitable for use in all skin diseases.   
Mean overall DLQI scores ranged across studies from 4.9 (small effect on patient’s QoL) 
to 20.5 (very large effect on patient’s QoL). In studies which looked at differences across 
the dimensions of QoL, the areas that were most affected as measured using the DLQI 
were symptoms and feelings surrounding AD; patients felt embarrassed or self-
conscious due to their AD and symptoms such as itchy, sore, painful and stinging skin 
had a detrimental impact on their QoL (Finlay, 1996; Holm, Agner, Clausan, & Thomsen, 
2016; Holm, Wulf, Stegmann, & Jamec, 2006; Kim et al 2012;; Lundberg, Johannesson, 
Silverdahl, Hermansson, & Lindberg, 2000;Sánchez-Pérez, Daudén-Tello, Mora, & 
Surinyac, 2013).  
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Personal relationships were the least affected dimension of QoL (Finlay, 1996; Holm et 
al., 2006; Kim et al., 2012; Lundberg et al., 2000). Mozaffari et al (2007) found that 
patients perceived dressing, undressing and bath-time as being most problematic while 
the dimension ‘family activities’ was least affected. Holm et al (2016) also found that 
dressing was particularly problematic.  
Using the EQ-5D as a measure of QoL, daily activity and pain/discomfort parameters 
were reported to be most affected in patients (Lee et al., 2018).  Other less frequently 
used  QoL scales included the VQ Dermato and the Skindex-16. The VQ Dermato is a 
28-item questionnaire which was developed from the point of view of patients. It allows 
computation of seven dimensions; self-perception, daily living activities, mood state, 
social functioning, leisure activities, treatment-induced restrictions, and physical 
discomfort. All scales are linearly transformed to a 0-100 scales, with 100 indicating the 
worst QoL and 0 the most favourable. Skindex is an instrument developed by Chren 
(1996) assessing quality of life in patients with skin conditions. It is scored on a 7-point 













Table 3.3 Quality appraisal using MMAT  









Andersen, Nyeland, & Nyberg (2019) 25 25 25 0 75 
Arima et al (2018) 0 25 25 25 75 
Baron, Morris, Dye, Fielding, & Goulden (2006) 25 25 0 25 75 
Beikert et al(2014) 25 0 25 0 50 
Chen, Wu, Li, Ko, Yu, & Chen et al., (2012) 0 25 0 25 50 
Chrostowska-Plak, Reich, & Szepietowski (2012) 25 25 25 25 100 
Coghi, Bortoletto, Sampaio, Junior, & Aoki (2007) 25 25 25 25 100 
de Bruin‐Weller et al (2019) 25 25 25 25 100 
Eckert, Gupta,  Amand, Gadkari., & Mahajan (2016) 0 25 25 25 75 
Finlay (1996) 25 25 0 25 75 
Fivenson et al (2002) 25 0 0 0 25 
Grob, Revuz, Ortonne, Auqueir, & Lorette (2005) 25 25 25 25 100 
Haeck et al (2011) 0 25 0 25 50 
Higaki et al (2004) 25 25 0 25 75 
Holm, Agner, Clausen, & Thomsen, (2016) 25 25 25 0 75 
Holm, Esmann, & Jemec (2004 25 25 25 0 75 
Holm, Wolf, Stegmann, & Jemec (2005) 25 25 0 25 75 
Kiebert et al (2002) 25 0 0 0 25 
Kim, Li, Seo, Jo, Yim, Kim, et al (2012) 25 25 25 25 100 
Kong, Han, Lee, & Son (2016) 25 25 0 25 75 
Kwak & Kim (2017) 0 25 25 25 75 
Lee et al (2018) 0 0 25 0 50 
Linnet & Jemec (1999) 0 25 25 25 75 
Lundberg, Johannesson, Silverdahl, Hermansson & 
Lindberg (2000) 
25 0 25 25 75 
Maksimovic, Jankovic, Marinkovic, Sekulovic, 
Zivkivic, & Spiric (2012 
25 25 0 25 75 
Mikołajczyk, Rzepa, Król, & Żaba, (2017). 25 25 25 0 75 
Misery et al (2007) 25 25 25 25 100 
Misery et al (2017) 25 25 25 25 100 
Mozaffari et al (2007) 25 25 0 25 75 
Noh, Kim, Park, Hann, & Oh (2013) 25 25 0 25 75 
Sanchez-Perez, Dauden-Tello, Mora, & Surinyac 
(2012) 
25 0 25 25 75 
Silverberg et al (2018) 0 25 25 25 75 
Torrelo et al (2013) 25 0 0 25 50 
Treudler et al  (2019) 25 25 25 0 75 
Wittkowski, Richards, Griffiths, & Main (2003) 0 0 25 25 50 
Note: 25-criterion met, 0- criterion not met/unable to determine. 
 
3.3.5 Quality of Life and Disease Severity 
Twenty-one studies explored the relationship between disease severity and QoL of 
which twenty studies looked used the DLQI. All of these studies but one reported 
significant correlation between disease severity and DLQI; the more severe the disease, 
the lower the QoL.  In seven of these studies, QoL using the DLQI was compared with 
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disease severity measured using the SCORAD (Baron, Morris, Dye, Fielding, & 
Goulden, 2006; Chrostowska-Plak, Reich, & Szepietowski, 2013; Haeck et al., 2011; 
Holm et al., 2016; Kim et al., 2012; Kong, Han, Lee, & Son, 2016; Linnet & Jemec, 1999). 
These studies were pooled together using random effects meta-analysis (See Figure 
3.2).  The sample-weighted average correlation between HRQoL and disease severity 
was r+ = .44 (CI 0.27; 0.59), indicating a medium-sized relationship (Cohen, 1992), with 
greater disease severity relating to poorer QoL. There was significant heterogeneity in 
the results (χ2 = 13.78, p < .05). This could partly be explained by the small correlation 
reported by Haeck et al. (2011).  
 
Figure 3.2. Meta-analysis of studies measuring QoL using DLQI in relation to SCORAD 
 
Two studies (Coghi, Bortoletto, Sampaio, Junior, & Aoki, 2007; Maksimovic et al., 2012) 
used the EASI disease severity measure in relation to DLQI. Both studies found 
statistically significant relationships between QoL and disease severity (ps < .05); QoL 
was perceived as being poorer with increasing disease severity, with personal 




Ten studies (Anderson et al., 2020; Beikert et al., 2014; Holm et al., 2006; Kiebert et al., 
2002; Lee et al., 2018; Lundberg et al., 2000; Mozaffari et al., 2007; Sanchez-Perez, 
Dauden-Tello, Mora, & Surinyac, 2013; Silverberg et al., 2018; Wittkowski, Richards, 
Griffiths, & Main, 2004) explored relationships between patient-assessed disease 
severity and DLQI scores and reported statistically significant medium to large sized 
correlations whereby an increase in disease severity was associated with a decrease in 
QoL. Two studies (Holm, Esman & Jamec, 2004; Mikolajczyk, Rzepa, Król, & Żaba, 
2017) also explored gender differences and found a significant positive correlation 
between patient-assessed disease severity and DLQI score (p < .001) and between 
visible regions and DLQI score (p = .001) for women, however neither of these 
correlations were observed in men.  
Two studies (Fivenson et al., 2002; Higaki et al., 2004) assessed severity using the Rajka 
and Langeland scoring system which measures clinical course, severity, and extent of 
AD. Both studies found statistically significant correlations between disease severity and 
QoL. Highest correlations found were between disease severity and symptoms and 
feelings; higher disease severity was related to worsening symptoms and feelings as a 
result of AD.   
Twelve studies used the SF-36 to measure QoL either alongside the DLQI or on its‘ own. 
This scale consists of 36 questions and is a multi-purpose tool that is generic as opposed 
to one that targets AD only (Ware & Sherbourne, 1992). This scale comprises of sub-
scales which provide a physical and mental health summary measure as well as an eight 
scale profile of well-being scores and functional health. The lower the score in the 
measure the more disability i.e., a score of 100 is corresponds  to no disability and a 
score of 0 is corresponds to the highest disability. The eight subscales of the SF-36 are: 
social role functioning (SF), and mental health (MH), physical functioning (PF), bodily 
pain (BP), vitality (VT), general health perceptions (GH), physical role functioning (RF), 
emotional role functioning (EF),  
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Ten of the twelve studies using this explored the relationship between SF-36 scores and 
disease severity (Arima et al., 2018; Coghi, Bortoletto, Sampaio, Junior, & Aoki, 2007; 
Eckert et al., 2017; Fivenson et al., 2002; Holm et al., 2006; Kiebert et al., 2002; 
Lundberg et al., 2000; Maksimoc et al., 2012). Nine studies found significant correlations 
between disease severity and the SF-36, with increased severity associated with poorer 
QoL. However one study (Maksimoc et al., 2012) found no significant correlation 
between any SF-36 subscales and clinically measured disease severity (EASI). The 
correlations between the SF-36 and disease severity across the nine studies ranged 
from small to large-sized. The mean physical dimension scores appeared to be less 
impaired in AD patients compared to the mean mental component scores of the scale 
(Chen et al., 2013; Coghi et al., 2007; Fivenson et al., 2002; Holm et al., 2006; Kiebert 
et al., 2002; Misery et al., 2007).  
3.3.6 Quality of life in patients with AD compared to healthy controls or other 
patient groups 
A total of 16 studies compared QoL in adults with AD to that of healthy controls.  Eleven 
studies used generic QoL scales such as the SF-36 to enable comparison across groups 
(Arima et al., 2018; Chen et al., 2013; Eckert et al.,2016; Fivenson et al., 2002; Kiebert 
et al., 2002; Kwac & Kim, 2017; Lee et al., 2018; Lundberg et al., 2000; Maksimoc et al., 
2012; Silverberg et al., 2018; Treudler et al., 2020), three studies used dermatology 
specific QoL scales to make comparisons (Linnet & Jemec, 1999; Mozaffari et al., 2007; 
Noh, Kim, Park, Hann & Oh, 2013) and three studies (Holm et al., 2004; Misery et al., 
2017; Silverberg et al., 2018) used both generic and dermatology specific scales.  
Overall QoL was significantly poorer in those with AD compared to healthy controls and 
domains such as mental health and social functioning were affected to a greater extent 
in AD patients (Holm et al., 2006; Holm et al., 2016; Mozaffari et al., 2007; Silverberg et 
al., 2018; Treudler et al., 2020) . In a recent study by Misery et. al (2017) scores on the 
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mental dimension of the SF-12 were lower in AD patients with visible area involvement 
compared to those without (p<0.001).  
Two studies compared QoL between vitiligo and AD patients (Beikert et al., 2014; Noh 
et al., 2013) and found significantly lower QoL in the AD groups compared to the vitiligo 
groups (ps<0.001). Four studies also compared QoL between psoriasis and AD patients 
(Beikert et al., 2014; Eckert et al., 2016; Grob, Revuz, Ortonne, Auqueir & Lorette, 2005; 
Lundberg et al., 2000). Two of these studies found that AD patients had significantly 
lower QoL than patients with psoriasis (Beikert et al., 2014; Grob et al., 2005) whereas 
Lunderberg et al. (2000) found significant differences in the physical and mental 
functioning domains; with AD patients scored better than patients with psoriasis. Eckert 
et al. (2016) found no significant differences in QoL ratings in patients with psoriasis or 
AD. Grob et al. (2005) also compared AD with chronic urticaria and found that AD 
patients were more affected by skin discomfort than chronic urticaria patients.  They also 
had lower scores in relation to ‘treatment induced restrictions’ compared to those with 
chronic urticaria. 
3.3.7 Predictors of Quality of Life 
Five studies conducted multiple regression analyses in order explore predictors of QoL 
(Beikert et al., 2014; Holm et al., 2004; Maksomovic et al., 2012; Noh et al., 2013; 
Wittkowski et al., 2003). Beikert et al (2014) found that skin dryness, (p<0.007), sleep 
disturbances (p<0.016), pruritus (p<0.001), facial involvement (p<0.001), genital 
involvement (p<0.01), and the affected body surface area (p<0.001) were significant 
predictors of QoL. Noh et al (2013) carried out multivariate regression analyses to 
determine predictors of QoL, and found that age significantly predicted DLQI scores. 
Wittkowski et al (2003) found that 46.7% of the variance in DLQI scores was explained 
by disease severity, and psychological factors such as depressive symptoms (p<0.001), 
however, demographic factors such as age and duration did not significantly contribute 
to variance in DLQI scores. Holm et al (2004) performed linear regression analyses with 
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mental and physical components as dependent variables and demographic factors such 
as age and gender as independent variables. An effect of gender was seen on mental 
components, where women had lower HRQoL than men (p=0.019). Age was found only 
to influence the physical components of SF-36; reduced QoL was seen with increasing 
age. Maksimovic et al (2012) found that age was a significant predictor of the physical 
functioning and role physical domain of the SF-36, whereas family history of disease 
was a significant predictor of SF-36 bodily pain domain and DLQI personal relationships 
domain. 
3.4 Discussion 
This systematic review examined the impact of AD on QoL in adults. The DLQI and the 
SF-36 were the most frequently used scales to measure QoL in patients with AD, and 
studies in this review looked at QoL in relation to disease severity, other chronic skin 
conditions, or healthy controls. The qualitative synthesis of results and meta-analysis 
show that there is a consistent relationship between increasing AD severity and poorer 
QoL in adults, and adult patients with AD have poorer QoL than healthy groups.  Findings 
are more equivocal for comparisons with other chronic skin conditions. 
Twenty out of the 21 studies that measured QoL in relation to disease severity found 
increased disease severity was significantly related to poorer QoL. This finding is 
consistent with reviews looking at QoL in children with AD (Clarke & Eiser, 2004; Lewis-
Jones, 2006). Almost all adult patients had mild to moderate AD in the studies included 
in this review. Interestingly, in paediatric studies where more patients had moderate to 
severe AD, QoL correlated less well with disease severity than the adult patients with 
mild to moderate AD in this review (Hon et al., 2008; O’connell, 2004). The consistent 
finding that disease severity was related to QoL underscores not only the importance of 
offering both dermatological and psychological treatment to patients, but also the need 
to incorporate QoL screening tools in dermatology. Nonetheless, AD is a complex 
condition and QoL cannot solely be explained by severity of the disease as most studies 
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reported low to medium correlations between the two variables. One factor that may 
influence QoL and may explain differences between studies is time of recruitment 
whereby patients could be experiencing a flare-up during recruitment, thus affecting QoL 
scores; this is especially the case if participants were recruited during dermatology visits.  
 
All studies that compared QoL in AD patients to healthy controls found significantly lower 
QoL in AD patients. However, four studies used the DLQI measure to explore this 
difference; the DLQI is a dermatology specific questionnaire with questions that are not 
suitable for use in a sample of the general population. In such cases, generic QoL 
measures such as the SF-36 should be employed. When using the SF-36, better 
physical QoL was reported by studies in this review compared to mental QoL. This is in 
line with a systematic review carried out looking at QoL in psoriasis patients (De Korte, 
Mombers, Bos & Sprangers, 2004). The SF-36 is probably not sensitive enough to 
measure the physical limitations of AD due to its generic nature; questions relating to 
walking abilities for example are unlikely to be relevant to this group.   
Studies comparing QoL to other chronic skin conditions had mixed results, but for those 
comparing vitiligo and AD patients, significantly lower QoL was seen for AD. This may 
be because vitiligo is not accompanied by symptoms such as itching, inflammation, and 
sleeplessness. Symptoms such as pruritus have more of an impact on QoL than visual 
aspects; indeed, this review found that the area of QoL most affected was symptoms 
surrounding AD. Studies reporting better physical and mental functioning scores in 
patients with AD compared to those with psoriasis and poorer scores in patients with AD 
regarding skin discomfort compared to urticaria suggests that pruritus is the dominant 
factor that interferes with everyday life. Further, the contrast between lower scores 
related to ‘treatment induced restrictions’ in patients with AD and better scores in patients 
with chronic urticaria suggest that topical treatments can be highly restrictive to patients. 
Indeed, alternative/complementary therapies for AD, such as Chinese herbal therapy 
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have become increasingly popular (Hughes, Ward, Tobin, Keegan, & Kirby, 2007; Tan, 
Zhang, Chen, Xue,, & Lenon, 2013). 
Many of the participants in the included studies were female.  Partly this reflects health 
care utilization, whereby women use more health services and an estimated 67% of 
women worldwide make all medical choices in society (Legato, 1999); in this case, most 
of the participants were out-patients in dermatology clinics. Only one study looking 
primarily at gender differences in QoL and AD and found no significant correlation 
between disease severity and QoL in males but a significant positive correlation was 
present in females. Thus, the extent to which the AD severity is correlated with QoL in 
in relation to females rather than males deserves further research attention. Lesions 
located in visible areas have been found to affect women more than men (Holm et al., 
2004) possibly because women may have a higher ideal of culturally determined 
physical appearance than men so more attention is given to the skin.  Gender differences 
have been found in other allergic conditions with females presenting more complex 
allergy-related conditions compared to males (Mandhane, Greene, Cowan, Taylor, & 
Sears, 2005) and so further research in relation to AD is needed. 
3.4.1 Limitations of the studies in this review 
The heterogeneity in tools used to measure disease severity made it impossible to pool 
results across all included studies. The SCORAD and EASI are generally preferred by 
researchers over patient-assessed severity or visual analogue scales as they are 
validated measures of disease severity. However, they do not cover all issues affected 
in AD patients, for example, SCORAD only measures disease severity over the 
preceding three days, therefore long-term severity effects on QoL cannot be inferred. 
Nevertheless, studies that included both patient-assessed severity and objective 
measures found relatively strong correlations between the two, indicating that patients 
can self-assess their disease severity accurately.  
All studies included in this review used cross-sectional methods to assess QoL in relation 
to disease severity. Results using this methodology should be interpreted with caution 
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as it’s impossible to determine cause and effect. Future studies should utilise prospective 
designs and collect more longitudinal data to strengthen predictive power of 
psychological and clinical variables of QoL.  AD is generally better during the summer 
and worse in winter (Baicker, Chandra, & Skinner, 2005). Only one study specified the 
season.  
Although the quality appraisal for the studies showed that the majority had good to 
excellent ratings, many suffered from methodological weaknesses, such as the use of 
small sample sizes which can be determined based on an expected prevalence of atopic 
dermatitis in adults of 10% (Cork, Danby, & Ogg, 2019), a sample size of 250 would 
provide an adequate estimate with a maximum expected sampling error of ±4.4 
percentage points at the 95% confidence level. Other issues included the use of non-
validated measures, absence of statistical testing and incomplete presentation of QoL 
data such as descriptive statistics. In addition, some studies used dermatology specific 
questionnaires to determine QoL in healthy controls.  This review only included 
intervention studies if they had a baseline measurement of QoL to ensure homogeneity 
of studies.  
3.4.2 Conclusions and directions for future research  
This study is the first systematic review and meta-analysis conducted on adults and 
demonstrates that AD influences all aspects of the lives of adult sufferers. Results 
support findings from previous research on similar skin conditions (De Korte, et al., 2004; 
Parsad, Dogra & Kanwar, 2003) and in children (Lifschitz, 2005; Lewis-Jones, 2006; 
Clarke, & Eiser, 2004).  The present review points to several areas for future research. 
In the present review, overall scores were difficult to interpret because of the variability 
of scores and the absence of formal reference values or norm scores, or the absence of 
formal comparisons with population norms. More research with validated psychometric 
scales is needed to generate a consistent body of knowledge of overall QoL of patients 
with AD. Furthermore, application of both generic and disease- or dermatology-specific 
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quality-of-life questionnaire which cover the full range of quality-of-life issues are 
needed. 
Second, data on the relationship between specific AD characteristics and QoL suggest 
that itch, sleep disturbances, and exacerbations in facial and genital body areas (Beikert 
et al., 2014) could be relevant predictors of quality of life, as reported by a few studies in 
this review, (Wittkowski et al., 2004; Beikert et al., 2014; Noh et al., 2013). A deeper 
insight into these relationships is important because of consequences for disease-
severity measurement in quality-of-life research; indeed, a more qualitative approach 
would help uncover some of these issues. 
Researchers in dermatology are encouraged to utilise validated and clinically relevant 
QoL measures for patients that provide accurate measurement of quality of life and allow 
for subsequent comparison of results across studies. Factors such as sleep disturbances 
and pruritus should be included when determining QoL and future studies should also 
further explore gender differences in QoL in adults with AD; only a few studies in this 
review considered these factors. Longitudinal study designs are also needed to explore 
what factors related to AD cause differences in QoL ratings.
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Chapter four:  A qualitative enquiry into the experiences of living with atopic dermatitis 
in adults 
4.1 Introduction 
This chapter presents the findings of a qualitative study which explored participants 
experiences of living with AD. The findings of this chapter have now been accepted for 
publication in the European Medical Journal. 
 As outlined in chapter one, AD sufferers report poorer HRQoL and greater psychological 
distress compared to a healthy population and those with other medical conditions (Kiebert et 
al., 2002; Lapidus & Kerr, 2001; Linnet & Jemec, 1999; Lundberg et al., 2000). In fact, as many 
as one-third of adult patients with severe AD being unable to keep their jobs due to flare-ups 
of the condition (Shum, Williams, Docherty, & Jones, 2000). The systematic review (chapter 
3) established that many studies have found a significant correlation between disease severity 
and QoL- increased severity is found to be related to poorer QoL. Furthermore, all studies in 
the review that compared QoL in AD patients to healthy people found that QoL was 
significantly lower in AD patients. Notably, all studies included in the review used cross-
sectional methods to assess QoL in relation to disease severity. Results using this 
methodology should be interpreted with caution as it is impossible to determine cause and 
effect. Furthermore, data on the relationship between specific AD characteristics and QoL 
suggested sleep disruption and body surface area affected by AD could be relevant predictors 
of quality of life. A deeper insight into these relationships is crucial for disease-severity 
measurement in quality-of-life research; indeed, a more qualitative approach would help 
uncover some of these issues. 
It is important to consider the experiences of living with atopic dermatitis in long-term 
perspective. ,Existing research does not fully explicate the impact of living with and managing 
this long-term often life-long condition  Indeed experiences of living with different long-term 
conditions vary greatly from one another; diseases such as cancer may cause severe and 
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continuing complications, whereas chronicity in skin conditions like  AD is one that 
encompasses distinct influences on daily quality of life, such as the failure to prevent recurrent 
acute exacerbations and to secure day-to-day control over the condition. Due to the lack of 
cure for AD, these experiences may be combined with uncertainty regarding the management 
of and psychosocial reaction to the condition. According to Jobling (2001), the public response 
to skin conditions does not tend to be one of empathy and compassion, but rather disregard 
or lack of interest in its’ implications on those who have it, in addition to feelings of 
stigmatisation and prejudice  
AD is often associated with negative connotations and moral evaluation such as the 
association of dirtiness attached to patients with AD, in addition to fears of contagion and 
infection (Jobling & Naldi, 2006). These responses to the skin condition are deeply rooted in 
culture and history. These factors amongst others may help explain why QoL is affected in AD 
and similar skin conditions to similar extents as other long-term and often severe conditions 
including cancer and diabetes (Silverberg, 2018). Although there are a number of published 
cross-sectional studies that explore quality of life in relation to AD using clinical and objective 
measures, subjective experiences of living with the condition may be a more powerful 
determinant of the to which QoL is affected (Fivenson et al., 2002). Existing quality of life 
measures do not encompass, summarise and convey the full life experiences of living with AD 
(Finlay, 2001) as they rely on a limited number of questions with response categories that 
assess QoL in a particular time-frame e.g. a day or week preceding the assessment.   
There is a notable paucity of studies that utilise in-depth qualitative methods to explore the 
lived experiences of adults with AD As mentioned earlier, all research assessing QoL in adults 
with AD is quantitative and much is cross-sectional. However, there are few qualitative studies 
on other similar skin conditions such as psoriasis that explore experiences of living with the 
disease using in-depth semi-structured interviews and qualitative analysis (Ersser, Surridge, 
& Wiles, 2001; Jobling, 2005).  Consequently, there is lack of knowledge about the 
experiences of adults living with AD. Interviews with AD patients could help explore and 
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uncover issues that are not easily addressed in qualitative research, thus allowing for a more 
in-depth exploration of the extent that AD impacts an individual’s daily life.   Given the paucity 
of high quality qualitative research in this area and the need to AD patients’ experiences in 
more depth, an inductive qualitative approach was deemed the most suitable method to collect 
this data The aim of this study was to understand participants’ experiences of living with atopic 
dermatitis using semi-structured interviews. 
4.2 Methods 
4.2.1 Study design and setting 
This was a qualitative study using semi-structured interviews conducted with adults with AD, 
face-to-face at Aston University or via telephone. Ethical approval (appendix 3) for the study 
was obtained from the School of Life and Health Sciences Ethics Committee at Aston 
University (Ethics application no. 1125).  
4.2.2 Sampling strategy  
Our aim was to recruit participants of different ethnic backgrounds, perceived severities, and 
ages in order to allow for contrasts and comparisons. Inclusion criteria for this study were 
adults aged 18 or above with clinically diagnosed atopic dermatitis. The exclusion criteria for 
the study were participants living outside the UK, and those under the age of 18. 
4.2.3 Participants and recruitment 
Participants were identified through advertising the study at Aston University, with the use of 
posters, and e-mails sent to students and staff. The study was also advertised on Facebook 
Eczema support groups and Twitter.  A total of 19 participants were recruited; four were 
identified through the University, five were identified through word of mouth and snowballing 
techniques, and ten were identified through social media. 
Participants consisted of one male and eighteen females, with a mean age of 34 years (age 
range 19- 52). All participants had concomitant atopic conditions. Ten participants were White 
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British, six were Indian British and three were Pakistani British. Disease duration ranged from 
seven to fifty years. Fifteen participants were being treated by a dermatologist, and seven 
participants had a family history of atopic dermatitis. Current medications taken by participants 
included topical corticosteroids, oral immunosuppressants, antihistamines, and over -the- 
counter creams and ointments.  (Table 4.1). 












Asha 27 Indian 
British 
27 Food Allergy, hay 
fever 
8/10 Y 
Tamar 44 Pakistani 
British 
42 Allergy 8/10 N 
Sid 26 Indian 
British 
8 Food allergy 7/10 Y 
Amy 32 White British 30 Hay fever 8/10 Y 
Pooja 38 Indian 
British 
17 Asthma 6/10 N 
Katy 34 White British 34 Hay fever, Food 
allergy 
5/10 N 
Karen 47 White British 46 Asthma 7/10 Y 
Stephanie 43 White British 43 Food allergy 6/10 N 
Leah 31 White British 27 Asthma 7/10 N 
Navjot 25 Indian 
British 
25 Food allergy 5/10 N 
Emily 37 White British 36 Asthma, Food allergy 8/10 N 
Fatema 19 Pakistani 
British 
19 Food allergy 6/10 N 
Lorraine 48 White British 42 Asthma, Hay fever 7/10 Y 
Tess 52 White British 48 Food allergy 5/10 N 
Roslyn 34 White British 32 Hay fever 8/10 Y 
Kiran 28 Indian 
British 
25 Food allergy, Hay 
fever 
7/0 N 
Needa 28 Pakistani 
British 
28 Hay fever, Asthma 8/10 N 
Becky 19 White British 19 Asthma, Food allergy 7/10 N 
Manpreet 29 Indian 
British 
27 Hay fever 4/10 Y 
 
Participants read participant information sheets (appendix 4) and completed consent forms 
(appendix 5) before taking part in the interviews. Those who took part in the interview via 
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phone calls were sent information sheets and consent forms by post and returned them back 
to the research team using a pre-paid envelope.  
4.2.4 Data collection 
An interview schedule (appendix 6) was developed based upon the findings of the systematic 
review (chapter 3).  Issues such as sleep, career and physical activity which are commonly 
found to be disrupted in AD patients were also explored. Questions were prepared and 
formatted in a manner which allowed participants to discuss in as much depth about their 
experiences as possible, as the intention was to allow for an exploration of their experience 
without drawing upon any pre-existing theories. Participants’ experiences of living with AD 
daily in general, their relationships with significant others, their experiences with treatment and 
management of the condition as well as physical and psychological implications of living with 
AD were explored in interview. 
Prior to taking part in the interviews, participants completed a demographic questionnaire 
(appendix 7) which included ethnicity, age, gender, details surrounding their diagnosis 
(duration, age of diagnosis, diagnosed by whom), family history, and participant assessed 
disease severity which was rated on a scale of one to ten, with ten representing the most 
severe.  
Questions were framed in an open-ended manner, asking participants to begin by discussing 
their diagnosis of the condition  in order to establish rapport between the researcher and 
participant. Once this was established, the researcher moved on to more sensitive topics such 
as exploring the impact of AD on personal relationships. The interviews were audio-recorded, 
transcribed verbatim. and were conducted at a place and time that was convenient to 
participants-six by phone and 13 in person at the university and lasted on average 35 minutes 
(range: 25 to 55 minutes). No participants withdrew from the study. The researcher verbally 




4.2.5 Data Analysis  
Data was transcribed verbatim, names replaced by pseudonyms and analysed thematically 
(Braun & Clarke, 2006) recognising the interaction between the researcher and the data. 
Thematic analysis has six clearly defined steps: familiarisation with the data, generation of 
initial codes, searching for themes, reviewing themes, defining and naming themes, and 
producing the report. The researcher familiarised themselves with the data through a process 
of reading and re-reading the interview transcripts and then coded the transcripts in detail, 
using annotations to identify patterns in the participants’ use of language to describe or 
evaluate their experiences.  These patterns were explored and discussed with both 
supervisors, alongside any contradictions within and between the participants’ accounts. 
Through this process the researcher identified preliminary themes and conceptualised a 
‘theme’ as a pattern of meaning which illuminated something distinctive about participants’ 
experience of living with atopic dermatitis and/ or which resolved or conceptualised any 
conflicting ideas identified within or between the participants’ accounts.  
4.2.6 Reflexivity  
Within the context of the current study, the researcher was involved in telephone or face-to-
face contact with participants and therefore reflected upon how prior experiences and 
assumptions might influence interaction with participants. Although the researcher was invited 
into participants’ lives, it was important to be mindful as the researcher was merely a guest in 
participants’ spaces; respondents were therefore given the lead in ‘setting the pace’ of the 
interview. Adopting this approach for the interviews allowed the participants exercise a 
measure of control over the interview process, as it was imperative that they felt at ease to 
discuss their experiences and not coerced in any way. By keeping a reflexive diary throughout 
the process, the researcher was able to learn from the interview process and understand 





Five super-ordinate themes were developed from the analysis of the interviews: Experiencing 
threats to inner sense of self; Living with the visibility of AD; Coping with threats to physical 
capacity due to pain and management; Developing confidence in the management and nature 
of AD; Contrasting reactions and support from others. During the interviews, many of the 
participants referred to AD as eczema, thus these words have been used inter-changeably 
through-out the interview transcripts.   
4.3.1 Experiencing threats to inner sense of self  
This super-ordinate theme encapsulated participants’ narratives surrounding the 
psychological impact of AD, such as issues relating to confidence and self-esteem, clinical 
depression and anxiety and impact on mood. This theme was reflected in all participants’ 
accounts thus was a very commonly occurring notion.  The two aspects to this super-ordinate 
theme involved the various emotions that participants with AD discuss experiencing because 
of their condition and issues with self-consciousness.  
This theme of recurrent heightened emotional distress captured the notion that although some 
participants identified feeling ‘happy’ some of the time, many often experienced periods of 
intense emotional suffering that they attributed largely to the unpredictability of their condition 
and loss of control over their flares. Narratives were punctuated with words that powerfully 
identified their suffering: ‘worry’, ‘fear’, ‘anger’, ‘pain’, ‘sadness’, ‘depression’, ‘frustration’, 
‘horrible’, and ‘embarrassment’. Worry or fear (associated with flares), sadness, dysphoria, or 
depression, and anger and frustration were connected to and therefore appraised as 
emanating from the experience of having flares and suffering with the condition for such a long 
duration. This sense of frustration was closely linked to uncertainty surrounding the allergens 
and triggers. Pooja describes “drowning” in her own misery when she gets a flare-up: 
“…at that point I was just like, I’m not going to do any work, I’m not going to go to college when 
I’m like this, I’m just going to sit here and just going to drown in my own misery…”(Pooja) 
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Living with a long-term condition like AD often resulted in an altered view of self. A few 
participants discussed that their condition had become such a strong part of them that they 
could not imagine a life with AD, with Becky describing it as a ‘constant presence’ whereby 
she could not imagine not being ‘itchy everyday’. Participants reported that AD was 
responsible for unsightly physical appearance and this often resulted in them conveying 
various emotions especially during times when their AD was more severe and prevalent on 
areas of the body visible to others. Periods of uncontrolled AD were characterised by low 
mood for some participants. Some used emotive language to describe how they felt about 
periods of uncontrolled AD. Participants described their mood using words such as ‘snappy’ 
and ‘hot-headed’ in times of flare-ups. Katy cited her mood being so low that she stayed 
confined to her room for “days”: 
“…it affected my mood like when I mentioned how I didn’t leave my room for days because 
my skin was so bad and I was just sort of in there in sort of my own den of skin you know, and 
sort of not wanting to go out and see anyone or leave the room…” (Katy) 
Many participants discussed the degree to which their condition threatened their sense of self. 
The tone of some of the narratives reflected an underlying desire to be ‘normal’ and a steadfast 
belief that if their AD were to be cured, it would confer on them a state of normalcy. It reflected 
their hope for an idealized ‘normal’ self.  For example, Asha illustrates a low emotional 
appraisal of her own worth, to the extent that she perceives those without AD as normal: 
“…if I woke up on day and my eczema was gone, I actually think I would pass out. It has taken 
over my life so badly, everyday is sort of centred around it… what I do… what I think… how I 
feel…. I just want to be normal like everyone else you know? Its consuming me as I get 
older…” (Asha) 
There appeared to be differences between those who were diagnosed with AD at an early age 
and those who were diagnosed at a later age. Many participants who were diagnosed with AD 
at a young age made references to how self-consciousness in particular was an issue for them 
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when they were younger. Despite the severity of their condition remaining the same or 
worsening, as they got older their AD did not bother them as much, as their priorities changed, 
and they had more to focus on than their appearance. An example of this is demonstrated in 
the following excerpt, where Karen describes that despite her AD being as severe as ever, 
she no longer cares about others’ perceptions of her: 
“…when I was younger would say yeah because It just made you more self-conscious uh, so 
I would only wear like long sleeve tops or high necks long trousers, now I don’t care I’ll go out 
in a tankini it doesn’t matter…” (Karen) 
A feeling of alienation was also prevalent in participants’ accounts with many discussing the 
desire to live a ‘normal’ life and not be ‘different’ from others Many participants talked about a 
constant awareness of their AD and discussed experiencing low self-esteem and of being 
extremely self-conscious about their appearance. As Katy explained:  
“…I’m more self-conscious of other aspects oy eczema for example rather than the 
pigmentation…it sounds really horrible but like, I think ‘does my skin smell’ for example, and 
then like I get sort of self-conscious because like my colleague said “oh you smell like my 
boyfriend”, I said what do you mean and she said “do you use the same cream as him?” and 
I said I use diprobase, and diprobase is  like an old person cream and I was like well that’s not 
really a compliment is it…” (Katy) 
Fatema described that due to her religion, she covered up her skin, but was doubtful of 
whether she would have the confidence to allow the affected skin to be visible to others as 
she felt that people within her community would judge due to a lack of understanding. In the 
following citation, Fatema describes that if covering up was not part of her culture and religion, 
she would not have the confidence to show her skin : 
“…my confidence is really like low because of my skin, like sometimes I just sit there and roll 
up my sleeves and look at my skin like it’s just its such horrible skin it’s like a daily thing like, 
every time I get changed I look at my skin like I don’t like it, like it, if I didn’t dress like this, 
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would I ever show parts of my body, I don’t think I would have the confidence to be honest 
which is a shame…” (Fatema) 
Similarly, Needa explained that when she visits Pakistan, she feels more judged and less 
confident than in the United Kingdom, where she believes people are more educated about 
AD.  
Many participants also reported feeling bad-tempered, feeling down, depressed, and being 
less tolerant when they had flares. In fact, four participants described being diagnosed with 
clinical depression as a direct result of their AD. Sid had extensive facial scarring due to his 
AD, which resulted in severe clinical depression, suicidal thoughts, and social withdrawal: 
“…I used to be depressed, I had depression. Little things like my skin was so bad on my face 
that I didn’t want to laugh like it hurt to laugh or smile as well, yeah it did affect my mood a lot 
when my skin was really bad I was always alone I always wanted to be by myself not around 
people not even family, this was more so when I was in university so like twenty-one years 
old…” (Sid)  
He went on to say that once he received laser surgery to correct his scars, his depression 
alleviated, and confidence increased. Becky was also diagnosed with clinical depression and 
anxiety which she described as being a direct result of her AD. She describes feeling 
withdrawn at times whereby she wants to ‘sit very still’ in her own ‘little bubble’. There were 
times when these participants felt that they had lost their will to live. The participants used 
distraction as a way of coping.  They described how they chose not to think/ focus on their 
condition or just tried to forget it when feeling down, which could be adaptive and helpful in 
such situations. The purpose of this conscious denial was to sustain emotional functioning and 
therefore be able to live a normal life: 
“…it has also had a really bad psychological impact coz when I’m doing things I don’t have to 
think about anything, thinking about it makes it worse in that sense coz you are constantly 
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looking at it and constantly seeing how it looks and scrutinising it and things like that…”. 
(Fatema)  
The appearance and visibility of their AD, the reaction of others and restrictions experienced 
all adversely affected participants’ emotional well-being. Many also worried about the future 
development of scars/pigmentation and this worry led to feelings of low self-confidence which 
in turn caused introversion and self-consciousness, social anxiety whereby many participants 
were fearful of engaging themselves in social situations, feelings of low mood and despair, 
anger, annoyance and frustration towards their condition and a resulting sense of 
hopelessness and helplessness.  
Thus, this theme captures the extent to which living with AD leads to extensive emotional 
suffering, and in times also gives rise to severe clinical anxiety and depression. To put in 
context the mental impact, Amy simply said: 
“Eczema more than anything for me is mentally draining more than physically draining, it’s 
affected me more psychologically” (Amy) 
4.3.2 Living with the visibility of AD 
Atopic dermatitis alongside its characterisation of intense pruritus and inflammation of the skin, 
also presents itself as cracked, dry, sore and reddened. In time, severe and persistent AD can 
give rise to complications such as pigmentation of the skin, thinning of the skin, wrinkles and 
scars. Many participants in the study felt that the visibility of AD contributed to issues with body 
image whereby many felt stigmatized, judged, and attempted to cover their skin as much as 
possible. They also found themselves comparing their skin to others- often people they were 
close to, such as family members and friends. The two sub-themes capturing this are body 






Most participants were dissatisfied with the appearance of their AD. They felt that their AD 
looked unsightly and consequently perceived themselves as abnormal. Their scars, 
pigmentation and inflammation acted as a constant reminder to the participants and others of 
their continued suffering. Many felt stigmatized by their condition, particularly when their AD 
was prevalent on visible areas such as the face, neck and arms. They believed that others 
would judge them as having other conditions such as scalp AD being mistaken for hair lice, or 
their condition being contagious. They appeared to care deeply about what others thought of 
their AD and strived to keep it hidden so as not to raise any questions or thoughts; Stephanie 
explains in the following excerpt about her fear of what others thought of her condition: 
“…I’d be worried about you know whether they were looking at it, I would be looking at them 
trying to see if they were their eyes were you know sort of drawn to my eczema, I try my very 
very best not to let my hands wander and start scratching so you know I try to be aware you 
know a bit more vigilant if I was meeting somebody new…” (Stephanie) 
Many participants also felt extremely self-conscious of their condition, to the point that they 
felt the need to conceal their condition (e.g. wearing long sleeves, covering their legs and feet, 
wearing corrective foundation on areas with scarring/pigmentation). Amy appeared quite 
exasperated with the visibility of her AD and stated that because her condition was more 
prevalent on her face, she considers it as more severe than if it were elsewhere on her body, 
rating it an 8 out of 10 for severity:  
“…because it’s on my face I would say it’s an eight. Just for the fact that you know, I can’t, I 
can’t put on any make up, some days I just want to put a bag over my head, I don’t want to 
come in to work and face people…” (Amy)  
Feeling self-conscious in relation to their AD resulted in participants adapting their behaviour 
in ways to ‘hide’ their AD such as not liking to see their reflection in the mirror or having their 
photographs taken. Participants also discussed how their AD made them look ‘ugly’ or 
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‘horrible’ with Stephanie explaining that due to having AD on her hands, she felt compelled to 
hide her hands when shaking hands with others by flipping down the back of her hand. Tamar 
also explains in the following extract how AD has affected her body image, and this is primarily 
due to post-inflammatory pigmentation, which is a common outcome of severe AD. Like 
Tamar, other participants also felt vulnerable when exposing their condition to the world: 
“…I have got pigmentation all over, I have got discoloration, I don’t go out without my 
foundations um… it makes me feel really conscious, especially when you’re talking. I would 
not be able to talk, sit across and, then speak with somebody eye to eye contact…” (Tamar) 
Comparison to others 
Through participants’ accounts of living with atopic dermatitis, many expressed a sense of 
injustice, describing ways in which atopic dermatitis threatened their personal identity and they 
made negative comparisons with other people. They reported the unfairness of having to live 
with the condition and focussed on personal characteristics that they believe had been 
damaged by living with AD, including not feeling physically and sexually attractive, strong or a 
good parent.  
Many participants felt envious of other people being able to engage in activities or live a life 
that they wished they could. Fatema for example, stated that she wished she had good skin 
and every time she looked at her family members she was reminded that she was the only 
one suffering. Emily, who was part of a mum’s club, describes feeling ‘envious’ of those in the 
club as they did not have to endure the maintenance regime that comes with AD. She also 
described feeling left out due to not being able to wear cosmetics and clothes that others were 
able to: 
“…sometimes I just feel a bit left out of the clothes and make up conversation and the, you 
know they tend to have really busy lives where they can fit lots in and you know they’re not 
having to go home and put their cream on in between and sometimes I feel a bit left out of 
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those conversations. A little bit envious to be honest because there’s the insider that wants to 
be doing a lot more and then I just can’t…” (Emily)  
There were however participants who compared themselves to AD patients who were “worse” 
than them, and ‘people who have been sort of bed bound and not being able to go to work or 
school or whatever’ (Katy) due to their AD, and therefore rated their own severity relative to 
the cases of AD they had come across. For example, Katy described how in comparison to 
those she had seen bed-bound, her AD was only a ‘good five out ten’.  A few participants also 
compared AD to other conditions, as Becky explained ‘there are far worse conditions to have 
like cancer’. 
Overall, the visibility of the condition appears to have a major impact of participants’ daily lives 
and can result in the condition being perceived as contagious. This is particularly problematic 
when AD is visible on the face and neck. Many participants take measures to conceal their 
AD, and often find themselves comparing their condition to others.  
4.3.3 Coping with threats to physical capacity due to pain and management  
Atopic dermatitis alongside its’ mental implications, affected participants physically.  A number 
of participants discussed the anguish surrounding the inability to lead normal lives due to the 
severe symptoms of the condition such as skin inflammation and pain. These periods of 
exacerbations appeared to greatly affect engagement in physical activities, social interactions, 
financial security, sleep and work productivity. Many of these limitations in physical functioning 
were alleviated by good treatment regimens.  
Many participants reported pain and itch. Pain could be severe and was described as ‘stinging’ 
or ‘sore’ and words such as ‘raw’ and ‘wet’ were used to described inflamed skin. Others 
reported symptoms related to inflammation and the altered texture and sensation of their skin, 
often resulting from years of having the condition.  
Limitations in physical functioning due to pain and discomfort from AD were a distressing 
experience for participants and impacted participants’ ability to perform everyday tasks such 
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as housework, self-care, and leisure activities. The impact of these physical limitations was 
also expressed as a feeling of being an outsider in a world full of healthy people. Many hoped 
to live as normally as possible and overcome limitations brought on by their condition. Some 
participants expressed concerns regarding other aspects of their daily lives, such as having to 
change bed-sheets more often than they would like due to them being covered in ointment, 
having to wash clothes more regularly, having to carry pillow cases and duvet for overnight 
stays away from home: 
“…when I go away where am I going to go is there going to be a bath that I can use for my 
skin to soak, I tend to take my own pillowcase so I know that it’s got some bedding that I know 
has been washed, so it’s those things that I would say affects what I do and where I go…” 
(Karen) 
Washing and physical activity were also problematic for many participants due to being unable 
to face the sensations when cracked or dry skin came into contact with water or sweat. Several 
participants also discussed impairment to movement being one of the biggest problems faced. 
AD around joint areas, feet or hands impaired their ability to move and carry out everyday 
tasks. Movement was often described as painful; Becky, a dance student with AD prevalent 
on her joints was often unable to attend classes due to the flare-ups in these areas. She 
discussed how moving her joints hurt and when her AD was exacerbated, she limited her 
movement to the extent that she ‘sits very still’ because of the pain. She described feeling 
‘trapped’ both emotionally and physically. She also described leaving her classes ‘crying in 
pain’:    
“…it always feels and looks like I’m a bit tired and it’s stiff and that’s really [long pause] weird… 
and I rely a lot on movement because I’m a dancer and I’m always like stretching, dancing 
and moving and then when that all hurts, I just kind of sit still, and I know this sounds really 
bad, but I tend to go really still because I know every movement can like hurt and things and 
then I feel like trapped and sit still and don’t move at all…” (Becky) 
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Several participants reported being prescribed sedating antihistamines due to lack of sleep 
caused by AD symptoms.  Fatigue meant that participants needed more hours of sleep than 
usual, although they were not able to get them. Extended naps during the day and earlier 
bedtimes further reinforced how, physically, these participants were different from people 
without AD. A few participants reported not being able to concentrate or being less productive 
at work due to lack of sleep. Stephanie explained how lack of sleep due to AD resulted in 
fatigue during the day and lack of concentration at work.  
“…sleeplessness is the worst and then it’s just a horrible cycle because then you’re awake 
and then you’re scratching more it’s just a vicious cycle just goes on and on you know until 
you only have three or four hours of sleep in the nights it’s just absolutely you know, just zaps 
you of energy…” (Stephanie)  
Participants with good treatment response experienced improvement in their physical 
condition. However, several participants receiving treatment also described unpleasant side 
effects such as weight gain after using oral medication and fear of infertility.  Many participants 
described discomfort which resulted from the use of emollients and creams, with some not 
being able to wear certain materials due to the emollient ‘sticking’ to their clothes or having to 
wash bedlinen frequently. In the following excerpt, Tamar explains how she did not receive 
support from her family, and was in an ‘unhappy marriage’ which ended mainly due to her AD 
and its complications: 
“…my family hasn’t given me the support I needed… I've honestly got to say… because um… 
as I said when I was sixteen, I got married and I was stuck in a really bad marriage, until about 
40 years old…I was on Methotrexate for many years and I think I wasn’t able to have children 
because of that. My husband…he left me because of this. They should have told me about 
infertility…”(Tamar) 
Impact on the family was a commonly recurring theme, especially for women with small 
children. This was discussed by several women.  For example, Emily feels that she is not a 
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good enough mother to her children as her AD prevents her from being able to give them her 
full attention as seen in the following excerpt. Similarly, other participants with young children 
and those with partners felt that they were absent from their social lives their family in times of 
flares, and had to rely on others to compensate for this absence:   
“I do find it much harder to accept having it because I do feel that there are times when I won’t 
be able to do things for the children and I just feel so ill, um, and occasionally my little girl my 
4 year old, says she wished that my eczema would go away, go away forever!  It is something 
that they notice and they’re aware of…” (Emily) 
Many also often felt restricted in clothing due to irritation and pain that certain materials 
caused, visibility of blood on light fabrics, and flaky skin on dark fabrics: 
“…one thing I didn’t mention is wearing dark clothes, I get dry skin, it’s a nightmare because 
the dry skin just gets like say it’s a vicious cycle and to break it I use betnoscalp I think, it’s like 
an anti-fungal treatment to use in your head. It’s just… black is a no-go for me, flaky skin falling 
on my clothes, so yeah…” (Amy) 
Several participants cited that having AD has impacted them financially with many stating that 
they have had to arrange for Pre-Payment Certificates (PPC) to ease the financial burden. 
This certificate which is valid for a specified period is ideal for patients with many prescriptions 
that need to be purchased regularly: 
“…so obviously I get the PPC so that’s like a 100 pounds a year isn’t it? But then on top of 
that obviously you know you see things and you’re like come on I’ll try that because that’s 
telling me it’s going to fix my skin and you’re like I know it’s not but I’m going to try it anyway 
so like, and sometimes those can be quite expensive can’t they…” (Manpreet) 
Additional to the cost of medication, Stephanie acknowledged that having to purchase clothes 
of skin-suitable materials and extra bedding has an indirect financial impact on her.  
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Participants’ work life was also impacted in various ways. Many participants had sick leave at 
some point in their career due to their AD. Needa discussed having to take two weeks off work 
due to her condition being severe, and at this time she could not move or be around water.  
Being a hairdresser, it would have affected her ability at work, therefore she just had to ‘sit 
tight’ at home. Karen also described having to resign from her job due to complications caused 
by AD which meant she had surgery and had to be hospitalized:  
“…when I first took the job when I was first qualified in 2003, I started the job in July and by 
the Christmas I was in hospital because my skin was so bad because of the stress of the job. 
Um so I spent about three weeks in hospital and I think I had about six weeks off all together. 
Um, It was just everything, an infection, the last time I had a staph infection and it was just the 
stress of the job…” (Karen) 
 A few participants described needing to change jobs due to the stress involved exacerbating 
their condition. Amy felt that she was unable to apply for job promotions due to her AD limiting 
her ability to perform more challenging tasks, as a result of it leaving her fatigued and lacking 
energy. Despite the limitations faced by many, the majority expressed that their colleagues at 
work were understanding of their condition and accommodated it well. Some participants could 
work from home if their condition got worse. The excerpt below demonstrates the empathy 
expressed by Amy’s colleagues at work towards her condition:   
“…luckily my job is not forward facing in the sense that I have to deal with people outside of 
my office, but  I explained that some days it can be horrific and if it is horrendous, they said 
just work from home, don’t bring yourself to come in… so people are understanding in that 
sense…” (Amy) 
Navjot explains how her work colleagues could see her flare-up around her eyes as it was 
very visible; she describes her face that day was ‘gross’. The visibility of the condition on her 
face ruled out any disbelief from her work colleagues which had been present in the past:  
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“…my face is gross, look at my eyes and cracked skin, they could see that it was visibly really 
sore so I think that helped, where as if it was something they couldn’t see then they would be 
like “uhhh you’re just saying it”…” (Navjot)  
A few participants reported a lack of confidence in the long-term management of their AD. 
Continuous and impractical treatment regimens with regular follow-up consultations interfered 
with daily lives. The slow progress of treatments was often frustrating. Participants discussed 
a ‘trial and error’ strategy with their treatment and many, despite living with the condition for 
most of their lives, were unable to treat their condition successfully for a sustained period of 
time. Roslyn, like many others, explained how she had to plan beforehand for the prospect of 
a flare up, and took the necessary measures such as carrying medication with her on journeys. 
Others also appeared to do the same, with Karen having to carry her own bedding with her on 
overnight stays away from home. Emily engaged in constant washing of her hands in order to 
avoid any bacterial infections that could arise as a complication of AD:  
“…I just can’t enjoy stuff as much as other people just because I would have to plan for it, so 
if I was going somewhere, I mean my handbag is just full of pots and tubes and stuff. If I’m 
going somewhere I would have to think right, am I going to be comfortable in what I’m wearing, 
am I going to have enough creams to keep me going through the day, am I going to have a 
bath, am I going to be back too late to have a bath and it’s just…” (Roslyn) 
Only a few participants stated that they were able to manage their condition themselves and 
that their coping strategies had improved with time. For example, Katy cited that she goes to 
her doctor’s appointment knowing exactly what she wants and Amy discussed that she knew 
best what works for her condition:  
“…I just sort of learnt to know what to do what to ask for if I go to a doctor, or sort of how to 
generally manage it myself…” (Katy) 
Many participants also described how their condition has led them to avoid social events and 
activities, and it was not uncommon for them to describe themselves as being social isolated. 
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Some felt ashamed of how they look and wanted to isolate themselves from social situations. 
Social isolation that was not deliberate was also a recurring theme. Some participants 
described how family, friends and/or the general public sometimes acted towards them in ways 
that were hurtful. A few mentioned not participating in social events, avoiding eye contact, and 
having to deal with inappropriate questions about their condition. In the following excerpt, Katy 
describes confining herself to her room during a period when her AD was severe.  Similarly, 
others also recall missing prominent events such as weddings due to flare-ups:  
“…I moved away I lived in a flat with some friends and there were periods then when my skin 
got so bad that like I remember, quite distinctly that there was a time I didn’t really leave my, 
because you know you have like there en suites um, I really didn’t leave my room for like two 
days and it got to a point where like my flat mates put a note under my door…” (Katy) 
Several participants described missing out on social activities due to the fear of an impending 
flare-up, with Amy describing her fear of a flare-up on her wedding day which was in a few 
months’ time. She stated that she would not be able to dress up how she would like but that 
the unpredictability of the condition meant that there was no way she could predict a flare-up. 
Other participants also provided examples of how their social life was affected by their 
condition. They made references to the way they were affected when they went out with 
people from their social circles, such as Sid wanting to hide his face in public and not engaging 
in activities that would draw attention to him, and Amy  wearing clothes that would conceal her 
AD when with her friends. In fact many contemplated socialising when experiencing a flare-
up. A few participants also described their reluctance of staying away from home for long 
periods of time, such as when going on holiday. Stephanie regularly spends time away from 
home and carries her pillow and duvet with her each time, due to the fear of unknown materials 
causing a flare-up: 
“…I work in another part of the country um so I have to stay there but I have to take my own 
bedding with me because the bedding in the hotel I stay at would be too hot too heavy so um, 
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I take my own bedding with me just so that I can be cooler um, but sometimes I’ve been so 
itchy and not able to sleep that I just have to wrap myself in towel…” (Stephanie) 
Although  numerous participants felt less sociable and generally had a strong desire to be 
alone and avoid situations where they could be observed: such as shopping, using public 
transport or participating in social activities, a  few participants acknowledged that despite a 
flare-up of their condition, they did not let this get in the way of their social life, but instead 
considered measures to overcome barriers to their social life: 
“…I was able to go camping last year for the first time ever um, because my consciousness of 
‘oh I need to be somewhere where I can get to a bath or whatever’ and I did four nights in a 
tent, which I’ve never done before so to have done that was like wohaaay [that’s really good] 
so that’s really good…” (Karen)  
Many participants showed hesitance in meeting new people and discussed how they would 
try and avoid situations where they had to communicate with people who do not know of their 
condition. For example, Mandy discusses how she feels self-conscious when shaking hands 
with people who she does not know well: 
“…when I have to meet new people at work- because my job involves me having to see new 
clients all the time- I get really scared that when I shake my hands with them, they will wonder 
‘oh what’s wrong with her hands?’ because they are so rough and wrinkly…” (Mandy)  
Consequently, in addition to threats to inner sense of self, physical pain and discomfort 
affected many areas of participants’ lives. This paired with the management of the condition 
resulted in disrupted sleep, social engagement and participation in physical and leisure 
activities, meant that a large part of participants’ daily lives were affected. There was however, 





4.3.4 Developing confidence in nature and management of AD 
Participants used a variety of coping mechanisms in an attempt to manage and improve their 
daily lives. , Some discussed the use of active strategies such as avoiding triggers and having 
strict maintenance regimens, whereas others used distraction in order to cope with their 
condition such as comfort eating. Many participants reported a sense of control over their 
situation, and this was more so in those who had been diagnosed with AD at an early age.  
mechanisms used to cope and manage the condition varied between participants and seemed 
heavily reliant on past experiences.  
Developing mechanisms to help live with AD  
In order to cope with their AD, a number of participants discussed the use of distraction and 
avoidance strategies as a mechanism to maintain daily functioning and improve their quality 
of life. Methods of escapism included consumption of pharmacological medication such as 
painkillers and sedating antihistamines comfort eating  and focussing on daily stressors (e.g. 
finances) In the excerpt below Lorraine discusses one of her coping strategies that she 
acknowledges is not very helpful: 
“…my confidence was low, so obviously, what I did was I turned to food a little bit, and when 
it gets bad, I still do turn to food, and I know which doesn’t really help, it’s a really vicious cycle 
which I’m trying to break, comfort eating basically…” (Lorraine)  
 Other participants engaged in activities that they were aware would exacerbate their AD. They 
felt that not engaging in these activities would result in them missing out on enjoyable 
activities. An example of this can be seen in the following excerpt whereby Navjot discussed 
knowingly engaging in an enjoyable activity even though she knew it had a detrimental impact 
on her AD. She acknowledges later in her interview that if she limits herself from taking part 
in certain activities, her QoL would be compromised: 
“…I try not to let it affect me um and if, even if I know it’s going swimming in the ocean [I: 
yeah], I know that’s going to really affect me, I’m like oh I’m in Vietnam, on a beach, with my 
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boyfriend like, its once in a lifetime and I’m like forget it I’m going to do it and then deal with 
the consequences later [laughs] which I think you have to otherwise it will affect your  life…” 
(Navjot) 
Many participants also identified instances that demonstrated resilience or defiance. These 
participants refused to succumb to discrimination as a result of AD and took it upon themselves 
to find a solution. In one example, Needa described how she assumed responsibility to change 
her situation by educating her family and relatives about the condition and taking it in her own 
hands to ‘monitor’ AD in her relatives who suffer from it: 
“…I was obviously none the wiser, I was a child, how to use, what to use, when to use it, when 
to stop. I don’t think education was very good, so now as an adult with nieces or nephews that 
do have eczema, what I have educated their parents who don’t have eczema “this is how to 
do it, don’t use too much of that”. So I am making sure it’s being monitored…” (Needa) 
These participants displayed optimism within their accounts and the importance of a positive 
attitude in maintaining a good QoL- an ‘I cannot let it affect me’ attitude. The ‘mind-body’ 
connection and the importance of having a positive outlook to guide the future was discussed, 
whereby thinking positively about their condition would result in an improvement in their AD.  
Many participants had managed to integrate AD into their sense of self, even though it had 
negative effects on various aspects of their lives. This was a process that was helped by 
duration (as time passed, they learnt to accept their condition), and by acceptance from family 
and friends. In the following excerpt, Tess explains how one of her mechanisms to improve 
QoL consists of ‘keeping up appearances’ ;  this makes her feel better on the inside, and helps 
her maintain a better QoL: 
“…I think well actually I am going to put on some make up because it will make me feel a bit 
nicer about myself, but you know there’s things that other people do like you know like oh that 
would help me, I’ll try rubbing that in to my feet for a bit and the there’s me thinking well actually 
that’s a bit pointless you know so um, like I said I try not to let it get to me…” (Tess) 
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Striving for sense of control in the face of unpredictability  
Another recurrent theme was the idea that at some point after being diagnosed with AD, 
participants had made a conscious decision to assume responsibility of their condition, rather 
than let doctors or family members manage it for them. Several participants appeared to feel 
in control of their condition, with a few citing that it would not limit them, and they were ‘past 
that stage’ where it would control their lives; indeed, many of the participants described the 
condition having had more of an impact on them when they were younger. A sense of control 
over their AD appeared to be a means of maintaining a ‘normal’ QoL, Katy states that the 
condition ‘can affect quality of life’ but the aim was not to let it. As the duration of AD increased, 
participants attempted to prioritise it less within their daily lives. They described accumulating 
enough knowledge and experience of living with the condition to become relatively 
desensitized to the effect it was having on them. For example, Stephanie, like Navjot engaged 
in activities that might exacerbate her AD, such as physical activity, because she was 
determined not to let it stop her: 
 “…I try not to let it sort of control anything. I don’t think I’ve ever turned anything down just 
because I’ve got eczema but it would probably make me enjoy things less because it’s difficult 
as I might run but at the end of the run I’ll be feeling sweaty and itchy and whatever so it might 
affect the quality of experience but it wouldn’t stop me doing anything. I do everything within 
my control so if I was going somewhere and it would be a long journey, I just take lots of cream 
with me…” (Stephanie) 
Stephanie described doing ‘everything possible’ to prevent a flare-up, suggesting that certain 
aspects of her condition were out of her control and there was only so much that she could do 
to prepare for a potential flare-up. Sid however, described wanting to be control of his 
environment so staying indoors would be ideal for him, whereby he could control the 
temperature to obtain the ‘perfect conditions’ for his AD as can be seen in the excerpt below. 
Later on, in the interview, Sid discussed losing weight, being mindful of his diet, and cooking 
his own food which contributed to a reduction in his AD; losing weight consciously, and 
110 
 
controlling his diet was perhaps a way for him to compensate for the things he could not control 
such as his flares : 
“…like I would rather be inside where I know I can, I’m in control of the environment inside so 
there’s perfect conditions for me…I get really warm yeah…I’ve always felt really hot yeah so I 
used to bring my ice water to just try and get my temperature down…” (Sid) 
Emotions surrounding the unpredictability of flare-ups and loss of control reflected participants’ 
worry about “what if” a flare-up starts, and this concern introduced a great amount of 
uncertainty in their lives. Due to many participants not knowing what their triggers were, they 
could only plan to a certain extent. Many participants did not know what to avoid and therefore 
could only anticipate or predict their allergens without certainty. Kiran explains in the following 
excerpt how the ‘unknown’ of AD has resulted in her comfort eating, and the stress of comfort 
eating further exacerbates her AD:  
“…some days depending on the flare up you feel lethargic so I’ve got this conscious bit, 
watching what I eat, trying to lose weight, and I have lost weight a little bit but I think because 
of the, the unknown about the eczema and when it’s going to flare up, I don’t know when I’m 
going to have a really bad like food day, you feel worse after comfort eating, it’s a vicious 
cycle…” (Kiran) 
Amy also explained that AD ‘takes a hold of your body’, the unpredictable nature of the 
condition meant that she had to brace for a potential flare-up at a forthcoming wedding, and 
her own wedding, where wearing cosmetics would trigger symptoms. She was one of many 
participants who were not aware of their triggers and described AD symptoms as 
unpredictable and something a patient should expect at any time without warning: 
“…this thing that takes a hold of your body, and you don’t know when it’s going to take a hold, 
you know we’ve got a wedding in October and I think to myself , god I just hope that it doesn’t 
flare upon that day and that’s that’s myself, when I get married that’s the worry ill have, 
because you know, and I said to my other half, I said ‘I’ll wear make-up on the day’ and he 
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said well wear it until we have the pictures and then take it off, he says it doesn’t make any 
difference, but its more me…” (Amy) 
Some participants discussed how flares were accompanied by apprehension due to lack of 
certainty of how the flare would be and how long it would last. A few participants also recalled 
that even when they were better, they were apprehensive of a flare returning and it was always 
‘at the back of the mind’. 
Many participants, through years of living with AD, developed strategies to help them manage 
their condition better. Some participants made a conscious decision gain control over their 
condition by taking necessary precautions to avoid flares and avoiding situations that would 
exacerbate their AD. The unpredictability of the condition however made it more problematic 
for participants to prepare for potential flares.  
4.3.5 Contrasting reactions and support from others 
When discussing health care professionals, the majority of participants passionately  felt that 
their GPs and primary care doctors did not understand the psychological impact of AD on 
them and there was a general idea amongst participants that GPs were not equipped to 
address and treat mental health issues that arose as a result of AD. Family and friends were 
a central part of participants’ support network and many felt that  those who knew them for the 
longest and those who had AD understood the participants’ situations best. Social isolation 
was also prevalent in many participants, particularly those with AD on areas of the body visible 
to others. As a result of this social anxiety, many missed out on important events and family 
functions- they were fearful of what others who were unaware of their condition would think of 
them.  
Dismissed by health care professionals  
Upon exploring perceptions of health care from GPs and dermatologists, many participants 
felt that there was a lack of adequate information on the condition itself, its management and 
prognosis provided by these health care professionals. One participant also felt that health 
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care was centred around children and not enough attention or resources were put towards the 
adult population.  
Some participants also reported that their GPs did not ask about the impact of AD on their life. 
Interestingly, many participants in the study said they were interested in having their GPs 
explore how their AD may be affecting them.  For example, Becky explained that GPs do not 
understand her condition and she would like to be referred to a mental health professional but 
does not believe that the NHS has enough funding to implement this as part of her treatment. 
A few participants also discussed that due to their clinicians not suffering from the condition, 
the extent of the impact AD had could not be appreciated.  
Several participants expressed having to ‘push’ for further tests or referrals after they were 
presented to their GPs with worsening symptoms. Complex relationships were evidence 
between health care professionals and participants in this study, with their perceptions of 
doctors’ expertise regarding AD being variable. Many felt that doctors were often dismissive 
of the seriousness of their condition and that this attitude reflected either the GPs’ lack of 
experience and interest in the area, or a lack of appreciation of the psychological impact of 
AD. Becky described never being referred to a mental health professional despite being 
diagnosed with clinical depression and anxiety and having asked ‘twice or three times’ to be 
referred to a ‘proper mental health doctor’ and not ‘just a nurse’. She discusses how it would 
be ideal to have one person who is specialised in her AD and mental health:  
“…I feel that it’s not their fault to be honest. If there was more resource and money in the NHS, 
maybe I could expect to see a psychologist you know, for how severe my eczema is affecting… 
I think if the dermatologist was combined with the psychologist so I only needed to see one 
doctor who would understand what m going through, you know it would be nice…” (Becky) 
For some participants, GPs’ pejorative or unsympathetic attitudes contributed to feelings of 
guilt or decreased self-esteem. In the following excerpt, Amy discusses the lack of scientific 
knowledge and understanding of AD which could affect patient care:   
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“…I just think they don’t understand eczema and I don’t think there’s one trigger for each 
individual I don’t think they’ve figured out one cause that they can associate which would make 
it a lot easier like breast cancer for example they know what specific gene, but eczema there’s 
so many different external factors they haven’t been pointed one which impacts more than 
others, so they haven’t got a common diagnosis, which I think kind of dilutes what they’re 
trying to sort of say to you...” (Amy) 
Unfavourable experiences with health care professionals, particularly GPs were not always 
seen as a failing on the doctor’s part. Many participants acknowledged that although they 
experienced negative outcomes in consultations, the nature of skin disease management is 
in itself complex. Many also appreciated various demands placed on GPs such as a ten minute 
limit for clinical consultations and the acknowledgement that AD is not life-threatening thus it 
was- at least in some part- understandable why it was trivialised by doctors. Dermatologists 
were often  perceived as knowledgeable in technical expertise. Some experienced positive 
encounters with dermatologists who showed empathetic approaches. But many felt that 
dermatologists appeared uninterested in the psychological burden of their condition. Leah 
discussed the way in which she was treated by her dermatologist: 
“… I used to see a dermatologist I used to see him every six weeks or something um they 
discharged me basically saying there was nothing they can do um, I’ve just got to deal with it 
now, it was severe at the time because I used to have to to wrap up in wet towels and stuff 
that’s how bad it got but umm it felt like everybody gave up on me then…” (Leah) 
A few participants expressed disbelief that a ‘simple condition’ like AD does not yet have a 
cure, and how it is not possible with medical ‘technology being so advanced’ that there was 
no known cure for the condition-.  A few participants appeared to relate the lack of cure for AD 
with  GPs’ lack of knowledge and lack of education of the general public regarding AD. With 
regard to health care professionals, numerous participants eluded that they were better 
‘doctors’ when it came to their condition than their GPs, and often took it in their own hands to 
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alleviate flare-ups and educate others of the condition rather than seeking medical help. As 
Nafisa describes in the following excerpt:  
“…I wouldn’t say my doctor told my parents about my eczema properly or even gave them 
any knowledge… I have nieces and nephews with eczema now and I’m always telling them 
what to do, what to put, what not to put… their doctors don’t give them the information they 
need either…” (Nafisa) 
Nafisa also described having had ‘insensitive’ comments from her health care professional 
whereby her neck pigmentation was likened to a ‘dirty neck’.  ‘Dirty neck syndrome’ is used to 
describe the post inflammatory hyper-pigmentation many AD patients- predominantly adults- 
develop on their neck. Even though she acknowledged that this was not a comment towards 
her, she did not appreciate it being called ‘dirty neck syndrome’. Others appeared to disagree 
with their GPs/dermatologists over their treatment and diagnoses. Corticosteroids due to their 
potency, are usually prescribed in limited quantities, however, in the following excerpt, Karen 
discusses this difference in opinion between her and her GP on the amount of corticosteroid 
prescribed, this in turn results in her perceiving a lack of understanding from her GP: 
“my GP, I would say I knows more about eczema than he does and I think that’s always been 
the case so whenever I go to the GP I tend to tell him what I want and he prescribes it, and 
we always have lots of discussion, even arguments,  where he says “here’s a 30 gram tube” 
when I say that that lasts me two days [both laugh] and they say things like “just use a fingertip 
amount” and I I’m like no what, I use an entire handful…”  (Karen)  
Relationships with significant others  
Participants stated that they did not generally engage in speaking about the impact of their 
condition to friends and family as they don’t want to be perceived in a negative light; many had 
anxieties that it reflected a sign of weakness. Participants of South Asian background were 
particularly reticent about talking about their condition to others for this reason. For example, 
Needa discussed that due to her family being ‘conservative’, she did not feel that she could 
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discuss her condition openly with them, similarly Nafisa also perceived a lack of education 
about AD in her family and relatives and therefore chose not to talk about her condition openly.    
The majority of participants however described feeling supported by their parents and siblings, 
especially in circumstances where their family members had a history of AD. While many 
participants reported strangers viewing their condition as contagious, most felt that this was 
not the case for friends and family who knew of their AD. Karen, for example explains that 
those that have known her for a long time are very accommodating of her condition; this is 
reflected in many participants’ accounts whereby an association is made between how well 
an individual knows the participant and the level of understanding portrayed by them: 
“…my friends and family are all great, I mean they know me well enough to know that if I’m 
having a bad day, will appear in the house in pyjamas and a dress and not go out because I 
can’t get dressed that day because I’ve been too itchy um, nobody tells me not to scratch, I’ve 
asked them not to so they know better um, I’ve got fabulous  support in terms of my skin 
because there’ve been times where I’ve been in hospital with my skin over the years um, and 
they have just accepted that that’s part of me…” (Karen) 
Nafisa discussed how she received negative comments from others about her condition, but 
this was mainly from the ‘third world countries’ she had visited to meet family. She described 
how people in these countries are more ‘direct’ and have ‘less etiquette’ than those in the UK. 
Her sense of frustration towards the lack of knowledge of these individuals is evident from the 
following passage:  
“…when I went to Pakistan a few years ago, everyone was looking at my skin and my scars 
and asking what had happened to my skin- I would never get this here, it’s always the third 
world countries where they don’t have the education and they are really direct about things. 
You kind of get blamed for your illness over there…” (Nafisa)  
Many participants discussed how their AD has had a negative impact on their intimate 
relationships. Some participants felt that engagement in sexual intercourse was inhibited by 
116 
 
flare-ups or the use of topical treatment on their skin. Stephanie describes not sleeping in the 
same bedroom as her partner due to her scratching keeping him awake at night, and then 
goes on to describe the ‘frustration’ he experiences when they have to sleep in one bed, such 
as when on holiday. She discusses, rather sadly, how their relationship has changed as her 
AD has become more severe:  
“…I think he finds it a bit frustrating in times say when we go on holiday and we do share a 
bed my scratching keeps him awake and once he starts to sleep it makes him irritable and 
frustrated and then I think he struggles a bit with understanding it…” (Stephanie) 
Other participants discussed how their partners have been understanding of their condition 
and it had no impact on their intimate relationships as their partners were aware of when the 
participants was comfortable enough to engage in such activity. This is highly dependent on 
the severity of their condition.  A few participants discussed having to open up to their partners 
when their relationships were in their early stages and being fearful of what their partners 
would think of their AD. This was described as a ‘hurdle’ to overcome. For a few women, 
physical limitations resulted in changes in roles especially a shift from care giver to care 
receiver with a few participants being dependent on others as a result. For example, Emily 
discusses how understanding her partner is with her AD, with him sharing the responsibilities 
that with AD, such as having medications on time. She likens her partner to a ‘carer’ although 
she still has the capacity to undertake these responsibilities herself: 
“… I can get a bit irritated by that almost, it feels like he’s my carer in that way, not my partner, 
so I guess some people can’t win um, but he’s incredibly understanding with me, with my 
skin…” (Emily) 
Some participants found that sometimes their AD was not taken seriously. They reported 
anger and low mood from being dismissed, trivialised, or disbelieved by members of the public, 
family or friends. A few participants described not feeling sufficiently supported by their parents 
and being told to ‘just get on with it’ or ‘just put some cream on’. One participant hesitantly 
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described how her mother had made a negative comment about her AD, and despite this 
happening years ago it was something that she could not forget: 
“…I remember when I was younger, I didn’t really feel I suppose I didn’t really feel supported 
by my… parents like I could have done, like I remember once when my mum said to me, like 
this was years and years ago so it’s one of those thing that just stuck, she was like saying 
about my legs that my legs look like snake skin, I was like [laughs] is that really what your 
mum says to you, you know, yeah, and then it’s a bit like oh you know yeah it’s not really 
helpful is it?...” (Katy) 
Numerous participants also discussed that those without AD would not be able to understand 
the condition and they did not expect people without AD to even comprehend what they were 
going through. Becky describes how, even though her mother was her ‘carer’ for her AD until 
aged 10, she does not grasp the full extent of how it affects Becky: 
“…if the whole of your back’s just weeping or something, and like you’re so constantly aware 
of it, I am not sure she can fully understand; you can’t really expect a non-eczema patient to 
understand what you’re going through…” (Becky) 
Overall, many participants discussed feeling misunderstood by their health care professionals 
and felt that they could not truly understand the extent of the condition on their lives, in 
particular, psychological impact. A few participants felt that they needed access to 
psychological support but were not offered this. Although the majority felt supported by their 
families and friends, a few, especially of South Asian descent, were less willing to talk about 
their AD.  A few participants had also received negative comments from friends and family.  
4.4 Discussion  
Summary of results  
The findings of this study support previous quantitative studies that have confirmed the 
profound impact of AD on the quality of life and mental health of adults.  In particular it is 
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highlighted that many participants reported a poor body image and confidence. The visibility 
of the condition appeared to affect participants greatly as they felt stigmatised. Participants 
discussed their life experiences of living with AD and offers explanations surrounding their 
diagnoses of the condition. This study also found a potential lack of public awareness 
surrounding AD, as well as lack of empathy from family and friends. Many participants 
discussed hesitation in discussing their condition with others in fear of being perceived in a 
negative light. The analysis also highlighted cultural and ethnic differences in experiences of 
living with AD.  
Upon exploring participants perceptions of their health care professionals, many discussed 
the lack of acknowledgement offered by HCPs on the psychological impact of AD. It was also 
frequently discussed within interviews that HCPs did not offer adequate information on the 
management of the condition, and although participants placed importance on effective 
treatment and prompt referrals, they also needed HCPs to empower them by communicating 
more effectively. Indeed, there was a strong sense that HCPs were not equipped with the 
knowledge to address the psychological impact that AD had on participants’ lives.  
Why did participants feel misunderstood by their health care professionals?  
The qualitative methodology employed by this study highlighted a number of complexities in 
relationships between health care professionals and adults with AD, most of which are not 
apparent in previous studies. Many participants discussed appreciation of time constraints 
amongst other factors to  illuminate apparent failings of health care professionals. The finding 
that a number of participants perceived their health care professionals having a primary role 
of treating their skin condition and ignoring psychological implications, is consistent with 
findings by of a New Zealand study by Bushnell, Mcleod, & Dowell (2005) who found that 
almost 40% of primary care patients with an impact to mental wellbeing have not disclosed 
them to their HCP. Reasons cited for this included the perception that a doctor is not a suitable 
individual to discuss mental health issues with, the stigma of mental illness and health care 
system issues such as time pressures during a consultation. An area that is largely unexplored 
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in current literature is how stigma attached to poor mental health may be an issues in skin 
disease settings, as skin disease itself is related to stigma. This may be further increased by 
the perceived trivialisation of AD as was found in this study and has been reported by Magin, 
Adams, Hagin, and Pond (2009). Thus those with AD may be increasingly reluctant to discuss 
mental health with their HCP; as such  this topic deserves further research.   
Why do AD patients perceive feelings of stigmatisation due to their condition? 
The findings of this study demonstrate the perceived effect of AD on body image, with many 
participants feeling extremely dissatisfied with the appearance of their condition and feeling 
compelled to cover areas of scarring and active disease. As a result of feelings of 
stigmatisation in social interactions, many participants were not willing to disclose their 
condition to others. AD appeared to be a family secret for some, and there was a sense that 
not many were willing to reveal this to others.  Discussions surrounding the condition with 
colleagues and friends were accompanied with suggestions for treatment and concerns about 
participants’ wellbeing, which caused feelings of separation from society. Many expressed 
unwillingness to disclose their condition to others due to the fear of compromising their existing 
relationships and current social situation.   
They were also unwilling to share their problem due to the general population not being 
equipped with sufficient knowledge of the condition, which could result in rejection by the 
society; this lack of knowledge was also present within families of a few participants.  
Participants in this study, such as Sid who had extensive facial scarring as a result of AD, 
spoke about it stopping him from being part of social events such as weddings. According to 
Newell (2000), patients with facial disfigurements exhibit similar levels of social  and 
agoraphobia  to patients with clinically diagnosed social phobia, in addition to higher levels of 
social avoidance compared to agoraphobic patients.  
Social support and its role in skin disease management has been acknowledged as a buffer 
of the consequences related to psychological stress (Picardi et al., 2005). The social 
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withdrawal and avoidance common in skin conditions such as AD can unfortunately result in 
a smaller support network in those affected (Lapidus & Kerr, 2001). Many participants in our 
study detached themselves from their families and friends, especially at times when their AD 
was active. For example Katy described hiding away in her room for days when her AD flared 
up.  Participants testified to feeling at ease with familiar others, who were perceived as able 
to see the ‘real’ person underneath and ignore superficial appearances. . Partners and families 
were the main providers of support, yet they themselves may be trying to deal with their own 
reactions and distress surrounding the AD. According to the 2012 survey of adults with skin 
conditions conducted by the British Skin Foundation, 29% of AD patients felt that their skin 
condition acted as a barrier to finding a partner and  20% also that their skin condition was the 
primary cause for the breakdown of their most recent relationship. One of the top three areas 
perceived as most affected by their skin condition were making friends which was ranked third 
after confidence and impact on their working life.   
Why were BME participants less willing to disclose their condition to others?  
In this study, BME participants were less willing to talk about their condition, with one South-
Asian participant acknowledging that her family in Pakistan was less accommodating of her 
condition than people in the U.K. BME participants were also less willing to discuss the impact 
of AD on their personal relationships, however, this impact appeared to be greater in this sub-
group in participants who did touch on the subject. For example, Tamar discussed that she 
was forced to marry when she was 16 years old, and due to her husband and his family not 
being accepting of her AD, she had to resort to divorce. She blamed the failure of her marriage 
and inability to conceive purely on AD and the lack of understanding of the condition in her 
community.  Skin diseases have been found to be particularly associated with taboos and 
belies in different cultures (Tatum, 2010). Within a multi-cultural society such as the UK, it is 
vital for doctors and other health care professionals to acknowledge that some patients from 
black and ethnic minority groups may present with different social and psychological needs 
(Baker, Mead & Campbell, 2002). Beliefs and myths surrounding skin disease has the 
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potential to profoundly impact the patient and their ability to cope with the condition- false and 
often derogatory interpretations of the condition were prevalent in some accounts of 
participants in this study. Thus it is important to gain an understanding of these implications in 
order to provide effective care to patients. Thompson et al. (2010) reported that British Born 
South Asian women suffering from vitiligo reported high levels of stigmatisation and this was 
influences by, and affected, cultural practices.  
Another aspect that is often not explored in previous studies is the role of gender in perceptions 
of living with AD. This is potentially more significant in cultures where a woman’s marriage and 
career prospects may be damaged  due to suffering with a skin condition. In some cultures, 
women may also bear the chief burden for support and treatment of family members with AD. 
There is also concern surrounding patients who are unable to speak English and whose 
access to medical care may be compromised by the lack of sympathetic suitably trained 
interpreters.  As such, further research is warranted in this area and on similar skin conditions 
in an attempt to fully understand the impact of cultural beliefs and how they impacts patients’ 
abilities to cope with their condition, as it is not a widely researched area. 
4.4.1 Strengths and limitations 
This is the UK first qualitative study exploring quality of life and mental health in adults AD 
patients known to the researcher at the time of writing. Unlike the vast majority of studies 
exploring QoL in adults with skin conditions, this study had an ethnically diverse and large 
sample, which allowed for comparisons between sub-groups as BME participants made up 
almost half of our study sample. Issues such as the role of AD in intimate relationships and 
the implications of visibility in AD were among factors that I was able to explore that have not 
been explored widely in quantitative studies.  However, the study lacked male participants, 
which does not allow for comparison between genders and the findings may not reflect the 
experiences of men with AD. Additionally, AD diagnosis in the study was self-reported using 
demographic questionnaires; the questions did however explore details surrounding 
diagnosis, disease duration, and treatment for AD. Eleven participants were recruited through 
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an on-line AD support group on Facebook therefore this sub-set of participants do not 
represent all patients with AD, as they have different characteristics and coping strategies due 
to being part of a wider platform of AD sufferers. However, the participants were representative 
of the heterogeneous population of patients with AD in terms of age duration. Subtype and 
history of disease also varied, adding to a broadening of the findings. There were also no 
notable differences between participants recruited from support groups and the University for 
AD severity. 
4.5 Conclusion and directions for future research 
This study revealed the importance of acknowledging and recognizing AD as a complex long-
term condition that causes significant psychosocial implications on patients. Findings of this 
study emphasize the need for more integrated and accessible psychological support for adults 
with AD. Quality of life domains should be identified, assessed and addressed in clinical 
settings and the role of specialist psychologists within Dermatology should be considered. 
Availability of support material may help adults better manage and prepare for the impact of 
AD on their daily lives. This study’s findings may help raise awareness in health care 
professionals of the complexity of AD and the need to assess and manage these patients 










Chapter five:  An investigation of quality of life and mental health in adults with atopic 
dermatitis compared to healthy people 
5.1 Introduction  
This chapter presents a cross-sectional quantitative study that examines the relationship 
between QoL and mental well-being in adults with AD and compares QoL and mental well-
being in this group to a healthy control group. As detailed in the first chapter, in developed 
countries, the prevalence of AD has increased two to threefold over the last three decades 
(Grillo, Gassner, Dunn, & Hudson, 2006) and is expected to keep increasing gradually. 
Relative to children and adolescents with the condition, little research has been conducted on 
the impact AD has on HRQoL of adults, despite adults representing a more severe and 
persistent subset of all cases of AD (Hoare, Li, & Williams, 2000).  
The systematic review highlighted numerous methodological issues with studies exploring 
HRQoL in adults. Some of these included the sole use of recruitment through dermatology 
clinics. This has highlighted the significance of exploring the relationship between 
psychological and clinical factors in AD. However, Long, Funnell, Collard, & Finlay (1993) 
emphasised that these relationships also need to be explored in those recruited from the 
general population as opposed to clinics only. Members of the National Eczema Society (NES) 
in their study felt dissatisfied with at least their initial clinical consultations. This dissatisfaction 
may have contributed to motivation in seeking help and support elsewhere, thus possible 
disability and distress in relation to their AD may be unrecognised   in studies recruiting from 
clinics.  
Most current published literature focuses on the reduction of cases, alleviation of symptoms 
or treatment. There are few studies investigating the relationship between AD and quality of 
life (QoL), depression or anxiety disorders, and findings are inconsistent (e.g. Ginsburg, 
Prytowsky, Kornfeld, & Wollland, 1993; Hashiro & Okumura, 1997; Slattery & Essex, 2011) 
partly due to different measurements used for HRQoL, distress and disease severity. 
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Moreover, most current research includes small sample sizes of less than 250 (e.g. Linnet & 
Jemec, 1999; Maksimovic et al., 2012; Mikolajczyk et al., 2017; Noh et al., 2013; Wittkowski 
et al., 2004) and does not differentiate between clinically diagnosed and self-diagnosed AD.  
The relationship between demographic variables such as age and gender, psychological 
factors, clinical manifestations of AD and quality of life have also been investigated in 
numerous studies (e.g. Holm, Esmann, & Jemec, 2006; Fivenson, 2002; Mozaffari et al., 2007; 
Misery et al., 2018) and whilst many studies have found associations between AD severity 
and quality of life, others have questioned these findings due to methodological problems or 
weak associations(Witkowski et al., 2003). However, there is a paucity of studies that control 
for these demographic factors to ascertain predictors of QoL and mental well-being. 
Additionally, other demographic factors such as ethnicity are seldom taken into consideration 
despite significant differences between ethnic groups in severity and prevalence of AD 
(Brunner & Guttman-Yasky, 2018). Moreover, some studies use dermatology specific 
questionnaires to determine QoL in healthy controls (Birdi, Cooke, & Knibb, 2020). 
Studies examining the association between AD and mental health are very limited, and 
findings are inconsistent (Hashiro & Okumura, 1997; Slattery & Essex, 2011). These 
inconsistencies could be a result to varying study methodologies and other limitations such as 
small sample sizes and self-report of conditions without appropriate screening. Other issues 
include absence of statistical testing and incomplete presentation of QoL data such as 
descriptive statistics.  
There is also lack of research on AD in the United Kingdom, despite the UK having one of the 
highest prevalence rates of the condition in adults (5%). The majority of previous research on 
QoL and mental health in AD has been conducted in France, Germany, Spain, Sweden and 






 the aims of this study are to overcome some of these issues by using validated quality of life 
and mental health measures to explore the relationship between these variables and AD in a 
large UK adult population (>250 AD patients) with clinically diagnosed AD. Mental health and 
HRQoL in AD patients is also compared with healthy controls using measures appropriate to 
both populations. Exploring QoL and mental health is of potential value in performing risk-
benefit analyses of precarious clinical decisions, for example, in a situation whereby systemic 
therapy with possible side effects is prescribed.    
5.1.2 Hypotheses 
This study proposed four main hypotheses: 
Hypothesis 1: There are significant relationships between QoL, disease severity and mental 
health variables 
Hypothesis 2:  QoL and mental health variables is significantly more impaired in adults with 
AD compared to healthy people  
Hypothesis 3: socio-demographic factors, disease severity and mental health significantly 
predicts QoL in adults with AD 
Hypothesis 4: There are significant differences in adults with AD for socio-demographic and 
clinical factors   
5.2 Methods 
 5.2.1 Study design  
This study was cross-sectional and measured quality of life, disease severity and 
psychological variables using validated questionnaires in both AD and healthy control groups. 
NHS/HRA ethical approval (appendix 8) was gained prior to commencing data collection 
(REC# : 18/NE/0228).  
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5.2.2 Participants and Procedure 
All participants were adults recruited from either a dermatology clinic in Birmingham, where 
they were provided a web-link by the Principal Investigator during their clinical appointments 
or responded to an advert on social media platforms such as Facebook & Twitter, an online 
Qualtrics survey panel, or Aston University. All questionnaires were completed anonymously 
online on Qualtrics. After reading participant information (appendix 9) and completing an 
online consent form (appendix 10), participants  were presented with a socio-demographic 
questionnaire followed by validated psychometric measures assessing general quality of life 
(WHOQOL-BREF), psychological stress (PSS), anxiety, and depression (HADS). Participants 
with atopic dermatitis also completed a validated measure of disease severity (POEM) and 
AD related QoL (Skindex-29). All participants were asked whether they had clinically 
diagnosed AD or were otherwise healthy with no long-term conditions. Those with clinically 
diagnosed AD were asked questions surrounding their diagnosis, medication, disease 
duration, family history, as well as socio-demographic information. 
5.2.3 Measures 
Demographic and Atopic Dermatitis questionnaire 
Demographic information was collected, such as age, gender, occupation and ethnic 
background (appendix 11).  For adults with AD, information surrounding diagnosis, medication 
and family history was also collected. 
Skindex-29 
The Skindex-29, a questionnaire  developed to comprehensively assess the effects of skin 
disease on health-related quality of life, was created by Chren, Lasek, Quinn, Mostow, & 
Zyzanski, in 1996.This scale consists of 30 times of which 29 questions are assigned to three 
scales each scored separately. The scale also provides an overall score for quality of life and  
covers areas surrounding emotions, functioning, and symptoms. Each question assesses the 
impact of the skin condition on an individual’s quality of life over the previous week, with a 
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higher score related to a bigger impact of AD on life. The scale has good internal consistency 
and test-retest reliability (Cronbach’s alphas > .70) (Chren, 2012) This scale was completed 
by people with AD and the internal consistency for this study sample was high (Cronbach’s 
alpha=0.88).  
Patient Oriented Eczema Measure (POEM)  
The POEM (Charman, Venn, & Williams, 2004) is a measure that is used to subjectively 
assess disease severity in skin disease and focuses on the illness as experienced by the 
patient. PEOM is deemed suitable for use in clinical trials, epidemiological studies, outpatient 
clinic audit and is recommended by clinical guidelines including those issues by the National  
Institute for Health and Care Excellence (NICE).In order to assist clinicians and patients in 
understanding their POEM scores, five severity bandings have been established ranging from 
clear or almost clear to very severe disease; a higher score relates to more severe disease. 
Internal consistency for this scale is high (Cronbach alpha = 0.88), and test-retest reliability is 
also good , with 95% of scores falling within 2.6 points on repeat testing (mean score 
difference, 0.04; SD, 1.32) (Schmitt, Langan, & Williams, 2007). This scale was completed by 
people with AD and the internal consistency for this sample was high (Cronbach’s 
alpha=0.87). 
Perceived Stress Scale (PSS -14) 
The PSS-14 measures the extent to which situations in an individual’s life are appraised as 
stressful. . It was developed in 1983 (Cohen, Kamarck, & Mermelstein, 1983). It has been 
utilised in assessments of stressful situations, effectiveness of stress reducing interventions 
and exploration of associations between physical disorders and psychological stress. The 
scale has good reliability (Cronbach’s alpha = .78) (Lee, 2012).  PSS-14 consists of 14 items 
that are purported to form a unidimensional scale of global perceived stress and a higher score 
relates to greater distress. The PSS was completed by both AD and control groups and the 
internal consistency was high (Cronbach’s alpha= 0.79). 
128 
 
 Hospital Anxiety and Depression Scale (HADS)  
The HADS was originally developed in 1983 by Zigmond and Snaith and is a commonly used 
measure for determining levels of depression and anxiety that a patient is experiencing. It is a 
fourteen item questionnaire that yields ordinal data. Seven items relate to depression and 
seven relate to anxiety. . Each question on the scale is scored from 0-3 with a higher score 
relating to greater anxiety or depression.. Both subscales (anxiety and depression) have been 
found to be internally consistent, with values of Cronbach's coefficient (alpha) being 0.80 and 
0.76, respectively (Bjelland Dahl, Haug, & Neckelmann, 2002). The HADS internal 
consistency for this study sample was high for both anxiety and depression subscales (0.82 
and 0.75, respectively). This scale was completed by both the AD group and control group. 
World Health Organisation QoL Scale- Brief Version (WHOQoL BREF) 
The WHOQoL-BREF (Skevington, Lofty, & O’ Connell, 2004) is a 26-item QoL scale, using a 
1 to 5 Likert scale, which measured four major domains: physical, psychological, social 
relationships and environment. There are also two one-item questions, which look at overall 
quality of life and satisfaction with health. The scale has good reliability for physical health, 
environmental and psychological domains (alphas range from 0.80 to 0.82) but only marginally 
good for social relationships domain (0.68). The internal consistency for this study sample was 
high for all sub-scales, ranging from 0.78 to 0.84. This scale was completed by both the AD 
and healthy control groups. . 
5.2.4 Data Analyses 
Statistical analyses were conducted using SPSS for Windows (version 22, SPSS, Chicago, 
IL, USA). Tests were carried out to explore distribution of the data normality indicators included 
Box-plots, Kurtosis and Shpairo-Wilk test, These indicated 14 outliers in the data which are 
omitted from analysis; ; the data were normally distributed with no skewness. Post-hoc power 
calculations with alpha set to 0.05 were computed and showed the study to have 63% power 
to detect differences with medium effect sizes and 99.9% power to detect differences with 
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large effect sizes between the AD and healthy controls.  ANCOVAs, which controlled for 
differences in demographics, and t-tests were used to explore differences between groups, 
whereas Pearson’s correlations were used to detect relationships across variables for 
continuous data and chi-squared tests were used for categorical data. Predictors of quality of 
life were analysed using multiple regression which adheres by a number of assumptions 
including: a linear relationship between QoL and the independent variables, multivariate 
normality, homoscedasticity and no multicollinearity. All tests carried out were two-tailed and 
significance levels were set at p<0.05or p<0.01. Bivariate correlations were also conducted 
between disease severity and QoL in AD groups  
5.3 Results  
5.3.1 Participant characteristics  
There were 301 participants (56.5%) with AD, and 232 healthy controls (43.5%). No healthy 
controls had any long-term conditions including skin conditions, arthritis or diabetes. All 
participants with AD reported being clinically diagnosed with the condition. None of the AD 
participants reported any long-term physical health conditions such as arthritis or diabetes. 
The participant sample consisted of 390 (73.2%) female and 143 (26.8%) males, 378 (70.9%) 
were White, 139 (25.9%) were Asian, and 17 (3.2%) were Black. The majority of participants 
were aged between 25-39 (N=262, 49.2%), 131 (24.6%) participants were aged between 18-
24, 124 (23.3%) were aged between 40 and 60, and 14 (2.6%) were aged 61 and above. In 
the AD group, 43 participants (14.3%) had been recruited via the dermatology clinic, and 258 
participants (85.7%) using social media and Qualtrics panel. There were no significant 
differences in socio-demographic characteristics,  QoL, anxiety, depression or stress between 








Table 5.1 Participant characteristics [n(%)] 
 AD  Control Total 
Total 301 (56.5%) 232 (43.5%) 533 (100%) 
Females 221(73.4%) 169 (72.8%) 390 (73.2%) 
Males 80(26.6%) 63 (27.2%) 143 (26.8%) 
White 178(59.1%) 200 (86.2%) 378 (70.9%) 
Asian 115(38.2%) 23 (9.9%) 139 (25.9%) 
Black 8 (2.7%) 9 (3.9%) 17 (3.2%) 
18-24 78 (25.9%) 53 (22.8%) 131 (24.6%) 
25-39 162 (53.8%) 100 (43.1%) 262 (49.2%) 
40-60 55 (18.3%) 69 (29.7%) 124 (23.3%) 
61+ 5 (1.7%) 9 (3.9%) 14 (2.6%) 
GP diagnosis 174 (32.6%)     
Dermatologist diagnosis 110 (20.6%)     
Paediatrician diagnosis 17 (3.2%)     
Family History 158 (52.5%)     
Child Diagnosis 132 (44%)     
Adolescent diagnosis 81 (27%)     
Adult diagnosis 87 (29%)     
Allergies 145 (48.2%)     
Asthma 140 (46.5%)     
Topical Corticosteroids 162 (53.8%)     
Emollients 139.00 (46.20%)     
Dupilumab 10.00 (3.30%)     
Calcineurin Inhibitors 34.00 (11.30%)     
Oral Corticosteroids 33.00 (11.00%)     
Antibiotics 20.00 (6.60%)   
 
When comparing socio-demographic characteristics, there were no significant differences 
across AD and control groups for occupation and gender. There were also no significant 
clinical and demographic differences in AD participants recruited from the dermatology clinics 
compared to the general population. There were however more participants aged 25-39 in the 
AD group (55%) compared to the control group (43%), x2(3) =13.47, p=0.004. There were also 
significantly more White participants in the control group (86.2%) compared to the AD group 
(59.1%), and more Asian/Indian participants in the AD group (38.2%) compared to the control 
group (9.9%) x2(2)=54.65 p<0.001. Therefore, all analyses comparing groups controlled for 




5.3.2 Differences in Quality of life, Stress, Anxiety and Depression between healthy 
controls and atopic dermatitis groups  
The first set of analyses looked at differences between the healthy control group and atopic 
dermatitis group (table 5.2). There were statistically significant differences between AD 
participants and controls for physical QoL (F(1, 533)= 2.27, p<0.001 and 𝜂2𝑝= 0.05), overall 
health-related QoL (F(1,533)=26.72, p<0.001, 𝜂2𝑝=0.04)., and anxiety (F(1,533)=6.51, 
p=0.01, 𝜂2𝑝=0.01); those with AD reported lower QoL in these domains and higher anxiety 
compared to healthy control groups. There were no significant differences between both 
groups for environmental QoL, psychological QoL, social QoL, overall QoL, depression and 
stress.  
Table 5.2 Quality of life, anxiety, depression and stress means scores (standard deviations) 
for adults with and without atopic dermatitis 
 AD group  
M(SD) 
Control group  
M(SD) 
WHOQOL-BREF   
Overall QoL 3.32 (1.03) 3.37 (1.02) 
Overall Health-related QoL 2.83 (1.14)** 3.32 (1.01)** 
Physical QoL 12.1 (2.84)** 13.56 (3.19)** 
Psychological QoL 11.6 (3.12) 12.14 (3.62) 
Social QoL 12.71 (4.08) 13.41 (3.79) 
Environmental QoL 13.28 (2.92) 13.22 (3.1) 
Perceived Stress Scale 29.84 (7.19) 28.49 (8.11) 
HADS anxiety 11.17 (4.09)* 10.29 (4.84)* 
HADS depression  8.66 (3.84) 8.66 (4.21) 
** p<0.001, *p<0.05 
5.3.3 Predictors of QoL in AD patients 
In participants with AD, poorer overall QoL, health-related QoL, physical, psychological, social 
QoL, greater stress, anxiety, depression and disease severity were significantly related with 






Table 5.3. Pearson’s correlations between atopic dermatitis specific quality of life, stress and 
mental health in AD groups 






PSS 0.36** 0.39** 0.32** 0.29** 
HAD-A 0.34** 0.31** 0.36** 0.25** 
HAD-D 0.24** 0.20** 0.32** 0.07 
POEM 0.68** 0.65** 0.58** 0.74** 
Overall QoL -0.18** -0.17* -0.22** 0.08 
HRQoL -0.33** -0.33** -0.26** -0.34** 
Physical -0.38** -0.38** -0.37** -0.29** 
Psychological -0.32** -0.35** -0.28** -0.21** 
Social -0.16* -0.19** -0.16* -0.08 
Environmental -0.08 -0.09 -0.08 -0.03 
* Correlation is significant at the 0.05 (2- tailed), ** correlations significant at the 0.001 level 
(2-tailed)  
 
Socio-demographic variables, mental health variables and quality of life were entered into a 
multiple regression model to explore the extent to which they predicted QoL measured using 
Skindex-29. Demographic characteristics such as age, gender, and ethnicity as well as 
characteristics related to AD such as concomitant conditions, medication, family history and 
age of diagnosis were entered first and explained 23.7%  (R 2  = 0.23, adj R2=0.15)   of the 
variance in QoL (F(26,248)= 2.96, p<0.001). This model was significant however only the 
presence of allergies, asthma, and oral cortico-steroid medication significantly predicted QoL. 
Corticosteroid medication contributed the most towards QoL in this model.  
The addition of anxiety, depression, stress, overall QoL, health-related QoL, physical, social, 
environmental and psychological QoL explained a further 19% (R2 =0.42, adj R2=0.34) 
variance in QoL (F(35,296)=11.79, p<0.001). The regression model was significant however 
only physical QoL, environmental QoL and stress significantly predicted AD-specific QoL. In 
this model, environmental QoL was the most important predictor of skin-related QoL. 
The final model with the addition of AD severity, predicted a further 17.9% (R2 = 0.61, adj 
R2=0.54) of variance in QoL (F(25,296)= 0.95, p<0.001) This model was significant, with 
physical QoL, environmental QoL, stress and AD severity predicting skin-related QoL . In this 




Table 5.4 Predictors of atopic dermatitis specific quality of life in adults with AD 
 Unstandardized 
β 
Standardised β 95% CI 
Lower Upper 
Model 1 
Gender  0.12 0.06 -0.11 0.34 
Topical corticosteroids 0.06 0.06 -0.07 0.19 
Emollients 0.03 0.02 -0.17 0.23 
Antihistamines -0.13 -0.05 -0.49 0.24 
Immunosuppressants -0.20 -0.07 -0.59 0.18 
Oral corticosteroids 0.46 0.17* 0.09 0.84 
Sedating antihistamines -0.09 -0.03 -0.66 0.47 
Antibiotics 0.33 0.10 -0.18 0.85 
Dupilumab 0.14 0.03 -0.46 0.74 
Calcineurin inhibitors 0.19 0.07 -0.19 0.57 
Diagnosis  0.05 0.03 -0.16 0.26 
Allergy -0.23 -0.14* -0.44 -0.03 
Asthma 0.26 0.15* 0.05 0.46 
Food allergy  0.17 0.09 -0.07 0.41 
Ethnicity  0.36 0.21 0.10 0.62 
Age 0.09 -0.01 -0.26 0.23 
Family history -0.03 -0.02 -0.23 0.17 
Model 2 
Gender  0.08 0.04 -0.13 0.28 
Topical corticosteroids 0.06 0.06 -0.05 0.17 
Emollients 0.05 0.03 -0.13 0.24 
Antihistamines -0.13 -0.05 -0.46 0.20 
Immunosuppressants -0.27 -0.10 -0.63 0.08 
Oral corticosteroids 0.36 0.13 0.02 0.71 
Sedating antihistamines 0.01 0.00 -0.50 0.52 
Antibiotics 0.34 0.10 -0.12 0.81 
Dupilumab 0.10 0.02 -0.44 0.63 
Calcineurin inhibitors 0.20 0.07 -0.14 0.54 
Diagnosis  0.06 0.03 -0.14 0.24 
Allergy -0.17 -0.10 -0.36 0.01 
Asthma 0.27 0.16 0.08 0.45 
Food allergy 0.06 0.03 -0.15 0.28 
Ethnicity  0.12 0.07 -0.14 0.39 
Age 0.12 0.07 -0.10 0.35 
Family history -0.01 -0.01 -0.20 0.19 
Stress 0.02 0.15* 0.00 0.04 
Anxiety 0.03 0.14 0.00 0.06 
Depression 0.03 0.12 -0.01 0.07 
Physical QoL -0.07 -0.24** -0.12 -0.03 
Psychological QoL -0.02 -0.06 -0.07 0.04 
Social QoL -0.01 -0.06 -0.04 0.02 
Environmental QoL 0.09 0.30*** 0.04 0.14 
Overall QoL 0.10 0.11 -0.02 0.21 
Health-related QoL -0.07 -0.09 -0.18 0.05 
Model 3 
Gender  0.02 0.01 -0.15 0.19 
Topical corticosteroids 0.02 0.02 -0.08 0.11 
Emollients 0.07 0.04 -0.08 0.22 
Antihistamines -0.04 -0.02 -0.32 0.23 
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Immunosuppressants -0.19 -0.07 -0.49 0.11 
Oral corticosteroids 0.20 0.07 -0.09 0.49 
Sedating antihistamines -0.19 -0.05 -0.62 0.23 
Antibiotics 0.19 0.06 -0.19 0.58 
Dupilumab 0.14 0.03 -0.31 0.59 
Calcineurin inhibitors 0.09 0.03 -0.20 0.37 
Diagnosis  0.10 0.06 -0.06 0.26 
 Allergy -0.19 -0.11 -0.34 -0.03 
Asthma 0.06 0.04 -0.10 0.22 
Food allergy 0.11 0.06 -0.07 0.29 
Ethnicity  0.09 0.05 -0.13 0.31 
Age 0.20 0.11 0.01 0.38 
Family history 0.06 0.03 -0.10 0.22 
Stress 0.02 0.13* 0.00 0.03 
Anxiety 0.02 0.09 -0.01 0.04 
Depression 0.01 0.03 -0.02 0.04 
Physical QoL -0.06 -0.21** -0.11 -0.02 
Psychological QoL -0.03 -0.10 -0.07 0.01 
Social QoL -0.01 -0.05 -0.03 0.01 
Environmental QoL 0.06 0.20** 0.02 0.10 
Overall QoL 0.07 0.09 -0.02 0.17 
Health-related QoL 0.04 0.05 -0.06 0.13 
Disease severity  0.07 0.53*** 0.06 0.08 
*p<0.05, **p<0.01, ***p<0.001 
 
Further analyses were conducted with each of the Skindex subscales- psychosocial 
functioning, emotions, and symptoms- as outcome variables. Disease severity and Physical 
QoL significantly explained 31% (R 2 = 0.62, adj R2=0.57) % of the variance in AD Symptoms 
(F(35, 296)= 12.13, p<0.001), as measured by Skindex-29. Depression, disease severity, 
physical QoL, and environmental QoL significantly explained 33% ((R2= 0.54, adj R2=0.48) of 
the variance in psychosocial functioning (F(35,296)=8.73, p<0.001). Finally, disease severity, 
physical QoL, psychological QoL, and environmental QoL explained 34% ((R 2  = 0.57, adj 
R2=0.51) of the variance in the Emotions sub-scale. Disease severity was the most important 
predictor of QoL scores for both the symptoms and emotions sub-scales (Standardised β= 0.6 
and 0.51, respectively). 
5.3.4 Differences in socio-demographic and atopic dermatitis characteristics 
 For the following analyses, in order to address the likelihood of type 1 errors, a stringent 
significance value of 0.01 was adopted instead of 0.05. Quality of life in this section is 
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measured using the Skindex instrument. There was a statistically significant difference 
between severity of AD and skin-related QoL (F(4,296)= 59.23, p<0.001) with post-hoc tests 
illustrating that this difference lay between all five categories of the POEM index; clear, mild, 
moderate, severe, very severe and QoL. Those with clear AD (M=1.7, SD=0.65) reported 
significantly better QoL compared to those with mild AD (M=2.4, SD=0.7), moderate AD 
(M=3.0, SD=0.64), severe AD (M=3.69, SD=0.57) and very severe AD (M=4.14, SD=0.88).  
 Socio-demographic and atopic dermatitis specific differences were sought for disease 
severity, anxiety, depression, stress and QoL; only significant findings have been reported in 
this section. Those with asthma reported significantly higher AD severity levels than those 
without asthma (t(275)=-5.38, p<0.001). They also reported significantly lower QoL than those 
without asthma (t(275)=-3.74, p<0.001). Participants who suffered from food allergy alongside 
their AD also reported poorer QoL compared to those who didn’t (t(299)=-3.75, p<0.001), and 
higher self-reported AD severity compared to those who reported not suffering from food 
allergies (t(299)=-3.58 p<0.001). Table 5.5 reports means and standard deviations for the 
significant differences detailed in this section.  
There was a significant difference between age of diagnosis and disease severity, whereby 
those diagnosed as children had higher severity of AD than those diagnosed as an adolescent 
or adult (f(2,297)=8.91, p<0.001). Post-hoc tests showed that the difference lay between 
diagnosis as a  child and adult (p<0.001). There were no significant differences between being 
diagnosed as child, adolescent or adult and QoL, stress, anxiety or depression.  
When exploring the type of medication taken by AD patients, those on topical corticosteroids 
reported significantly lower QoL (t(295)= -4.05, p(0.001) and higher disease severity (t(295)=-
5.89, p<0.01) than those who reported not taking topical corticosteroids. Additionally those 
who took antihistamines also reported lower QoL (t(296)=-2.08, p=0.009) and higher AD 
severity (t(296)=-2.75, p=0.006)  compared to those who did not. Similarly AD participants 
who were prescribed immunosuppressant medication also reported lower QoL (t(296)=-2.56, 
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p=0.01) and higher disease severity (t(296)=-3.052, p=0.002) compared to those who did not.  
Participants who were prescribed oral corticosteroids also reported lower QoL (t(296)=-5.401, 
p<0.001) and higher disease severity (t(296)=-5.72, p<0.001).  compared to those who were 
not.  
Those who took medication to help them sleep also reported lower QoL (t(296)=-2.64, 
p=0.009) and higher disease severity  (t(296)=-4.103, p<0.001) compared to those who were 
not prescribed this medication. Participants on Dupilumab reported lower QoL (t(296)=-2.164, 
p=0.004)  compared to those not prescribed this medication. Finally, those on calcineurin 
inhibitors reported lower QoL (t(296)=-3.64, p=0.001)  and higher severity (t(296)=-3.65, 
p<0.001) compared to those not on this medication.  
There was a significant difference between ethnic groups for severity, depression, and QoL. 
Asians reported higher disease severity (F(2,298)=5.2, p=0.006), compared to White  and 
Black  participants. Asian participants also reported lower QoL(F(2,298)=7.04, =0.001) 
compared to White and Black  participants.  White participants reported higher depression 
levels (F(2,298)=3.52, p=0.001) compared to Asian and Black participants.  
When exploring gender differences, female participants reported significantly higher AD 
severity (t(299)=-2.7, p=0.007), and lower QoL (t(299)=-2.81, p=0.005) compared to males. 
However males reported higher depression levels compared to females  (t(299)=2.16, 
p=0.002). Participants who were not currently under the supervision of a dermatologist 
reported significantly better QoL compared to those who were. Finally, there was also a 
significant negative relationship between stress and age, whereby increasing age was related 










Table 5.5 Mean scores with standard deviations for differences between socio-demographic 
groups and AD specific characteristics.  
 White [M(SD)] Asian [M(SD)] Black [M(SD)] 
AD Severity 15.52 (6.28) 18.67 (8.46) 12.75 (8.32) 
QoL 3.21 (0.85) 3.54 (0.84) 2.75 (1.11) 
Depression 9.11 (3.65) 7.92 (4.02) 7.80 (4.23) 
 Female [M(SD)] Male [M(SD)]  
AD Severity 16.93 (6.82) 14.58 (6.25)  
QoL 3.40 (0.86) 3.01 (0.86)  
Depression 8.35 (4.01) 9.45 (3.23)  
Differences between groups for quality of life 
 Yes [M(SD)] No [M(SD)]  
Antihistamines 3.60 (0.83) 3.20 (0.86)  
Asthma 3.46 (0.81) 3.09 (0.87)  
Calcineurin Inhibitors 3.76 (0.73) 3.26 (0.86)  
Dupilumab 3.91 (0.31) 3.30 (0.87)  
Food Allergy 3.59 (0.82) 3.26 (0.87)  
Immunosuppressants 3.67 (0.84) 3.27 (0.86)  
Oral Corticosteroid 4.06 (0.62) 3.23 (0.85)  
Sedating Antihistamine 3.80 (0.73) 3.28 (0.87)  
Topical Corticosteroids 3.50 (0.90) 3.10 (0.77)  
Differences between groups for disease severity 
 Yes [M(SD)] No [M(SD)]  
Antihistamines 19.11 (6.66) 15.88 (6.66)  
Asthma 18.02 (6.39) 13.91 (6.33)  
Calcineurin Inhibitors 20.17 (5.01) 15.78 (6.77)  
Children Diagnosis 17.90 (6.8) 14.32 (6.26)  
Corticosteroids 13.88 (5.96) 18.88 (6.73)  
Food Allergy 18.32 (6.92) 15.39 (6.47)  
Immunosuppressants 19.60 (6.73) 15.86 (6.63)  
Oral Corticosteroids 22.30 (4.75) 15.53 (6.58)  
Sedating Antihistamine 21.95 (5.54) 15.86 (6.63)  
 
5.4 Discussion 
Measurement of QoL has drawn a lot of attention recently in patients with chronic skin 
diseases. Both health care professionals and researchers have attempted to evaluate the QoL 
of patients with AD using various methods, with many studies showing that patients with AD 
experience severe impairment in their QoL and emotional well-being compared with a healthy 
general population (Lundberg et al., 2000, Maksomoc et al., 2002; Holm et al., 2006). 
It is not surprising that AD has a great impact on HRQoL because of the chronic clinical course 
of the disease. Since it has no definitive cure, patients with AD suffer not only from the 
138 
 
symptoms caused by the disease itself, but also from a high and life-long psychosocial and 
economic burden (Hay et al., 2014; Dalgard et al., 2015; Blome et al., 2016). 
This study investigated the association of AD with HRQoL and several psychological variables 
in adults living in UK. Adults with AD reported lower physical and health-related quality of life 
compared to healthy controls. These findings are in line with the systematic review and meta-
analysis reported in chapter 3, that explored QoL in adults with AD and found that all studies 
included in the review reported lower QoL in AD patients compared to healthy controls (Birdi, 
Cooke, & Knibb, 2020). Physical QoL may be affected to a greater extent due to the physical 
discomfort and pain that arises as a result of AD (Mozzafari et al., 2007; Vakharia et al., 2017). 
However, when using generic QoL measures such as the SF-36, physical QoL is affected to 
a lesser extent compared to mental QoL (De Korte  Mombers, Bos, & Sprangers, 2004). This 
may be due to generic measures not being sensitive enough to measure the physical 
limitations of AD e.g. questions relating to walking abilities are unlikely to be relevant to an AD 
group (chapter 3; Birdi, Cooke, & Knibb, 2020). A number of studies have also used 
dermatology-specific measures such as the DLQI to compare QoL in AD patients and healthy 
controls (e.g. Mozzafari et al., 2007; Linnet & Jemec, 1999; Noh et al., 2013; Silverberg et al., 
2018). The DLQI is a dermatology specific questionnaire with questions that are not suitable 
for use in a sample of the general population. In a critical review of dermatology specific and 
generic HRQOL measures in dermatology, the WHOQOL-bref has been deemed a promising 
generic measure (Both et al., 2007) above and beyond other measures such as SF-36.  
 This study also found that AD patients reported higher levels of anxiety compared to healthy 
controls, but no significant differences were found between the two groups for stress and 
depression. The incidence of mental health issues among dermatological patients has been 
found to be approximately between 30% and 40% (Ghosh, Behere, Sharma, & Sreejayan, 
2013). Most frequent symptoms reported as a basis for distress and anxiety are disfigurement 
and itching causing significant insomnia, and sleep deprivation leading to fatigue, mood 
lability, impaired functioning and suicide in a few cases (Gilchrest , 1982). Furthermore, 
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frequent bullying and embarrassment due to disfigurement leads to social stigma and social 
isolation.  Disfigurement caused by AD can lower patients’ self-esteem, in turn increasing the 
propensity to suffer from anxiety and depression (Nyugen, Koo, & Cordoro, 2016; Wittkowski, 
Richards, Griffiths & Main, 2004). However, many studies, like this study, report conflicted 
findings when exploring anxiety and depression in AD patients  (Slattery & Essex, 2011; 
Thyssen et al., 2018; Whiteley, Emir, Seitzman, & Makinson, 2016;).It is likely that the 
combination of social isolation, anxiety, depression and disease severity forms a vicious cycle 
in those with AD (Oh et al., 2010) The inconsistency in findings between AD and depression 
and anxiety disorders may be due to the various study methodologies including varying 
anxiety/depression scales and limitations in previous studies including the use of non-
validated symptom questionnaire instead of validated measures. Furthermore, many of the 
studies mentioned above did not adjust for atopic comorbidities and demographic 
characteristics in their analyses.  
Disease severity was associated with stress, anxiety, depression and QoL, such that more 
severe AD was related to higher stress, anxiety, depression and QoL. Disease severity also 
significantly predicted QoL even after controlling for demographic characteristics and AD-
specific characteristics. This finding is consistent with the systematic review in chapter three 
which found that higher disease severity was significantly related to poorer QoL in the majority 
of the studies. The studies in the review were largely based on small sample sizes and 
recruited through dermatology clinics only. This larger-scale study recruiting from both 
dermatology clinics and general population using POEM to assess disease severity, the 
preferred core tool for assessing patient-reported symptoms in AD trials (Chalmers et al., 
2016; Spuls et al., 2016), adds further support to this finding. Severe AD can decrease sexual 
desire, affect interpersonal relationships, reduce work productivity and affect leisure and social 
activities( as was found and discussed in chapter 3). Those affected by AD are more restless 
in their sleep, wake more often, spend less time asleep and report daytime fatigue (Jafferany, 
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2007; Picardi, Mazzotti & Pasquini, 2006). These factors offer potential explanation for the 
relationship between disease severity and psychological health.   
Although psychological variables and disease severity predicted quality of life to a greater 
degree than socio-demographic variables, the impact of clinical and psychological variables 
on AD need to be explored in greater detail. Some earlier explorations have ascertained that 
psychological factors are correlated with clinical manifestations in AD  (Badia, Mascaro, & 
Lozano, 1999; Eun & Finlay, 1990; Linnet & Jemec, 1999) although they suffer from 
methodological issues including the lack of reliable and valid clinical measures of QoL and AD 
severity in addition to the use of aggregated scores from AD samples (Badia, Mascaro & 
Lozano, 1999; Eun & Finlay, 1990). WHOQoL-BREF was included as a QoL measure in the 
regression model to predict skin-related QoL due to the different aspects of an individual’s 
daily life being explored by both these measures; the generic measure focuses on general 
daily life activities that are applicable to the majority of a population, whereas the Skindex is 
primarily focused on the impact of living with skin conditions. This study found that 
corticosteroid use was a significant predictor of QoL even after controlling for psychological 
and demographic variables. Although not reported before, it is not surprising as even short-
term administration of topical corticosteroid may interfere with collagen production and result 
in skin atrophy, hypopigmentation or secondary infection, especially with long-term use 
(Kang et al., 2001). Allergic sensitization also predicted QoL even after controlling for 
demographic and psychological variables, contrary to previous research that has found no 
significant influence of allergy on QoL in AD patients (Holm, Agner, Clausen, & Thomsen, 
2018).  
When exploring demographic and AD-specific characteristics, this study found that those 
diagnosed as children and adolescents reported higher disease severity than those diagnosed 
as adults. This may imply that factors earlier on in patients’ lives had a long-lasting impact on 
their disease severity (Ben-Gashir, Seed, & Hay, 2004). Follow-up studies are needed to 
measure the association over a longer period. Participants in this study prescribed topical/ oral 
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corticosteroids, antihistamines, immunosuppressants, sedating antihistamines, antibiotics, 
dupilumab, and/or calcineurin inhibitors to manage their AD reported lower QoL and higher 
disease severity compared to those who were not on these medications. These is a notable 
lack of exploration of the impact that standard therapy has on participant QoL in AD. Charman, 
Chambers, and Williams (2003) conducted a systematic database search and found that 
quality of life was assessed in only three clinical trials. As there is no remedy available that 
can cure AD and repeated treatments are necessary to achieve a stable and convenient skin 
condition, the most important factor to the patient, however, is the question ‘which treatment 
improves the individual’s quality of life the best?’ (Schiffner et al., 2003). One can assume that 
the use of different medications should have lowered disease severity in participants in this 
study, however in this study, medication was related to worse AD severity. Many factors such 
as side effects, length of time taking the medication (‘treatment hopping’), and strength of 
medication could explain why those taking these medications reported increased disease 
severity (Hoare, Li,  & Williams, 2000; Schiffner et al., 2003).  
This study found increased disease severity and lower QoL in Asian participants compared to 
White and Black participants. This finding has been reflected in previous literature where 
Asians tend to present more severe skin symptoms such as lichenification (thickening of the 
skin) compared to Whites (Leung, 2015; Noda et al., 2015) and are at higher risk for 
developing post-inflammatory dyspigmentation (Alexis, 2007; Alexis, 2014). 
Hyperpigmentation of the skin is often more visible in black and minority ethnic patients as a 
result of the contrast with normal skin tone (Child et al., 1999; Ortonne, 2008) Often, the 
resulting dyspigmentation may be more distressing than the skin findings of AD itself.  The 
use of common disease severity scales such as SCORAD and EASI that rely on the 
measurement of skin plaques (erythema) dramatically underestimate the severity of AD in 
darker skin types (Ben-Gashir, 2002; Vachimaron et al., 2012). This study also found that 
White participants scored higher on the depression scale compared to ethnic minority groups. 
This is a finding that has not been reflected or explored in the past, but White adults have 
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been found to be more willing to report suffering from depressive symptoms compared to their 
minority-ethnic counterparts (Alergria et al., 2008; Sidney et al., 2011; Young et al., 2001).  
Females in this study also reported higher disease severity and lower QoL compared to males. 
This finding is in line with Holm et al (2004) who found that QoL in women are impacted more 
than men as a result of AD lesions located in visible areas of the body. It can be speculated 
that women have a higher culturally determined ideal of physical appearances compared to 
men and as a result pay more attention to their skin, therefore increasing the sensitivity of self-
reported skin involvement. Males in this study however, reported higher levels of depression 
compared to females. This is contrary to a gender-specific association with AD and depression 
suggested by Timonen et al. (2003) where biological factors may explain higher rates of 
depression in females than males. The majority of adults with AD in this study were aged 
between 25-39 and the severity of AD tended to decrease with age.. This is a finding in line 
with other studies on age-related changes in the severity of AD which appear to decrease with 
age (Harrop et al., 2007; Kim et al., 2015). Nonetheless, as skin-barrier function often does 
not recover with age in genetic AD, its’ symptoms persist  up until adulthood (Cork et al., 2009) 
reinforcing the fact that adults with AD need regular life-long monitoring. 
5.4.1 Strengths and limitations 
This study has a number of strengths. Firstly, it is the largest population based study on adults 
with AD in the UK to date. The use of a culturally diverse sample and adjusting for a number 
of socio-demographic factors, as well as using a number of recruitment techniques, enabled 
generalisation of the findings in the UK population, unlike the majority of current studies which 
recruit primarily using dermatology clinics. A survey conducted in Nottingham found that only 
6% of patients with AD were referred for specialist advice in a 12 month period, the exact 
reasons for referral were not reported (Emerson, Williams, & Allen, 1998). Only cases of 
severe or difficult AD are often referred to a dermatologist where there is a  lack of adequate 
progress despite use of adequate quantities of emollients/topical steroid preparations 
according to NICE. More recently, Schofield, Grindlay, and Williams (2009) found that GPs 
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only refer approximately 6.1 % of the dermatological cases they see to secondary care. 
Considering the above, it is important to use recruitment strategies above and beyond 
dermatology clinics and this is one of the very few studies that utilises other means of 
recruitment to complement dermatology clinics. Future work should aim to include participants 
recruited through a variety of platforms, such as social media, to ensure that a generalisable 
group of participants has been studied and adults with wider-ranging AD can take part in such 
studies. As mentioned above, this study used well-validated assessments of AD severity and 
controlled for multiple confounding variables in multivariate models.   POEM, WHOQoL-BREF, 
HADS, PSS and Skindex   have been found to have excellent  overall face validity, construct 
validity, internal consistency, reliability and/or responsiveness. Additionally POEM is the 
preferred assessment of AD symptoms for clinical trials by the Harmonising Outcome 
Measures in Eczema group (Chalmers et al., 2014; Coutanceau & Stalder, 2014; Heinl et al., 
2017; Vakharia et al., 2018), and this study used Skindex as opposed to DLQI- the more 
commonly used QoL instrument- for a number of reasons. Skindex-29 has better sensitivity to 
clinical severity with minimal floor effect (Fernandez-Penaz et al., 2012,  higher rating of skin 
involvement than using the DLQI (Wervers et al., 2017) and of  the  dermatology-specific  
HRQOL  tools,  it has been deemed the most optimal available instrument (Both et al., 2007).  
This study has some also has some limitations, such as the use of surveys, which may be 
subject to false answers, giving the same answer repeatedly and receiving multiple surveys 
completed by the same responder (Silverberg, 2018). These however were not thought to be 
major concerns, given that less than 1% of surveys had the same responses for all the 
questions, and over 90% of surveys took 10 minutes or longer to complete. Additionally,  this 
study relied on self-reporting of AD diagnosis, and although relevant questions that assessed 
symptoms, diagnosis and clinical characteristics were asked, there may have been a number 
of participants in the study who were not clinically diagnosed with the condition. Given the 
cross‐sectional design of the study, it is difficult to ascertain the directionality of the 
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associations observed, although these relationships may be bidirectional. Future studies are 
warranted to address these points. 
5.5 Conclusion and directions for future research  
This study found that the severity of AD is significantly related to poorer QoL and mental health 
in a large UK sample. More severe AD was associated with worse mental health and QoL. 
The findings of this study emphasize the importance of the incorporation of mental health 
symptoms and QoL in clinical practice in order to determine disease burden and identify 
patients with anxiety and/or depression alongside their AD. Additionally, as some groups 
appear to be more affected psychologically due to their condition, psychological and 
















Chapter six: A prospective feasibility analysis of the relationship between 
psychological stress and atopic dermatitis  
6.1 Introduction  
This chapter presents findings of a longitudinal feasibility study exploring the relationship 
between psychological stress and AD severity in adults. As mentioned in the introduction 
chapter and elsewhere, AD severity and psychological stress appear to form a vicious cycle 
(Hashizume & Takigawa, 2006). Nonetheless, it remains unclear how stress affects AD. The 
hypothalamic-pituitary-adrenal (HPA) axis is found to be stimulated by psychological stress, 
which influences the development and progression of AD, causes epidermal barrier 
dysfunction, and lowers the itch threshold (Arndt, Smith, & Tausk, 2008).  
Numerous studies have found that the severity of AD and psychological stress are related. 
Early evidence for the this relationship suggested that the emotional stress related to a major 
life event is associated with the development of AD symptoms (Brown, 1972; Greenhill & 
Finesinger, 1942; Lammintausta, Kalimo, & Raitala, 1991; Wittkower & Russel, 1953). These 
studies however used interviews or validated questionnaires to assess psychological stress, 
which included parental divorce, family problems during childhood or death of a loved one. 
These findings should be interpreted with caution however due to lack of accuracy of 
individuals’ ability to recall childhood events or the time at which these events occurred may 
be too unreliable for accurate data to be obtained.  
Psychological stress is known to affect the immune and neuroendocrine systems, which are 
responsible for releasing hormones that regulate numerous systems such as heart rate, 
digestion, blood pressure and respiration (Ardnt, Smith, & Tausk, 2008). The skin barrier 
function is also negatively affected by psychological stress, which in turn could give rise to 
increased loss of moisture from the skin and susceptibility to infection. A compromised skin 
barrier is prevalent in those with AD as a result to reduced amount of the protein filaggrin, 
which plays an important role in the formation and structure of skin layers. Psychological stress 
146 
 
in AD patients may further reduce the skin’s ability to retain water and keep bacteria out (Arndt, 
Smith, & Tausk, 2008) Additionally living with a long-term condition such as AD can induce 
psychological stress and negatively impact QoL. Psychological stress is also one of the most 
commonly reported mental health issue by AD patients although little is known about how it 
contributes to the exacerbation of AD. 
Several cross-sectional studies illustrate significant relationships between psychological 
stress and disease severity in AD  (Kimyai-Asadi & Usman, 2001; Oh et al., 2010; Picardi & 
Abeni, 2001; Wright, 2005). Although these studies are cross-sectional, most report that 
psychological stress exacerbates AD, with patients experiencing a worsening of symptoms 
following exposure to stress  (Buske-Kirschbaum, Geiben, Hölligm, Morschhäuser, & 
Hellhammer, 2002; Hashizume & Takigawa, 2006; Kimata, 2003). This association has been 
well established in children and adolescents however there are a lack of population-based 
studies focusing on adults (Simpson, 2012; Silverberg & Hanifin, 2013).  
There is only one known published study (King & Wilson, 1991) that examined the relationship 
between stress and AD longitudinally. The authors found that interpersonal stress on day X 
significantly predicted severity of AD on day X+1 using lag-sequential analyses. This 
relationship was reciprocal as AD severity on day X also indicated stress level on day X+1. A 
diary technique was used in this fortnight long study of 50 participants. This chapter builds on 
King and Wilson (1991)’s findings by incorporating daily diary measures which may be too 
sensitive to detect changes, with weekly validated and robust psychometric measures of 
mental health and disease severity. Additionally, unlike this study, King and Wilson recruited 
through dermatology clinics only, which may result in stress and disease severity scores that 
are not generalizable to the majority of adults with AD living in the UK (Schofield, Grindlay, & 
Williams, 2009).Additionally, measuring psychological stress for two weeks may not be 
sufficient to detect changes in disease severity, as opposed to measuring this over a longer 
period of time as is the case in this study.  
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Notably, AD patients may suffer from increased stress levels as a result of the chronic 
condition or due to social skill deficit (Buske-Kirschbaum et al., 2004). The contribution of 
psychosocial stress in both maintaining and exacerbating AD is also emphasised by the 
effectiveness of psychotherapeutic interventions that incorporate relaxation techniques or 
stress management, which have led to significant improvement of AD symptoms (Chida, 
Steptoe, Hirakawa, Sudo, & Kubo, 2007). 
A consistent finding is that psychosocial stress and skin condition in AD appear to be highly 
related (Buske-Kirschbaum, Geiben & Hellhammer, 2001; Chida, Hamer, & Steptoe, 2008). 
Stressful situations are often accompanied by exacerbation of AD symptoms; however, 
worsening of skin condition may also elicit higher levels of psychological stress. Consequently, 
a vicious circle of emotional stress and skin condition can be initiated (Buske-Kirschbaum, 
Geiben, & Hellhammer, 2001; Senra & Wollenberg, 2014). Exploring this direction of 
psychological stress and AD further is needed as most existing research on psychological 
stress and AD in adults is cross-sectional, thus warranting the need for a longitudinal 
approach. 
Using a prospective design, it may be possible to overcome some of the limitations present in 
retrospective studies. Indeed, all studies focusing on AD, with the exception of King and 
Wilson (1991) ask participants to recall stressful events that happened in the past and this can 
range from a week to a year. Major stressful events may be better recalled, such as an 
earthquake (Kodama et al., 1999; Losiak, Blaut, Kłosowska, & Losiak-Pilch, 2019), however 
minor daily stressful events that could contribute to the exacerbation of AD may be forgotten 
with time when conducting a retrospective study with patients. Stress itself can interfere 
(Kuhlmann, Piel & Wolf, 2005). Costa, Zonderman, and McRae (1987) and Lida, Shrout, 
Laurenceau, and Bolger (2012) suggest the use of daily diaries to document AD symptoms in 
order to reduce retrospective recall bias. 
This feasibility study adheres to Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines (Elm et al., 2007). The STROBE Statement is a checklist 
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of 22 items that aids in the reporting of non-randomised pilot and feasibility studies (appendix 
12). The checklist compromises of 21 items which include the title, abstract, introduction, 
methods, results and discussion section. .  
The aims of this study were to: 
• assess the feasibility of a longitudinal approach using daily diaries 
• gauge how many adults with AD will complete diaries and measures for the 3 month duration 
and how many drop out of the study 
• explore the temporal relationship between psychological stress and  atopic dermatitis 
severity measured daily using diaries and weekly using validated psychometric instruments 
• explore the temporal relationship between psychological variables (anxiety and 
depression) measured weekly using validated psychometric instruments and disease 
severity  
6.2 Methods 
6.2.1 Study design  
This quantitative prospective study used validated measures of psychological variables and 
AD severity in AD patients completed weekly, in addition to daily stress and symptom diaries. 
The Life and Health Sciences Research Ethics Committee at Aston University granted the 
study ethical approval (appendix 13) prior to commencing data collection (application no. 
1428). All participants provided informed consent (appendix 14) before taking part. 
6.2.2 Participants  
Participants clinically diagnosed with atopic dermatitis, and aged 18 and above were all eligible 
for the study. Participants were recruited from October 2018 to December 2019, and a total of 





6.2.3 Measures  
Demographic and Atopic Dermatitis questionnaire 
Socio-demographic information was collected (appendix 15), such as age, gender, occupation 
and ethnic background including AD-specific information surrounding diagnosis, medication 
and family history. 
Patient Oriented Eczema Measure (POEM)  
The POEM (Charman, Venn, & Williams, 2004) is a subjective disease severity measure that 
is widely used in AD research. It focuses on the illness as experienced by the patient and has 
five severity bandings, with a higher score related to more severe disease. The POEM was 
completed by participants at the end of each week for 12 weeks and had high internal 
consistency for this sample (alpha=0.82) 
Perceived Stress Scale (PSS -14) 
The PSS-14 is a 14 item validated questionnaire developed in 1983 (Cohen, Kamarck, & 
Mermelstein, 1983)  that measures the degree to which one’s situations in life are appraised 
as stressful.. It is widely used in cross-sectional research and assessed the stressfulness of 
situations and the effectiveness of stress-alleviating interventions The PSS was completed at 
the end of each week for 12 weeks and had high internal consistency for this study 
(alpha=0.85).  
 Hospital Anxiety and Depression Scale (HADS)  
The HADS was originally developed by Zigmond and Snaith (1983) Is a commonly used 
psychometric measure to assess levels of anxiety and depression in patients. The HADS 
consists of fourteen items, seven of which relate to anxiety and 7 focus on depression. A 
higher score relates to greater anxiety or depression. The HADS internal consistency for this 
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study sample was high for both anxiety and depression subscales (0.82 and 0.75, 
respectively). This scale was completed once weekly for the 12 week period. 
Stress diary  
A modified version of King and Wilson (1991)’s diary was used. The diary consisted of a series 
of questions that assessed interpersonal stress. The diary was modified slightly and included 
a question on sleep (appendix 16), which has been identified in research as an issue for people 
with this condition (Kelsay, 2006; Chamlin et al., 2005). For those questions concerned with 
emotional reactions such as anger, participants rated their responses on a 3-point scale (0- 
no, 1- a little, 2- a lot). Secondly, participants were asked to state what AD related symptoms 
they have suffered from and rate the severity of their AD on a three-point scale (0- mild, 1-
moderate, 2-severe). Finally, participants were also asked to rate how well they slept the 
previous night on three-point scale (0- slept well, 1-somewhat, 2- not at all). Participants were 
asked to complete these diaries for one month, each night prior to retiring for sleep. These 
participants were instructed to avoid missing days when completing the diary, In order to avoid 
inaccurate recall at a later stage.  
6.2.4 Recruitment and Procedure 
Participants were recruited from Facebook through AD support groups. Participant information 
sheets, consent forms, diaries and questionnaires were posted to participants who responded 
to the study advert to their home addresses with pre-paid envelopes for participants to send 
back to the researcher. After reading participant information sheets (appendix 17) and 
completing written consent, participants completed the demographic questionnaire and 
validated psychometric measures at baseline. They then completed the daily measures and 
weekly measures for 12 weeks.  Participants were asked to join  a study-specific Facebook 
group where they were sent weekly reminders to complete the measures.  
6.2.5 Data Analyses 
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Statistical analyses were conducted using SPSS for Windows (version 23, SPSS, Chicago, 
IL, USA). Correlational analyses were conducted between AD severity and psychological 
variables for each week. Additionally, a cross-lagged panel model (CLPM) analysis was 
conducted to examine the ability of interpersonal stress to predict skin symptoms on the next 
day for each participant and vice-versa.  
6.3 Results 
6.3.1 Participant sample characteristics  
Thirty-six participants were initially recruited and sent study packs of which 21 participants 
returned study packs to the researcher. Nineteen participants out of 21 had no missing data 
(Figure 6.1). The researcher was unable to perform drop-out analyses as the 15 participants 
who did not complete the study did not send the study packs back to the researcher. Therefore, 
data from 19 participants have been analysed. All 19 participants were recruited through social 
media. All participants reported being clinically diagnosed with the condition and none of the 
participants reported any long-term physical health conditions such as arthritis or diabetes. 
The participant sample consisted of all females, 14 (73.7%) were White and 5 (26.3%) were 
Asian. An equal number of participants were aged between 25-39 (N=8, 42.3%) and 40-46 
(N=8, 42.3%), 3 (15.4%) participants were aged between 18-24.. Fifteen participants (N=15, 
78.9%) reported being diagnosed with AD by a dermatologist and four participants (N=4, 
21.1%) were diagnosed by their GP. Fifteen participants (N=15, 78.9%) reported family history 
of the condition. All 19 participants reported one or more concomitant atopic condition 
alongside their AD; 17 (89.5%) had hay fever, 14 (73.7%) reported asthma, and 11 (57.9%) 
reported suffering from food allergies. Eight (42.1%) reported suffering from all three 
conditions in addition to AD. There were no significant differences in age distributions, 


















Figure 6.1 Feasibility study recruitment flow chart  
6.3.2 Feasibility of the procedure 
The nineteen participants completed all measures and there were no missing data for the 
weekly or daily questionnaires. All but one of the participants completed the questionnaires 
without needing assistance/clarification. One participant wanted to clarify the time at which 
weekly questionnaires needed to be completed. Completion of the diaries required 
approximately five minutes a night, whereas completion of weekly questionnaires required 
approximately fifteen minutes to complete. Prior to participants being recruited, a study poll 
on Facebook suggested a high level of interest from members of an AD support group. All 
participants were recruited within a month through social media and communicated frequently 
Baseline  (n=36) 
Total participants included in the analysis 
(n=19) 
Total participants at 3 months (n=21) 
Incomplete data (n=2) 




with the researcher through this platform and via email. The study advertisement was posted 
on Facebook several times following the study poll.  
6.3.3 Weekly correlations and predictions between disease severity and psychological 
variables  
Mean disease severity, depression, stress and anxiety scores for each week were plotted on 
a line graph (figure 6.2) in addition to an illustration of one participant’s scores (figure 6.3).  
Although the figure does not show a clear pattern between disease severity and psychological 
variables, there were several significant correlations between the variables.  
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Figure 6.3 Weekly disease severity and psychological variable scores for one participant 
 
Pearson’s correlations were conducted for disease severity (POEM scores) and anxiety, 
depression and stress in the same week (Table 6.1).  There were significant positive 
correlations between disease severity and anxiety (r’s= 0.47-0.75), these correlations were 
medium to large for each week for the 12 weeks. Similarly, disease severity was significantly 
associated with depression for all 12 weeks apart from week 2; these correlations were also 
medium to large (rs=0.31-0.69). Psychological stress was also significantly correlated with 
disease severity for all 12 weeks, these correlations ranged from medium to large (rs=0.55-
0.72). 
 
Table 6.1 Pearson’s correlations between disease severity and psychological variables 
POEM Anxiety Depression  Stress 
Baseline  .55* .47* .63* 
Week 1 .65** .50* .62** 
Week 2 .47* .31 .52* 
Week 3 .51* .60** .70*** 
Week 4 .54* .69*** .55* 
Week 5 .48* .53* .55* 
Week 6  .55* .52* .69** 
Week 7 .72*** .59** .72*** 
Week 8 .69*** .57* .67** 
Week 9 .59** .69*** .58** 
Week 10 .55* .51* .6** 
Week 11 .66** .59** .66** 
Week 12 .75*** .69** .67** 
* p<0.05, **p<0.01 ***p<0.001 
Pearson’s correlations were also conducted for disease severity on week X, and stress, 
anxiety, depression on week X + 1 (Table 6.2). Disease severity was significantly positively 
correlated with anxiety the following week for all weeks apart from two. The correlations were 
medium to large (rs=0.4-0.69). Similarly, psychological stress was significantly correlated with 
disease severity in 10 out of the 12 weeks with medium to large correlations (rs=0.44-0.79). 
Pearson’s correlation between depression and disease severity were also significant in 9 out 





Table 6.2 Pearson’s correlations between disease severity on week X and psychological 
variables on week X+1 
 Anxiety  Depression  Stress 
Baseline & week 1  .57* .52* .64** 
Week 1 & week 2 .48* .38 .57* 
Week 2 & week 3 .43 .53* .46 
Week 3 & week 4 .48* .62** .44 
Week 4 & week 5 .40 .48* .52* 
Week 5 & week 6 .54* .38 .61** 
Week 6 & week 7 .48* .29 .57* 
Week 7 & week 8 .69** .59** .73*** 
Week 8 & week 9 .57* .47* .58* 
Week 9 & week 10 .48* .48* .59** 
Week 10 & week 11 .62** .62** .49* 
Week 11 & week 12 .66** .69*** .79*** 
*p<0.05, **p<0.01, ***p<0.001  
Three cross-lagged panel model analyses (appendix 18 ) were conducted to explore the 
temporal relationship between the psychological variables (stress, anxiety and depression) 
and disease severity.  When analysing cross-lagged model fit indices (Byrne, 2013), a non-
significant chi-square test is desired, which signifies that that the model approximates the 
underlying data and therefore should not be rejected (Bollen, 1989).  Additionally, the 
Comparative Fit Index (CFI) is examined with possible values range from 0.00 to 1.00, with 
higher values signifying a better fitting model (Ullman, 2006; Ullman & Bentler, 2003). Further, 
the Root Mean Square Error of Approximation (RMSEA)is considered as this accounts for the 
error of approximation in the population; values less than 0.05 are indicative of good fit and 
values as high as 0.08 represent several errors of approximation in the population (Browne & 
Cudeck, 1993). Lastly, the Tucker-Lewis Index (TLI; Tucker & Lewis, 1973) produces values 
that range from 0 to 1, with higher values indicating a good fit (Hu & Bentler, 1999). 
The cross-lagged models indicated poor-average fit for stress and severity (χ2(1800) = 1677, 
p<0.001; CFI = 0.54, TLI = 0.67, RMSEA =0.43, 95% CI [0.42,0.46]), anxiety and AD severity 
(χ2(1654) = 1066.98, p<0.001; CFI = 0.32, TLI = 0.21, RMSEA =0.12, 95% CI [0.09, 0.34]), 
and depression and AD severity (χ2(1435) = 1165.67, p<0.001; CFI = 0.06, TLI = 0.02, 
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RMSEA =0.61, 95% CI [0.54, 0.67]), due to a number of potential reasons that will be 
discussed later in this chapter. 
When exploring the temporal relationship between psychological variables and disease 
severity (table 6.3), disease severity on week X significantly predicted stress on week X+1 in 
eleven out of twelve weeks. Stress on week X also significantly predicted disease severity on 
week X+1 in eleven weeks. Similarly, bi-directional predictions were found for the majority of 
the 12 weeks when exploring disease severity, anxiety and depression. Disease severity in 
week X predicted anxiety on week X+1 in eleven out of twelve weeks, and anxiety on week X 
also predicted AD severity on week X+1 in ten weeks. Moreover, disease severity in week X 
predicted depression on week X+1 in ten out of the total twelve weeks and depression in week 






































Table 6.3 Standardized parameter estimates for random-intercept cross-lagged panel 
models on psychological variables (stress, anxiety and depression) and AD severity(SEV) 
(n=19) 
Stress 
Cross-lagged β SE Cross-lagged β SE 
SEV0→STR1 1.41*** 0.26 STR0→SEV1 0.45*** 0.09 
SEV1→STR2 135*** 0.25 STR1→SEV2 -0.06 0.10 
SEV2→STR3 1.51*** 0.30 STR2→SEV3 0.76*** 0.09 
SEV3→STR4 0.65** 0.20 STR3→SEV4 0.35*** 0.09 
SEV4→STR5 -0.18 0.18 STR4→SEV5 0.41*** 0.11 
SEV5→STR6 1.02*** 0.22 STR5→SEV6 0.37* 0.15 
SEV6→STR7 0.89** 0.28 STR6→SEV7 0.44*** 0.10 
SEV7→STR8 1.59*** 0.15 STR7→SEV8 0.49*** 0.07 
SEV8→STR9 1.30*** 0.26 STR8→SEV9 0.54*** 0.08 
SEV9→STR10 1.38*** 0.18 STR9→SEV10 0.50*** 0.10 
SEV10→STR11 0.89*** 0.22 STR10→SEV11 0.43*** 0.08 
SEV11→STR12 1.33*** 0.15 STR11→SEV12 0.48*** 0.08 
Anxiety  
Cross-lagged β SE Cross-lagged β SE 
SEV0→ANX1 0.80*** 0.17 ANX0→SEV1 0.79*** 0.18 
SEV1→ANX2 0.5*** 0.14 ANX1→SEV2 0.26 0.17 
SEV2→ANX3 0.73** 0.23 ANX2→SEV3 1.03*** 0.24 
SEV3→ANX4 0.61*** 0.11 ANX3→SEV4 0.95*** 0.15 
SEV4→ANX5 0.35 0.12 ANX4→SEV5 0.62** 0.20 
SEV5→ANX6 0.80*** 0.15 ANX5→SEV6 0.84*** 0.21 
SEV6→ANX7 0.41** 0.12 ANX6→SEV7 -0.16 0.11 
SEV7→ANX8 0.74*** 0.11 ANX7→SEV8 0.85*** 0.12 
SEV8→ANX9 0.56*** 0.11 ANX8→SEV9 0.96*** 0.19 
SEV9→ANX10 0.64*** 0.12 ANX9→SEV10 1.15*** 0.18 
SEV10→ANX11 0.63*** 0.10 ANX10→SEV11 0.76*** 0.18 
SEV11→ANX12 0.65*** 0.10 ANX11→SEV12 1.16*** 0.12 
Depression 
Cross-lagged β SE Cross-lagged β SE 
SEV0→DEP1 0.70*** 0.14 DEP0→SEV1 0.95*** 0.22 
SEV1→DEP2 0.53 0.19 DEP1→SEV2 0.30 0.21 
SEV2→DEP3 0.74*** 0.16 DEP2→SEV3 0.98** 0.30 
SEV3→DEP4 0.40*** 0.09 DEP3→SEV4 0.95*** 0.19 
SEV4→DEP5 0.28* 0.11 DEP4→SEV5 0.75* 0.30 
SEV5→DEP6 0.21 0.14 DEP5→SEV6 0.66 0.34 
SEV6→DEP7 0.43*** 0.09 DEP6→SEV7 -0.16 0.21 
SEV7→DEP8 0.51*** 0.09 DEP7→SEV8 1.01*** 0.19 
SEV8→DEP9 0.34** 0.11 DEP8→SEV9 1.19*** 0.28 
SEV9→DEP10 0.41*** 0.12 DEP9→SEV10 1.04*** 0.28 
SEV10→DEP11 0.59*** 0.10 DEP10→SEV11 0.89*** 0.25 
SEV11→DEP12 0.49*** 0.07 DEP11→SEV12 1.23*** 0.18 





6.3.4 Daily correlations and predictions between disease severity and psychological 
stress 
Mean disease severity, depression and stress scores for each day were plotted on a line graph 
(figure 6.4) alongside an illustration of scores from one participant (figure 6.5). Although the 
figure does not show a clear pattern between disease severity and psychological stress, there 
were several significant correlations between the variables that are reported below. 
 



























































































































































































































































The cross-lagged model (Figure 6.6)  results indicated that the model was a poor-average fit 
(χ2(1769) = 10557.87, p<0.001; CFI = 0.052, TLI = 0.001, RMSEA =0.52, 95% CI [0.51,0.53]). 
Figure 6.6 Cross lagged analysis snippet for psychological stress and disease severity for 10 
days with β coefficients. 
 
 
Severity on a given day significantly predicted stress the following day in two of the 30 days 
(day 1: β= -0.54, p<0.05, day 22= β=0.83, p<0.01). On day one, higher disease severity 
predicted lower stress levels on the following day, whereas for day 22 higher severity predicted 
greater stress the following day. Stress on day X predicted AD severity on day X+1 for three 
out of the 30 days (day 5: β=-0.62, p<0.001, day 22: β=0.74, p<0.001, day 29: β=-
0.41,p<0.05).On days five and 29, higher stress predicted less disease severity the next day 
whereas on day 22, higher stress predicted greater disease severity the next day (table 5.3). 
The covariances between stress and disease severity showed significant positive 
relationships for 23 out of 30 days; higher stress was correlated with increased disease 









Table 6.4 Standardized parameter estimates for random-intercept cross-lagged panel  
models on stress(STR) and AD severity(SEV) (n=19) 
Cross-lagged β SE Cross-lagged β SE Covariance β SE 
SEV1→STR2 -0.54* 0.22 STR1→SEV2 0.28 0.26 STR1↔SEV1 0.59*** 0.15 
SEV2→STR3 -0.14 0.21 STR2→SEV3 -0.15 0.24 STR2↔SEV2 0.62*** 0.62 
SEV3→STR4 0.08 0.24 STR3→SEV4 -0.32 0.18 STR3↔SEV3 0.62*** 0.14 
SEV4→STR5 -0.35 0.23 STR4→SEV5 -0.31 0.24 STR4↔SEV4 0.61*** 0.15 
SEV5→STR6 -0.18 0.24 STR5→SEV6 -0.62*** 0.17 STR5↔SEV5 0.56*** 0.16 
SEV6→STR7 -0.15 0.21 STR6→SEV7 0.15 0.22 STR6↔SEV6 0.26 0.21 
SEV7→STR8 -0.49 0.36 STR7→SEV8 0.5 0.28 STR7↔SEV7 0.92*** 0.04 
SEV8→STR9 -0.19 0.24 STR8→SEV9 -0.22 0.27 STR8↔SEV8 0.3 0.21 
SEV9→STR10 0.37 0.26 STR9→SEV10 -0.21 0.28 STR9↔SEV9 0.8*** 0.08 
SEV10→STR11 -0.35 0.37 STR10→SEV11 0.12 0.38 STR10↔SEV10 0.84*** 0.07 
SEV11→STR12 0.14 0.25 STR11→SEV12 0.29 0.26 STR11↔SEV11 0.64*** 0.14 
SEV12→STR13 0.05 0.3 STR12→SEV13 0.24 0.37 STR12↔SEV12 0.76*** 0.09 
SEV13→STR14 -0.15 0.23 STR13→SEV14 -0.17 0.23 STR13↔SEV13 0.47** 0.18 
SEV14→STR15 -0.13 0.26 STR14→SEV15 0.1 0.27 STR14↔SEV14 0.63*** 0.14 
SEV15→STR16 -0.33 0.32 STR15→SEV16 0.39 0.32 STR15↔SEV15 0.76*** 0.09 
SEV16→STR17 -0.32 0.55 STR16→SEV17 0.57 0.49 STR16↔SEV16 0.93*** 0.03 
SEV17→STR18 0.07 0.33 STR17→SEV18 -0.47 0.29 STR17↔SEV17 0.7*** 0.12 
SEV18→STR19 0.14 0.24 STR18→SEV19 -0.06 0.23 STR18↔SEV18 0.31 0.21 
SEV19→STR20 0.23 0.3 STR19→SEV20 -0.26 -.29 STR19↔SEV19 0.72*** 0.11 
SEV20→STR21 0.02 0.34 STR20→SEV21 0.03 0.33 STR20↔SEV20 0.75*** 0.1 
SEV21→STR22 0.83** 0.29 STR21→SEV22 -0.17 0.38 STR21↔SEV21 0.83*** 0.07 
SEV22→STR23 0.25 0.26 STR22→SEV23 0.74*** 0.22 STR22↔SEV22 0.73*** 0.11 
SEV23→STR24 -0.07 0.24 STR23→SEV24 0.19 0.25 STR23↔SEV23 0.18 0.22 
SEV24→STR25 0.01 0.25 STR24→SEV25 -0.16 0.2 STR24↔SEV24 0.39 0.19 
SEV25→STR26 -0.00 0.29 STR25→SEV26 -0.27 0.28 STR25↔SEV25 0.8*** 0.08 
SEV26→STR27 -0.04 0.3 STR26→SEV27 -0.13 0.28 STR26↔SEV26 0.7*** 0.12 
SEV27→STR28 -0.16 0.22 STR27→SEV28 -0.33 0.23 STR27↔SEV27 0.54** 0.16 
SEV28→STR29 0.13 0.21 STR28→SEV29 0.11 0.2 STR28↔SEV28 0.47 0.18 
SEV29→STR30 0.16 0.25 STR29→SE30 -0.41* 0.21 STR29↔SEV29 0.39 0.19 










6.4 Discussion  
This study analysed data from 19 participants who completed daily diaries and weekly 
questionnaires. Twenty-one participants returned study packs to the researcher and 36 study 
packs were sent to participants who expressed interest in taking part in this study. Thus with 
the completion rate of 52%, the study provides preliminary support for the feasibility of 
establishing a longitudinal cohort of adults with AD. Recruitment and retention are challenging 
factors for researchers conducting longitudinal studies. For example, the more demanding or 
burdensome the study is, the more challenging the recruitment and retention rates are (Grove, 
Burns, & Gray, 2012; Panjari et al., 2008). When studies involve numerous data collection 
points, potential participants may be reluctant to commit or may enrol but underestimate the 
commitment involved in participating. This study included daily diaries which may have added 
some burden even though every effort was made to minimize this. Unfortunately, this study 
was not able to ascertain reasons for declining from all those who expressed initial interest in 
taking part in the study. Furthermore, only three participants out of the fifteen who did not 
return the study packs informed the researcher that they could not continue with the study due 
to various stressful events that prevented them from diligently completing daily diaries.  
Where the data were collected on a weekly basis, there was a problem of retrospective recall. 
Participants were prompted to describe their mood over the past seven days. A truly 
contemporaneous measure would ask participants to complete measures at the very moment 
they are prompted. The daily diaries however were short and purposefully designed to be 
answered on a 3 point Likert scale and should have taken no longer than five minutes to 
complete daily. Participants were approached to take part in follow-up interviews following the 
completion of diaries, however none of the 19 participants proceeded with taking part in them. 
The researcher did however receive feedback from six participants on Facebook; the feedback 
provided was positive with all six participants agreeing that completing the diaries and 
questionnaires was not a cumbersome task for them. One participant stated a sense of 
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‘epiphany’ as she observed patterns between the severity of her AD and stress when 
completing the diary.  
Lag sequential analyses for the relationship between psychological variables and disease 
severity revealed that both were  predictive of the other when measured weekly.. However, 
when exploring the temporal relationship between stress and disease severity using daily 
diaries, the study did not find a causation effect of stress and AD severity. The sample fit 
indices for all cross-lagged analyses were a poor-average fit. One major reason for this is the 
sample size; according to Kline (2005), an ideal sample size for structural equation modelling 
should be 100 participants or more. However, as this study was a feasibility study that aimed 
to, in addition to explore the temporal relationship between stress and AD severity, assess the 
success of running a longitudinal daily diary study, this issue of sample size could not be 
overcome. If this study was run with too large a sample size, it may have been unethical as 
participants would be subjected to burdens and increased risks (Altman, 1980). Additionally, 
a sample size that is too high could lead to preventable failure to reach the recruitment target 
(Lancaster, Dodd, & Wiliamsoon, 2004). Meanwhile a sample size that is too small would have 
an inaccurately estimated variance, impacting the design of a future full-scale study (Julious, 
2005).  
Psychological stress has been widely researched in the field of atopic dermatitis; a number of 
studies have found that patients with AD suffer from stress-related exacerbations (Arndt, 
Smith, & Tausk, 2008; Arck & Paus, 2006; Suárez, Feramisco, Koo, & Steinhoff, 2012). This 
contributes to an itch-scratch cycle that results in a state of high anxiety and stress (Arck & 
Paus, 2006). By using daily diaries and weekly measures, the aim of this study was to 
determine the direction of the relationship between stress and disease severity as much of 
present research points to a bi-directional relationship ascertained through the use of cross-
sectional surveys (Arndt, Smith, & Tausk, 2008; Oh et al., 2010;  Suárez, Feramisco, Koo, & 
Steinhoff, 2012). Considering the findings from the daily compared to the weekly measures, it 
is possible that the  physiological effects of stress, anxiety and depression may need some 
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lead time before resulting in disease exacerbation AD and therefore, daily measurements of 
stress and AD severity may not reflect the changes as well as weekly measurements might. 
The existence of a reciprocal relation between psychological variables and disease severity 
over a one week lag period suggests that the positive relation between the factors on the same 
week is the consequence of a complex interaction. Stress, anxiety and depression appear to 
be both a cause of the AD severity, and caused by the severity of the condition. These findings 
of the cross-lagged analyses must be interpreted with caution as has been mentioned above, 
the model fit indices were not ideal due to the small sample size.  AD, in addition to other 
dermatological diseases (e.g. psoriasis, alopecia areata, acne vulgaris) is considered a 
psychosomatic disease in which psychological factors have an impact on the development of 
disease and can increase the symptoms. Stressful events and active episodes of the disease 
are often related to a high level of psychological stress (Benea,  Muresian, Manolache, Robu, 
& Diaconu, 2001). On the other hand, AD as a disfiguring disease is a stressor itself with an 
influence on the psychosocial state of the patient and on the maintenance of the lesions (Arndt, 
Smith, & Tausk, 2008). 
This study found strong positive relationships between disease severity and psychological 
variables measured on a weekly basis using validated psychometric questionnaires. These 
correlations were medium to large sized and significant for the majority of the weeks. This 
finding is reflected in a number of cross-sectional studies that have found significant 
relationships between disease severity and psychological variables (e.g. Arndt, Smith, & 
Tausk, 2008; Kodama et al., 1999; Oh et al., 2010), however unlike the current study, these 
studies measured these relationships at one time-point, and many do not differentiate between 
the types of stressors explored. The mechanisms that underlie this relationship between AD 
severity and psychological stress are insufficiently understood. A probable mechanism that 
underpins these associations involves the roles of cytokines which help regulate the immune 
response in an individual (Wilson, Finch, & Cohen, 2002). Alternatively, stress may lead to 
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AD-relevant immunological changes via pathways such as the HPA axis (Buske-Kirschbaum 
et al., 2013).  
There are a number of potential reasons that may explain the positive relationship between 
stress and AD severity. Firstly, an increase in severity which is accompanied by itchiness, 
unsightliness, and soreness of a patient’s skin, may result in higher stress levels in 
interpersonal situations. Furthermore, higher levels of interpersonal stress may result in 
altered views of AD severity, in patients viewing their condition as more severe than it is. Third, 
severe AD may result in participants viewing their reactions to interpersonal events more 
negatively. Finally, this relationship could be a result of other factors such as participant 
response style.  
As discussed in chapters one and three, the vast majority of literature in this area has 
methodological drawbacks, such as retrospective in design, adjustment for confounder 
variables. King and Wilson (1991)’s study’s  clinical implications are limited as the duration of 
the study was only two weeks. In a further study focussing on adults with acne, Chiu, Chon 
and Kimball (2003) found significant relationships between acne severity and examination 
stress in students. This was a small-sized study in which confounding variables may not have 
been taken into account. The prospective nature of the current study enabled an exploration 
of changes in AD severity and psychological variables over an extended period and accounted 
for potential confounding variables in the analyses.  
To the researcher’s knowledge, this is the first study that uses social networking platforms as 
the means of recruitment for conducting a longitudinal study on adults with AD. Consequently, 
there are no published data with which to compare the success of this method. Nevertheless, 
the ability to recruit participants within 34 days is notable. Of the data returned, 19 out of 21 
study packs had no missing data, demonstrating a high degree of motivation among the study 
population. Many of these participants had completed a ‘study poll’ on Facebook to state their 
interest prior to taking part in the study.  
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Despite the successful use of social media in this type of research, there are a number of 
potential limitations unique to this method of recruitment. First, the degree of non-response 
bias could not be ascertained as the researcher was unable to determine a response rate.  
Additionally, there is potentially a selection bias in favour of young adults with AD, as they are 
more likely to be Facebook users. Duggan and Brenner (2013) found  a statistically significant 
difference among different age groups who were Facebook users, with  86% of all people 
aged 18-29 years old using the site compared to 73% of people aged 30-49, 57% of people 
50-64 and only 35% of people older than 64 years old. Indeed, the participants in this study 
were aged 18-49, there were no participants over the age of 50. In addition, the psychological 
stress  responses might also suffer from selection bias as those who suffer from higher stress 
levels may not be as active on Facebook as those who do not (Brailovskaia, Rohmann, 
Bierhoff, Schillack, & Margraf, 2019). Another source of bias within the study may result due 
to the fact that this study’s participants were recruited solely from the atopic dermatitis support 
group where adults may have increased health literacy and knowledge of their disease 
compared to those who are not part of a support group (Zaid et al., 2014).  
In addition to the above limitations this study was not able to recruit any males, although  
evidence suggests the presence sex differences in the skin-psyche relationship(Picardi et al., 
2001; Taieb, Finlay, & Myon, 2004). Measuring AD severity using self-report rather than 
objective measures is a further limitation. Self-report of skin disease has been used, however, 
in a number of large cross-sectional community-based studies of psychological and quality of 
life associations of skin disease (Arnold et al., 2004; Dalgard, Svensson, Holm, &  Sundby, 
2004; Dalgard, Svensson, Holm, &  Sundby, 2005)  and there is evidence for the validity of 
self-reported presence of skin disease (Dalgard, Gieler, Holm, Bjertness, & Hauser, 2008) and 
of self-reported skin symptoms (Dalgard, Svensson, Holm, &  Sundby, 2003; Fivenson, 2001) 





6.5 Conclusions and directions for future research 
This study has a number of clinical implications. The bi-directional prediction of stress and AD 
severity warrants further longitudinal examination, with the use of more methodologically 
sound measures such as physical measures of stress and objectively measures disease 
severity rather than patient oriented. Considering the increasing prevalence of AD and the 
psychological and psychosocial burden associated with the condition, remedial elements in 
exacerbation are important. Although psychological interventions and stress reduction 
techniques are proposed as supplementary treatments for AD, evidence for their efficacy is 
largely unconvincing (Magin, Sibbitt, & Bailey, 2009). The findings of this study indicate a 
rationale for these interventions and efficacy trials in addition to further longitudinal analysis. 















Chapter seven: General discussion 
7.1 Introduction 
This doctoral research sought to examine the quality of life and mental well-being in adults 
with AD. In order to achieve this, a multi- methods approach was employed to conduct the 
research. The prevalence of AD in adults has increased significantly in the last few decades 
(Hoare & Williams, 2000) and the current scenario suggests that it will continue to do so. In 
recent years there has also been a growing interest in exploring and addressing quality of life 
in AD patients. However, most published research on AD and quality of life is conducted 
outside the UK. The UK is unique due to its’ National Health System which offers treatment 
free of charge to its UK residents.  
This chapter will summarise the key findings of this PhD research project, compare findings 
from each of the empirical studies, and discuss how they integrate with each other and relate 
to existing literature. Methodological considerations will be presented, In addition to 
implications for practice, policy and future research.  
The overall discussion below builds on the previous chapter discussions and synthesises the 
findings of the thesis as a whole. The chapter will summarise the main findings of this thesis, 
consider the contribution of the thesis to wider knowledge regarding quality of life and mental 
health in atopic dermatitis and long-term condition in general. Additionally, this chapter will 
review the recruitment and data generation methods used and discuss strengths and 
limitations of the studies in this thesis, make recommendations for clinical practice and discuss 







7.2 Summary of main findings 
7.2.1 Systematic review and meta-analysis 
The aim of the systematic review and meta-analysis was to explore quality of life in adults with 
AD. Previous literature has largely investigated quality of life in infants and children with AD 
or families of those with AD. The systematic review found statistically significant relationships 
between disease severity and quality of life in adults with AD, as well as poorer QoL compared 
to healthy controls and those with similar skin conditions. Previous literature has largely 
investigated quality of life in infants and children with AD or families of those with AD.   The 
systematic review  also found methodological weaknesses such as small sample sizes and 
recruitment of study participants primarily through dermatology clinics. Socio-demographic 
and clinical factors were not taken into account by most of the studies in the review. 
Furthermore, a substantial number of studies investigating quality of life have been conducted 
in the US, therefore not directly applicable to the UK context due to varying health service 
models. A further gap in the literature was found regarding the use of dermatology-specific 
questionnaires used to measure QoL in healthy controls as opposed to generic QoL 
measures. Moreover, all studies in the review were quantitative and cross-sectional thus 
introducing the issue of causality. The review highlighted areas for future qualitative 
exploration such as sleep disturbances, personal relationships and impact of AD symptoms. 
Furthermore, the review highlighted a lack of prospective measurement of QoL and disease 
severity.  
7.2.2 Qualitative study  
The aim of the qualitative study was to explore the perceptions and experiences of adults with 
AD living in the UK. The findings of this study indicated several themes that are important to 
understand the experiences of living with the condition. The visible aspect of AD was 
perceived as playing an important role in participants’ day-today lives. As AD can give rise to 
complications such as scarring, pigmentation, wrinkling and thinning of the skin, stigmatization 
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and judgement by others played an important role in their lives. In this theme, participants also 
discussed often comparing themselves to others, either positively or negatively. The impact of 
visible skin lesions  on a participant’s quality of life and mental well-being is a highly under-
researched but important area. 
Psychological factors such as low mood, depression, dysphoria, anger and frustration were 
also prevalent in the vast majority of the participants in this study. Atopic dermatitis alongside 
its mental implications, affected participants physically, the pain and discomfort associated 
with the condition were discussed repeatedly. Limitations in physical functioning due to pain 
and discomfort from AD were a distressful experience for participants and impacted their ability 
to perform everyday tasks.  
This study also shed light on coping and management methods taken by participants in order 
to improve their daily lives. Some used active mechanisms such as maintaining stringent 
maintenance regimens and avoiding triggers, whereas others used more negative strategies 
such as comfort eating in order to cope with their condition. Health care professionals also 
played a significant role in participants’ experiences of living with the condition. The majority 
of participants perceived a lack of acknowledgement of the mental health implications by 
health care providers and a notion that GPs were not efficiently equipped to address and treat 
mental health issues that arose as a result of AD. Again, this a novel finding in adults with AD.  
This study also identified some differences in accounts between White and BME participants 
where BME participants were less willing to talk about their AD to others, and their AD was 
received more negatively by family and friends compared to White participants. Ethnic and 
cultural issues in AD are not widely researched and the majority of published literature on QoL 
and AD does not account for or record ethnic differences.  
7.2.3 Cross-sectional survey  
The aim of this study was to investigate predictors of QoL in adults with AD and compare QoL 
and mental health variables in adults with AD and heathy controls. The study recruited a total 
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of 533 participants- a sample size larger than 80% of the studies in the systematic review, and 
the largest known sample size of AD participants in the UK. Participants with AD reported 
significantly lower health related QoL, physical QoL, and higher anxiety compared to the 
healthy controls. Psychological stress, physical and environmental QoL and AD severity were 
significant predictors of skin-related QoL even after controlling for clinical and socio-
demographic factors in those with AD. Furthermore, patients who were prescribed medication 
such as topical corticosteroids and immunosuppressants reported lower QoL and higher 
disease severity compared to those who were not. This study also illustrated socio-
demographic differences for QoL and disease severity. The findings of this study support 
findings from the wider literature of the significant psychological impact AD has on adults in 
the UK. Medication, concomitant conditions, family history and socio-demographic 
characteristics play a significant role in the psychological burden of AD.  
7.2.4 Prospective longitudinal study  
The aim of the final study was to assess the feasibility of conducting a longitudinal diary 
analysis that explored the temporal relationship between psychological stress and AD 
severity. As discussed in earlier chapters, psychological stress and disease severity in AD 
appear to be bi-directionally related. However, most published studies have used cross-
sectional designs to explore this. This study recruited 19 participants all of whom reported 
suffering with clinically diagnosed AD. Participants completed daily stress diaries for a month, 
as well as validated psychometric questionnaires weekly for a total of 12 weeks. Psychological 
stress, anxiety and depression were highly correlated with disease severity for the majority of 
the  12 weeks. A causal relationship between stress and AD severity was not found in this 
study as measured using daily diaries however there was evidence for a bi-directional causal 
relationship from the weekly measures; psychological variables and disease severity 
appeared to be predictive of one another when measured weekly. Considerations for running 




7.3 Comparison of findings and relationship to existing literature 
This research has attempted to explore, from participants’ perspectives, the psychological 
impact of AD on their QoL and mental well-being. This was achieved through a qualitative 
study that used semi-structured interviews, a cross-sectional survey using standardised 
psychometric instruments and finally  a prospective analysis also shed light on the temporal 
relationship between AD and psychological factors in relation to disease severity.  
This section focusses on the findings of the studies as a whole and summarise the implications 
they have on the way quality of life in AD is assessed,  the view of health care professionals 
on management of AD and how those with AD perceive its’ impact. It is only through these 
findings’ applicability to the psychological care of AD patients that they are likely to be utilized 
by health care professionals and researchers and contribute to the patient in real life.   
7.3.1 Qualitative study  
The systematic review identified several gaps in existing literature including the lack of 
qualitative exploration of patients’ experiences living with AD. The qualitative study 
demonstrated the multi-faceted nature and complexities involved in living with AD, as although 
distinct super-ordinate themes were identified in this study, it was almost impossible to 
separate one from the other.   
The five overarching themes were supported with many smaller themes, however lived 
experiences, as expressed by participants, indicated  that these are not necessarily confined 
within one major category, but are entwined and overlap with one another. . Threats to inner 
self- which emerged as the first superordinate theme- clearly permeated every aspect of the 
participants' lives and had a major impact on emotional functioning and self-consciousness 
surrounding their AD. 
A number of studies that have explored the incidence of psychological distress have reported 
that adults with atopic dermatitis are at an increased risk of experiencing depression (Patel, 
Immaneni, Singam, Rastogi, & Silverberg, 2019; Silverberg et al., 2019; Yu & Silverberg, 
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2015). Most recently, a systematic review and meta-analysis of 106 studies (Patel et al., 2019) 
found that 25% of  AD patients presented with depressive symptoms, 17% had clinical 
depression and 13% had suicidal ideation. . Moreover, there was a higher prevalence of 
depression in those with compared to those without AD (20.1% vs 14.8%) 
The negative emotions experienced by individuals in the qualitative study extended beyond  
perceptions of grief and low mood.  The majority of the participants discussed intermittent 
periods of anxiety, anger, depression and frustration.  The unpredictability and uncontrollability 
of AD may to some extent promote the emergence of such feelings and support previous 
findings from studies with AD patients, such as those of Lapidus & Kerr (2001) who found that 
participants reported feelings of frustration and helplessness in relation to AD severity.  
A finding evident in published literature is the increased prevalence of depression in those 
with AD compared to patients of other chronic conditions and healthy people (Patel et al., 
2019). Depression is often thought to result as a consequence of living with AD and its’ 
severity, however this cannot be ascertained due to the array of additional variables that may 
be involved. Several cross-sectional studies (Hashiro & Okumura, 1997; Slattery & Essex, 
2011) have found significant associations between depression and AD severity, however once 
controlling for other variables such as socio-demographic characteristics, the strength of this 
significance weakens and even diminishes (Hashiro & Okumura, 1997; Slattery & Essex, 
2011). Anxiety and depression appeared to be prominent issues in the current study and many 
participants discussed that issues such as confidence and self-esteem contributed to 
hesitation in accessing relevant support from health care providers and social networks. There 
was a notion that their AD did not warrant GP time and resources and as a result discouraged 
them from raising concerns about depressive symptoms and emotional distress. These 
findings reflect others (e.g. Belson, Barker, Griffiths, Cordingley,  & Chew-Graham, 2013; 
Magin, Adams, Heading, Pond, & Smith, 2009), although Pollock (2007) found that psoriasis 
patients tried to ‘maintain face’ and conform to  the socially sanctioned role of the stoic, good 
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and uncomplaining patient in order to retain the social esteem and good will of others" (page 
175) during clinical consultations and therefore supressed signs of emotional distress. 
 This study also found the presence of a range of negative feelings at numerous times in 
participants’ daily lives. These feelings, whether fear, frustration or anger, often appeared to 
be linked to periods of AD exacerbations and the resulting limitations and role changes due to 
severe pain, discomfort and reduced physical abilities. This has not been reported in similar 
qualitative literature in the past, however Barlow and Williams (1999) found similar emotional 
distress from focus groups that explored parenting from the perspectives of parents and 
grandparents with arthritis, another chronic condition. The participants of their study also 
reported physical limitations, fatigue and pain which combined to interfere with their roles of 
parents.      
The current study also found that in addition to reduced physical abilities compromising 
domestic tasks, participants’ were concerned about their employment prospects and current 
jobs. . Twelve participants in the study reported being unable to attend work at some point 
because of disease exacerbation, whereas two participants had sought employment 
elsewhere in an attempt to earn a wage but not compromise their health. This finding was later 
mirrored in the quantitative study where those with AD reported significantly lower physical 
QoL compared to healthy adults. Participation in paid employment is a role that many adults 
may aspire to achieve and is central to many peoples’ life goals, however, being an AD sufferer 
may affect employment prospects and ability to retain a job. Individuals with severe skin 
conditions such as AD and psoriasis report  higher levels of employment and missing work 
more frequently condition (Kwak & Kim, 2017; Linden & Weinstein, 1999; Mansouri et al., 
2015).   
The participants utilised several strategies in attempts to be able to carry out everyday 
activities and stay independent. . Some of these involved taking a positive outlook on their 
condition, find alternatives to their triggers and educating others about AD- these were all 
positive adaptions and strategies designed to help the participant cope with the condition.. 
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Conversely, in an attempt to deal with their flare-ups, several participants described adapting 
an unhealthy lifestyle as a way of inducing ‘comfort’- clearly a negative coping strategy that 
may have deleterious implications for their health (Nyugen, Koo, & Cordoro, 2016; Ograczyk, 
Malec,  Miniszewska, & Zalewska-Janowska, 2012). 
An unclear finding in this study was the strategy employed with regard to social interaction for 
an element of contradiction existed. On the one hand, many participants reported feeling 
lonely and isolated, yet on the other, they reported frequently rejecting offers of help from 
friends and family, deliberately shunning social contact, reducing communication with friends 
and avoiding social events - the common reasons being that they felt a burden, or, perceived 
that other people didn't understand the disease, or people did not offer helpful advice to them. 
Although contradictory, this is an interesting finding, particularly as social support, either 
positive or negative has been proposed as an imperative coping source in managing illness 
and is perceived as a  barrier between a patient and the source of demands or stress related 
to a long-term condition, in addition to providing assistance in meeting needs (Lu, Duller, Van 
Der Valk, & Evers, 2003;  Ohya et al., 2001). In managing illness, one of the more challenging 
aspects is maintaining social support and preserving interpersonal relationships as coping 
mechanisms (Silver, Wortman, & Crofton, 1990).   
Social support, while not reported in AD literature, has been found to be predictive of pain and 
long-term functional disability in patients with chronic and long-term conditions, with 
quantitative aspects of the size of a social network and qualitative aspects of perceived social 
support playing a part.  An older study by Smith and Wallston (1992) found that perceptions 
of lack of support were associated with higher levels of inability to perform daily activities in  
those with long-term conditions such as arthritis. Similarly, numerous other findings discuss 
the increased pain associated with decreased psychological wellbeing  (Cohen et al., 2007; 
Patel, Peterson, & Kimmel, 2005; Waltz, Kriegel, & Bosch, 1998). These findings are reflected 
in studies exploring social support in similar skin conditions such as psoriasis (Cacioppo & 
Hawkley, 2003; Jankowski et al., 2012; Picardi et al., 2005).  
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Additionally, social support also contributes to the levels of psychological distress that 
individuals with skin conditions experience (Evers et al., 2005). Contributors to psychological 
distress in 248 adults with AD or psoriasis was explored by Evers et al (2005). The authors 
found that a lack of social support was the strongest predictor of psychological distress in both 
AD and psoriasis patients.    This finding suggests that the notion of perceived or actual social 
support may be complex as participants in the current study discussed a number of instances 
where they had intentionally avoided accepting social support.  
The interviews in this study gave the participants a voice and facilitated the identification of 
common themes. In order to explore these themes further, these findings were used to inform 
the  choice of measures implemented in the quantitative study (chapter 5).  
7.3.2 Quantitative study  
The systematic review (chapter 3) included studies that explored quality of life in AD patients 
and all studies in this review were cross-sectional quantitative studies. The review highlighted 
some weaknesses in current literature including the use of small sample sizes, the use of 
disease-specific quality of life measures in comparing healthy controls and those with AD, lack 
of UK based studies and lack of consideration of socio-demographic and clinical factors 
(chapter three; Birdi, Cooke, & Knibb, 2020). Thus, the quantitative study aimed to bridge 
these gaps by conducting a large-scale cross-sectional study in the UK.  
Several findings of this study mirrored findings of studies exploring QoL in adults with AD e.g. 
in this study, healthy controls reported significantly better health-related QoL compared to AD 
patients. This was an expected finding and supported the findings of the qualitative study 
where participants compared their lives to those without AD and reported feeling ‘envious’ due 
to the limitations AD had put on them. Moreover, all studies in the systematic review (chapter 
3) also found that significantly poorer QoL in AD patients compared to healthy controls.  
Similar to findings of previous literature, those with AD reported higher levels of anxiety 
compared to healthy controls (Oh et al., 2010; Thyssen et al., 2018; Yaghmaie et al., 2013). 
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The source of this anxiety is largely undetermined and calls for further investigation, 
particularly considering the variety of psychosocial issues found to impact QoL in those with 
long-term conditions. Krueger et al. (2001) identified some of these issues being related to 
workplace difficulties, suicidal ideation, social life and exclusion from public facilities. 
Numerous participants in this thesis’s qualitative study also reported feeling anxious in certain 
situations such as when required to socialise; some of these participants were prescribed 
anxiolytics. The quantitative study found no significant difference between healthy controls 
and AD patients for depression although the qualitative study found that a number of 
participants reported being diagnosed with depression. The cause for the increase in these 
psychological concerns in AD patients remains speculative. Although anxiety and depression 
are related to skin barrier damage, increased itchiness and ultimately increase in disease 
severity, a more probably explanation is the burden caused by the chronicity of AD; social 
isolation, disrupted sleep and itch which negatively affects mental wellbeing (Lewis-Jones, 
2006; Mathew al, 2016). The social stigma as a result of visible skin lesions may also 
contribute to an impact on mental wellbeing (Cacioppo et al., 2014; Magin, Sibbritt, & Bailey, 
2009).  
The quantitative study also found that physical QoL, environmental QoL, stress and AD 
severity significantly predicted skin-related QoL. These findings are in line with past literature 
which has ascertained strong relationships between AD severity and QoL (e.g.; Beikert et al., 
2014; Chrostowska-Plak et al., 2013; Kim et al., 2012; Silverberg et al., 2018); in fact, the 
systematic review and meta-analysis (chapter 3) found that all but one studies that explored 
this relationship found that as AD severity increases, QoL significantly decreases (Birdi, Cooke 
& Knibb, 2020). Furthermore, the qualitative study also discussed how participants who 
deemed themselves as ‘severe’ appeared to be more affected by their condition. This finding 
is reflected in current literature (e.g. Higaki et al., 2004; Holm et al., 2006; Misery et al., 2007; 
Silverberg et al., 2018).  
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 In addition to the above, the quantitative study also found that those with asthma and food 
allergies reported significantly poorer skin-related QoL and increased disease severity 
compared to those without these conditions. The reason behind this finding of those with 
concomitant conditions experiencing worse QoL than those with eczema alone is unclear. One 
possibility for this finding may be due to adults with concomitant disease presenting with more 
disease complications which consequently impacts their QoL. . Further research is needed to 
replicate and explain this finding as there is a paucity of literature that explores this despite 
the fact that many AD patients have accompanying conditions such as asthma (O’Connell, 
2004). Those with comorbid atopic diseases experience discomfort as a result of not only 
intense pruritus, sleep loss, but also coughing and/or wheezing, dyspnoea, concomitant nasal 
congestion and/or rhinorrhoea (Lee, Ahn, Noh, & Lee, 2011; O’Connell, 2004). Moreover, they 
may give rise to issues such as concern about personal relationships, adoption of special 
clothing habits and withdrawal from public places (Spergel & Pellar, 2003).  
The study also found that those who were prescribed topical corticosteroids, antihistamines, 
immunosuppressant medication, sedating medication, calcineurin inhibitors, Dupilumab and 
oral corticosteroids reported lower QoL and higher disease severity compared to those who 
did not take this medication at the time of the study. These findings reflect participants’ 
accounts of AD management in the qualitative study. When discussing medication, 
participants in this study often expressed anguish due to the side effects of taking medication 
and the impact these effects had on them and their families. At times, these were discussed 
at length and one participant stated that the side effects of taking immunosuppressants was 
worse than her condition itself. For many, medication was no longer seen as a means of 
therapy but rather an obligation that needed to be adhered to, whether or not there were any 
benefits.  This may be due to a lack of knowledge about treatments and their potential side 
effects in health care professionals; it is perceived as a significant contributing factor towards 
lack of adherence or anxiety regarding treatment failure and therapeutic regimes (Charman  
et al., 2003; Lawson et al., 1998). Many, after seeing no change to their AD, may try 
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complementary or alternative therapy, such as the use of herbal supplements, as a 
consequences of these anxieties or failure of conventional therapy. .  
Johnston, Bilbao, and Gaham-Brown (2003) found a significant relationship between ethnicity 
and the use of complementary medicine (CM), with more than half of those using this therapy 
citing lack of efficacy of conventional therapy and 17% having concerns about side effects. . 
Another reason as to why QoL may have been lower in those taking medication could be due 
to financial costs incurred by these patients. Although the studies included adults only in the 
UK which has universal healthcare for its’ citizens, there are a number of hidden costs to 
treating AD over and above health care costs (Fivenson et al., 2002; Herd & Williams, 2000; 
Su, Kemp, Varigos, & Nolan, 1998; Verboom et al., 2002). These include; cost of medication, 
loss of financial earnings (from sick leave), special diets, hospital/doctor related costs, extra 
cleaning and special bedding/clothes (Herd & Williams, 2000). Su et al (1998) reported that 
such costs relate directly to QoL and disease severity in AD with greater affects than those 
witnessed in other long-term conditions such as diabetes and asthma  (Su et al., 1998). 
The quantitative study also found that Asian participants reported significantly higher disease 
severity and lower QoL compared to their White and Black counterparts. This is a finding that 
enforces the qualitative findings presented in chapter 4, whereby Asian participants perceived 
their AD as more detrimental to their daily lives compared to White participants. Some Asian 
participants in the study discussed issues such as lack of knowledge in their culture, 
stigmatisation by loved ones, and a lack of willingness to discuss their AD with others. These 
issues appeared to be more impacted in Asian compared to White participants, with one 
participant concluding that her divorce to her husband was due to infertility caused by AD 
medication. The reason for this finding is unclear and warrant further investigation. Studies 
exploring the role of ethnicity and quality of life in patients and AD and psoriasis have reported 
similar findings whereby White participants report better QoL compared to BME participants 
(Boozalis et al., 2018; Kaufman, Guttman-Yassky, & Alexis, 2018; Shah, Stotland, Cheng, 
Ramos, & Caughey, 2011).  
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7.3.3 Feasibility study 
The final study in this thesis aimed to explore the temporal relationship between psychological 
stress and disease severity due to the bi-directional relationship assumed by a number of 
cross-sectional studies. The study employed a longitudinal approach that involved the 
completion of daily diaries over a period of a month, as well as weekly questionnaires over a 
period of three months. Although the findings of this study do not point to a causation effect 
between stress and disease severity for the daily diaries, psychological variables and AD 
severity were found to be predictive of one another when measured weekly. Being a feasibility 
study, it was reported in line with STROBE guidelines for reporting of feasibility and pilot 
studies (Elm et al., 2007). The finding that weekly disease severity was significantly correlated 
with psychological stress are reflected through the current literature (Arndt, Smith & Tausk, 
2008; Oh et al., 2010;Wright, 2005) and chapter 5 also found a significantly positive 
relationship between the two variables. Therefore although this is not a surprising finding, the 
significant positive relationship was consistent for majority of the weeks in the 12 week period.  
The number of participants were acceptable for a feasibility study (Julious, 2005), however 
the small sample size may have contributed to many indices violating assumptions for a ‘good’ 
model fit in the CLPM analysis. The CLPM should ideally be run with large sample sizes as 
the model fit statistics are sensitive to sample size (Byrne, 2013). A general rule of thumb for 
SEM analysis would suggest a minimum of 100-200 subjects; however, these rules can be 
overly conservative and not generalizable to each study in question (Iacobucci, 2010). Though 
the sample size was sufficient for the analyses conducted, a larger sample size would allow 
for better missing data imputation and more comparisons within the SEM model, such as 
relationships between the individual indicators across latent constructs, and for the addition of 
other covariates such as medication use and psychological variables.  
According to Lancaster et al. (2015), pilot and feasibility studies are not conducted to produce 
significant results (p<0.05) , and it has been suggested that the reporting of these studies 
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should be primarily descriptive (Lancester, Dodd, & Williamson, 2004; Grimes & Schulz, 2002) 
as testing a hypothesis requires a powered sample size which is usually not available in 
feasibility or pilot studies. Pilot studies aim to assess the implementation, retention, feasibility 
of recruitment, and assessment procedures of the novel study  with the aim that each of these 
factors can be quantified (Leon, Davis, & Kraemer, 2011). Study elements that are considered 
infeasible or inadequate should be modified in the full-scale  trial or removed altogether.  
The participants who did not complete measures over the 12 weeks did not send the 
researcher incomplete study packs, although they were prompted to do so numerous times. 
Thus, drop-out analyses could not be performed on the remaining seventeen participants who 
had volunteered to take part. Recruitment took place through atopic dermatitis support groups; 
advertising through social networking sites yields a greater percentage of valid consents, a 
greater percentage of individuals meeting eligibility criteria, a greater percentage providing 
content-specific data, and a greater percentage of participants who complete surveys than 
other methods of recruitment (Ramo, Hall, & Prochaska, 2010). Therefore, using social media 
to recruit participants is advantageous, however as discussed above and in earlier chapters, 
the demographic characteristics of Facebook users do not necessarily reflect the AD 
population. For this study specifically, it is useful to note that those who use Facebook 
frequently are also more likely to report higher levels of psychological stress (Labrague, 2014; 
Nabi, Prestin, & So, 2013; Beyens, Frison, & Eggermont, 2016). Thus, it is likely that 
participants had higher reports of psychological stress compared to the overall AD population. 
It would be useful therefore to recruit using a range of methods, including dermatology clinics 
to complement social media as was the case for chapter 5.  
Prior to commencement of the study, a ‘poll’ was initiated on Facebook and many support 
group users responded favourably stating the importance of such research. Indeed, the 
majority of the comments on the group are directed towards the lack of appreciation towards 
the mental health consequences of living with AD. Recruitment methods for this study differ 
from many previous prospective studies that explore stress and disease severity in skin 
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conditions (Chiu, Chon, & Kimball, 2003; Evers et al., 2010) where participants have been 
recruited from Dermatology outpatients clinics.  
In addition to issues with the sample size, the lack of a temporal relationship for the daily 
measures may also be due to the fact that as a whole, the participants  were experiencing 
only low-moderate levels of interpersonal stress that did not change much on a daily basis. 
Perhaps if all the participants experienced periods of both low and high levels of stress, a 
stronger relationship may be observed and this might be reflected in the findings from the 
weekly measures, which were completed over a much longer period of time. In fact, a few 
participants consistently reported no stress throughout the 30 day period. It may be of benefit 
to study participants over a period of time when they are likely to be  experiencing high levels 
of stress e.g. starting a new job. It would also be useful to explore the role of social support, 
coping responses and appraisal in mediating the possible consequences of stressful situations 
on participants’ lives. The qualitative study (chapter 4) revealed that participants deemed 
social support of great importance when discussing their experiences with AD. Additionally, 
mental health variables may be only one reason for changes in AD severity. . Climatic and 
allergic influences have also been implicated (Morren et al., 1994; Kantor & Silverberg, 2017). 
Therefore, it is possible that exacerbations of participants’ AD occurred at times as a result of 
these additional factors. It is also possible that a certain level of stress must be experienced 
prior to the physiological effects are observed in AD. 
It is important to note that daily stressors were the measure of  psychological stress in chapter 
six. The impact of daily stressors (e.g. getting late for work, misplacing something important) 
is found to be a significantly better predictor of health outcomes than major stressors 
(Chamberlain & Zika, 1990; Dekkers, Geenen, & Evers, 2001). Nonetheless, the relationship 
between various types of stressors, for example disease-related daily stressors or traumatic 
childhood events  (Evers et al., 2010; Evers, Lu, & Duller, 2005) should be explored to 
determine potential unique relationships with AD severity. Nevertheless, this feasibility study 
was carried out using daily diaries which enabled sensitive detection of changes in AD severity 
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and stress compared to using, for example monthly assessments which introduce other issues 
sauce as recall bias and higher attrition rates (Evers et al., 2010). 
 This study managed to recruit only female participants similar to chapters four and five in 
which women accounted for the majority of the sample. There is a possibility that men with 
AD react in other ways than women to stress-an issue that needs to be investigated further. 
The daily diary questionnaire seemed to work sufficiently well, as it was rated on a three-point 
scale and shorter than most validated stress questionnaires. Of course, scales like PSS could 
be used, but for the purposes of daily recording, it was important that the recording method 
was as easy as possible to perform.  The issue of stress is complicated, and it is often difficult 
to distinguish between exposure to stressors and the subjective state of stress. Participants 
were not given a definition of stress, instead, they were asked to use their own definitions of 
perceived stress.  
Relying on self-report is necessary for assessing emotional and other internal states as 
mentioned elsewhere in this thesis. However, there are potential limitations related to impaired 
self-awareness and recall bias for more objective problems like disease severity. The ability 
to provide a self-report of this was required for this study, which meant there was likely a 
difference in perceptions of what ‘severe’ meant for participants. A more suitable self-
assessed severity tool for future studies would be the POEM or patient-oriented SCORAD 
which are correlated well with doctor-assessed disease severity (Finlay, 2016). However, 
those able to provide a self-report are also likely the best candidates for psychological or 
behavioural intervention, therefore making the study sample still representative of those 
whose clinical care would likely be informed by these results (Juengst, Myrga, Fann, & 
Wagner, 2017).  
This study shows that like the other studies in this thesis, mental health variables correlate 
highly with AD severity. Furthermore, stress, anxiety and depression appear to predict disease 
severity and the disease severity also appears to significantly predict these psychological 
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variables a week after they are measured. This is a promising result and after addressing the 
issues discussed above, should be implemented into a full-scale prospective study. 
7.4 Recommendations for clinical practice  
The findings of thesis have a number implications for clinical practice. Perhaps the most 
important implication is the importance of awareness that adults with AD are at a higher risk 
of suffering from anxiety and depression. It is essential for health care professionals to prepare 
and offer suitable support to these patients. Further, findings reveal that a number of quality 
of life domains are affects in adults with AD, from physical to environmental. Thus, quality of 
life assessment needs to be incorporated into clinical assessments of AD where possible.  
 Findings from the qualitative study (chapter four) revealed the unpredictability of AD which 
results in difficulty managing the condition over time. Thus, health care practitioners should 
acknowledge and consider that severity of AD, and associated treatments, will change over a 
patient’s life. Adults with AD should liaise regularly with their health care professionals to 
ensure that their treatment allows control over their condition, or indeed, change treatment 
where necessary.  
Participants in chapters four, five and six were recruited using online support groups, amongst 
other recruitment platforms.  As many people rely increasingly on the internet, health care 
providers should provide accurate and up-to-date information regarding AD online. This 
information should be available from and on a trusted source for example, a hospital or a GP 
practice website. . Additionally, online communication pathways such as support groups 
should be regularly moderated by qualified professionals, which could enable AD patients to 
feel more supported by the health care system and enable more disadvantaged groups being 
informed.  Greene, Choudhry, Kilabu, and Shrank (2010) also emphasise that policymakers 
should consider that patients may seek social networking websites developed and patrolled 




7.5 Future directions 
A number of recommendations have been suggested throughout this thesis. This section will 
further summarise recommendations detailed in chapters three to seven.  Although this 
research provided insight into lived experiences of those with AD, more in-depth qualitative 
research which uses interpretative phenomenology is needed to explore these experiences in 
depth (Chapter 3). Qualitative research has the ability to yield rich explanations and 
perceptions of an individual’s world and how they make sense of living with the condition 
(Terry, Lyons, & Coryle, 2016). Using different types of qualitative methods such as photovoice 
which explores daily experiences in more depth would be beneficial.  
The vast majority of the participants in this thesis were recruited using social media platforms, 
yet there is limited information on how patients with long-term conditions use online platforms 
to keep informed and educated about their illness, as well as how they use support groups on, 
for example Facebook to support their AD. Using qualitative methodology would also enable 
adults with AD to discuss their experiences and understanding of using online media and 
social networking sites to manage their condition and gain information and the use of media 
for support and relationships with other adults in similar situations.  
 This thesis also found ethnic differences in experiences with AD and reporting of quality of 
psychological variables (Chapter four and five). Indeed additional qualitative evaluation would 
enable a more in depth exploration of these differences. Moreover, further qualitative research 
could investigate why black and minority ethnic adults appear to be more affected by their AD 
as well as gender differences in experiences of living with the condition.  
Additionally, research is needed to explore the role of health care professionals further, as 
participants in this thesis (chapter four) strongly perceived a lack of sufficient support from 
their health care providers. This was not assessed further in subsequent chapters thus it would 
be beneficial to explore how HCPs communicate with patients regarding the mental impact 
their AD has on them. Many health care professionals may choose pharmacological 
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treatments as their first choice to manage anxiety and depression, despite evidence for the 
effectiveness of psychological interventions in disease management. Astin, Beckner, Soeken, 
Hochberg, and Berman (2002) conducted a systematic review that explored the effectiveness 
of psychological interventions such as stress management, biofeedback and cognitive 
behavioural therapy in patients with long-term conditions. The authors found statistically 
significant, albeit small, effect sizes for self-efficacy, pain, depression and functional disability 
following treatment. Their data were based on twenty-five randomised control trials that 
compared findings from patient groups that received intervention to non-intervention control 
groups.  
Those with AD can also suffer from severe psychological and physical co-morbid conditions 
in addition to their condition, however this thesis excluded those with co-morbid long-term 
conditions. Therefore, research exploring the prevalence of co-morbid conditions in those with 
AD and how these patients manage and experience multiple conditions is warranted.  
7.6 Contributions  
It is important to recognise that there is not one more suitable method of research, and this 
thesis infers that it is the combination of input from dermatologists, patients and psychologists 
that needs to be incorporated together in order to have a positive outcome on prognosis and 
health status in adults with AD. Using multiple methods, the research in this thesis has firstly 
using a systematic review identified current literature exploring the impact of AD on quality of 
life, secondly through a qualitative study, uncovered psychosocial issues that were identified 
as detrimental to patients’ daily lives through their own perspective. Following this, a 
quantitative study employing validated psychometric measures investigated the impact of 
psychological variables on adult QoL. Finally, a feasibility prospective study enabled the 
exploration of the temporal  relationship between disease severity and psychological stress 
over a period of three months. The findings of these studies contribute  to the current 
knowledge that living with AD has an impact on many aspects of a person’s life. The 
systematic review also allowed the researcher to build on what is already known on the topic 
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and identify areas of weaknesses that need further investigation. Moreover, although 
acknowledging that findings from qualitative research should not be generalised, the areas of 
concern highlighted are notable. Cultural and ethnicity differences which have not been 
explored in the past, were evident in this UK study with BME groups reporting several 
differences in their experiences of AD compared to White adults. This is a notion that needs 
exploring in more detail as these differences were also evident in the quantitative study. The 
quantitative study also comprised one of the largest UK sample of adults with AD at the time 
of the study. These participants were not just recruited from dermatology clinics (as most AD 
samples are) but made use of online media platforms to diversify the sample further. Some 
novel findings were highlighted from this study including the impact of type of medication on 
quality of life and mental health (chapter 5). This study adds to the existing body of literature 
by controlling for socio-demographic and clinical variables, using a large sample size, and 
using a variety of platforms for recruitment of participants. Finally, by implementing the 
longitudinal prospective study design, the temporal relationship between disease severity and 
psychological stress was accessible to be assessed consistently by the same observer, which 
would have been impossible in a cross-sectional survey.  
Overall, this thesis has established that quality of life is highly compromised in adults with AD:  
findings illustrate that QoL in adults with AD reflects social, psychological, physical, 
environmental and spiritual/personal domains as demonstrated by the WHOQoL Group 
(2004).  The findings of this thesis however suggest that for adults with AD, quality of life 
concerns fall predominantly within the psychological, physical and social domains (Fayers & 
Machin, 2007; Testa & Simonson, 1996).The research in this thesis also found that AD-related 
symptoms such as pigmentation, inflammation and scarring are detrimental to one’s quality of 
life. Although this research has enhanced insight of the impact of AD on quality of life for adults 
within the UK, there is a need for further research which explored QoL in those with AD and 




7.7 Strengths and Limitations  
Although each chapter within this thesis identified strengths and limitations of the research, 
some of these were reflected across the studies in this thesis such as the use of online 
methods for participant recruitment and data collection. A number of benefits were considered 
when employing online methods for research; the most apparent was the ability to recruit a 
large sample of participants from a disease-specific population.     Additionally, using online 
methods for recruitment enabled the researcher to recruit participants living in different regions 
of the UK as opposed to a specific area. Furthermore, the use of online methods to recruit 
participants resulted in cost and time savings, for example in the quantitative study, it is highly 
unlikely that a sample of 560 participants would have been recruited in five weeks if 
participants were required to complete these measures in a face-to-face scenario as opposed 
to online. This was also found in Chapter Four where participants who were not able to take 
part in face-to-face interviews opted instead to take part over the telephone. .  
The researcher has severe AD therefore being diagnosed with the condition and sharing this 
participants may have resulted in participants perceiving the researcher as more relatable and 
approachable, facilitating recruitment and allowing participants to feel more at ease with 
sharing, often sensitive and emotion information. The researcher was also a member of the 
support group from which the majority of participants were recruited. This self-disclosure, 
defined as ‘the act of revealing personal information to others’ (Archer & Burleson, 1980, p. 
183), potentially aided in building a better rapport with participants.  
Meho (2006) and Moon (2000) advise that the researcher when conducting interviews should 
introduce and provide background information about themselves in order to encourage adults 
to participate in self-disclosure  Similarly, Johnson (2001) found that respondents were more 
likely to engage in open discussion in internet-based questionnaires when the researchers 
engaged in self-disclosure. Self-disclosure reciprocity has been identified as the situation 
where an individual is more willing to engage with self-disclosure if the person conversing with 
them has also engaged in self-disclosure (Moon, 2000).  Likewise, Valerian, Derlaga, and 
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Berg (2013) propose that if an individual provides information about themselves, the receiver 
is also more likely to do the same. The authors also suggest that this self-disclosure results in 
the recipient developing more of a liking for the self-discloser. The vast majority of participants 
in the studies were females; a study conducted in 1992 by Dindia and Allen concluded, through 
a large meta-analysis, that women were more likely to self-disclose to other women. 
Nonetheless, research exploring the impact of researcher gender on consequences of self-
disclosure and recruitment using Facebook is warranted.  Further exploration exploring the 
effects of the researcher’s gender on recruitment in predominantly female Facebook groups 
is warranted, as well as the potential outcomes for nature of the data collected and recruitment 
due to self-disclosure by the researcher.  
It is important to note that there are a number of limitations of using Facebook support groups 
to recruit participants. in addition to recruitment through dermatology clinic (chapter 5) and the 
university (chapter 4, 5 and 6) exclusion of participants from the studies was based on their 
self-report . For instance, in Chapter four, prior to participation, participants were required to 
confirm that they did not suffer from any long-term condition which was not related to their AD. 
Although, the majority of the participants were open about meeting the criteria, there is a 
possibility that participants may have suffered from other conditions and not disclosed this, 
hence taken part in the study.  
A strength of this thesis is the multi-method approach utilised (see Chapter Two for more 
detail). Using this approach enabled the exploration of participants’ lived experiences and as 
a result allowed the quantitative studies to be derived from these experiences detailed in 
Chapter four. Additionally, research questions to be explored qualitatively were recommended 
through the findings of the quantitative Chapters. For example, medication played an important 
role in QoL and disease severity in chapter five, and this identified the need for further 




This process is described as sequential, where the researcher uses another method to expand 
on the findings of one method (Creswell, Clark, & Garrett, 2003), for example, beginning with 
a qualitative design for exploratory purposes and following up with quantitative approaches to 
generalise findings to a population. Additionally, employing a mixed-method approach allows 
for the collection of data sequentially to understand research problems better (Crewell, Clark, 
& Garrett, 2003). Likewise, Denscombe (2008) advocates that using mixed-methods in 
research allows for a more comprehensive data production and a better way of building in 
initial findings and developing further analyses. Future research suggestions derived from 
quantitative findings in this thesis involve exploring the impact of different types of medication 
on QoL in those with AD and cultural differences in QoL reporting.  
7.8 Reflections through the research journey  
In this section, the journey whilst completing this thesis and a number of personal reflections 
shall be discussed, thus this section will be written in first person. Jasper (2005) states that 
reflective writing “acknowledges at the outset that what is presented is that relating and 
purporting to the experiences and perceptions of the author” (p.250).  As discussed in Chapter 
two of this thesis, I have been diagnosed with severe AD. AD affects everyone differently and 
my experience of the condition is on the severe end of the spectrum, with symptoms that have 
resulted in severe complications. It was my early diagnosis and experience of AD through 
adulthood that partly informed my decision to pursue this area of research.   
 I did not disclose my AD to participants during recruitment, however if asked why I was doing 
this research, I discussed my diagnosis and experiences of living with AD and how it 
developed my interest in the field. This discussion with my participants helped build rapport 
and may have enabled a more in-depth discussion of experiences. I have also been asked 
numerous times by colleagues, researchers, academics and friends about the reason for 
choosing this topic and the impact it has on me. I have reflected on these decisions and believe 
that although my diagnosis of AD enables me to be more empathetic towards participants, my 
experiences are largely different from many of my participants, therefore my research 
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analyses were grounded in the data and not my own experiences of AD. Additionally, I 
frequently had discussions with my supervisory team to ensure that my analyses accurately 
represented the data, in particular for the qualitative exploration (Chapter Four).  
A challenging aspect to my PhD was not my personal experiences, but rather the emotive 
nature of this research such as participants’ discussions of mental health and clinical 
diagnoses of psychiatric disorders in Chapter four. Nonetheless, although emotive, I regularly 
discussed them within my supervisory team.  As I was a member of the Facebook support 
group, another emotive factor was when recruiting through this group, I witnessed numerous 
Facebook posts on my own page due to being part of the group. At times these posts 
presented stories of patients who were in dire need of pharmacological and psychological 
interventions; this consequently had a negative impact on my mood. Therefore, after I 
completed participant recruitment for the feasibility study, I  limited the amount of posts I could 
see from these groups and also removed myself from a number of groups.  As such, online 
data collection and participant  recruitment tends to differ from face-to-face scenarios whereby 
in a face-to-face scenario you play the role of a researcher, being able to collect data from the 
participant and no longer be part of the participant’s life and experiences. However when using 
social media platforms such as Facebook, participants’ lives may become entwined with the 
researcher’s, thus it may be more challenging to remove yourself from the situation. This was 
overcome in the feasibility study whereby I recruited from the support group but created a 
designated study page where participants could join and receive study-specific updates and 
reminders. Overall, these experiences helped shape  my role as a researcher and enabled 
the development of both academic and interpersonal skills in an emotive context such as 
within this thesis.  
7.9 Concluding comments 
The findings of this thesis indicate that AD severely impacts the lives of adult patients both 
physically and psychologically. This research explored the lived experiences of adults with AD 
and identified issues perceived to be detrimental to their quality of life. A quantitative study 
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then proceeded to employ standardised psychometric instruments in order to investigate the 
impact of AD on QoL and psychological variables. Finally, a feasibility study allowed for the 
exploration of the temporal relationship between psychological stress and AD severity through 
the use of daily diaries and weekly measures. Whilst the research within this thesis has 
furthered understanding of the impact of AD on quality of life and mental health for adults living 
in the UK, there remains the need for research which explores further the quality of life in these 
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• What is already known about this topic?  
Atopic dermatitis (AD) has been found to affect quality of life (QOL) in adults with, studies reporting a 
greater impact on QoL with increased severity of AD.  Adults with AD also report poorer QoL 
compared to a healthy population and those with other medical skin conditions such as urticaria and 
psoriasis. 
 
• What does this study add? 
This paper provides the first systematic literature review and meta-analysis of the impact of AD on 
QoL in adults.  Across studies, increased disease severity significantly related to poorer QoL. 
Compared to healthy controls, adults with AD demonstrated significantly lower QoL but findings were 
mixed in studies that compared QoL in AD to other chronic conditions.  Research exploring gender 






















Background: Atopic dermatitis (AD) can affect quality of life (QoL) of adult patients, in whom the 
condition can be severe and persistent. There are currently no systematic reviews of the impact of AD 
on adults. 
Objective: This paper provides the first systematic literature review and meta-analysis of the impact of 
AD on QoL in adults. 
Methods: A systematic search was conducted using MEDLINE, Scopus, and Web of Science for 
articles published until October 2018. Inclusion criteria were a clinical diagnosis of AD, adult patients 
and QoL as an outcome measure.  Interventions were excluded. 
Results: A total of 32 studies were included. While QoL was assessed using Dermatology Life Quality 
Index (DLQI) in 25 studies, there was heterogeneity in the tools used to measure disease severity 
across studies. Meta-analysis of the seven studies that used the SCORAD to measure disease 
severity showed severity to be significantly related to poorer QoL. The remaining 18 studies also 
found increased disease severity significantly related to poorer QoL. When compared to healthy 
controls, AD patients demonstrated significantly lower QoL but findings were mixed in studies that 
compared QoL in AD to other skin conditions.  
Conclusions: The findings highlight the significant impact that AD has on QoL in adults and the need 
for validated and relevant QoL measures to be implemented in clinical assessments for AD. Areas 
that require further research include an exploration of gender differences in QoL and the use of 





Atopic dermatitis (AD) is a chronic debilitating inflammatory skin condition which mainly affects 
children but can also be present in adulthood1. AD is a significant health issue globally, with 
prevalence in children of 15-30% and 2-10% in adults2. The prevalence of AD in developed countries 
has increased two-to threefold over the past thirty years3. AD is characterised by symptoms such as 
itchy, red, dry and inflamed skin. It is a chronic condition in most people, and despite there being no 
cure for the condition, it can be managed well using emollients, topical corticosteroids and oral 
treatments such as antihistamines and immunosuppressant tablets. In the UK, 10-20% of all referrals 
to dermatologists and 30% of dermatology consultations are for AD4. A community study conducted in 
Scotland estimated that 38% of AD cases comprised adults over 16 years old5. Thus, although a 
relatively small percentage patients with AD are adults, studies also indicate a large 
percentage of adults seek treatment when compared to other age groups with AD.5,6.  
 
AD has been shown to have an impact on quality of life in children and adults7-9.  Quality of Life (QoL) 
is defined by the World Health Organization Quality of Life (WHOQoL) Group10 as an “individuals’ 
perceptions of their position in life in the context of the culture and value systems in which they live 
and in relation to their goals, expectations, standards and concerns” (p. 5). Health related QoL 
(HRQoL) is considered a valid indicator when monitoring health and service needs of patients11. 
Measuring HRQoL can help inform interventions to alleviate health conditions and is of potential value 
in performing risk-benefit analyses of clinical decisions for treatment, especially where systemic 
therapy with possible side effects is prescribed.  A review of the literature by Lifshitz7, which focused 
on the impact of AD on QoL primarily of infants, children, adolescents, and their families, reported that 
AD had a significant and lasting effect on HRQoL, in particular on psychological wellbeing and social 
functioning. A review by Lewis-Jones8 on QoL and childhood AD confirmed that QoL in children and 
adolescents was severely impaired with issues such as embarrassment and bullying affecting children 
psycho-socially and physically.  
 
Relatively little research has been conducted with adults who have AD, but the research that has 
been conducted suggests that all aspects of HRQoL are affected in adults with AD, and that HRQoL 
is more compromised in adults with AD when compared to adults with chronic urticaria and psoriasis9.  
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In addition, little is known about how HRQoL of AD patients varies with disease severity; the literature 
that has investigated this issue has found that greater disease severity is related to poorer 
HRQoL12,13. To draw together what is currently known in this area and identify gaps in knowledge, the 
present study reports the results of a systematic review and meta-analysis of the impact of Atopic 
Dermatitis on QoL in adult patients. 
 
METHODS 
Study searches were conducted using three electronic databases: MEDLINE, Scopus and Web of 
Science Core Collection. Databases were searched up to 24th October 2018 with no limit to the start 
date.  Search terms can be found in the supplementary information.  The initial search was conducted 
by the lead author; all members of the study team reviewed all full papers retrieved for evaluation. 
Inclusion/exclusion strategy and data extraction  
To be included in this review studies had to report data from adults. The legal age of adulthood differs 
according to country. This review included participants aged 18 and above or 16 and above if defined 
as an adult in a study, adolescents were excluded. Studies that combined adult and children data into 
one analysis were excluded. Studies that collected data from both adults and children, but reported 
data separately for these sub-groups, were retained in the review. Studies that measured QoL as a 
result of medical or psychological interventions were excluded. Study search was limited to English-
language articles on human populations. Case-reports and conference abstracts were excluded. All 
study types were included if they reported on a QoL measure.   
Outcomes 
The primary outcome in this review was QoL in adult patients with AD. QoL was measured either on 
its own, in relation to disease severity, compared to healthy controls or compared to patients with 
other conditions, such as psoriasis.  
Quality Appraisal  
The quality of the included studies was assessed using the Mixed Methods Assessment Tool 






Data synthesis   
Where studies reported QoL scores using the same instruments, results were pooled using meta-
analysis. In cases where pooling was not considered appropriate, detailed descriptions of study 
characteristics and results were reported alongside study quality.  
 
RESULTS 
Figure 1 outlines the search strategy following the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) standards15.  A total of 32 papers met inclusion criteria and were 
included in this systematic review. No mixed methods or qualitative papers included a measure of 
QoL, therefore all included papers in this review are quantitative and reviewed using narrative 
synthesis. Seven papers reported a correlation between the Dermatology Life Quality Index (DLQI) 
and a validated measure of AD severity (SCORAD). Correlations from these papers were pooled 
using random-effects meta-analysis in Comprehensive Meta-Analysis Version 3 (2005, Biostat Inc.). 
Table 1 reports study characteristics. Using the MMAT, 24 studies were of higher quality, scoring 75-
100% and eight studies were of lower quality, scoring 25-50% (see supplementary Table 1). 
 
Quality of Life 
The DLQI was used to measure QoL in 25 out of 32 studies included in this review. Mean overall 
DLQI scores ranged across studies from 4.9 (small effect on patient’s QoL) to 20.5 (very large effect 
on patient’s QoL). In studies which looked at differences across the dimensions of QoL, the areas that 
were most affected as measured using the DLQI were symptoms and feelings surrounding AD; 
patients felt embarrassed or self-conscious due to their AD and symptoms such as itchy, sore, painful 
and stinging skin had a detrimental impact on their QoL16-21. Personal relationships were the least 
affected dimension of QoL16,17,19,20. Mozaffari et al22 found that patients perceived dressing, 
undressing and bath-time as being most problematic while the dimension ‘family activities’ was least 
affected. Holm et al21 also found that dressing was particularly problematic. Using the EQ-5D as a 
measure of QoL, daily activity and pain/discomfort parameters were reported to be most affected in 





Quality of Life and Disease Severity 
Twenty studies explored the relationship between disease severity and QoL. Nineteen studies looked 
at this using DLQI in AD patients (see Table 2). Eighteen of these reported significant correlations 
between disease severity and DLQI; the more severe the disease, the lower the QoL.  In seven of 
these studies, QoL using the DLQI was compared with disease severity measured using the 
SCORAD 12,16,26,27,28,29,30. These studies were pooled together using random effects meta-analysis 
(See Figure 2).  The sample-weighted average correlation between HRQoL and disease severity was 
r+ = .44 (CI 0.27; 0.59), indicating a medium-sized relationship31, with greater disease severity relating 
to poorer QoL. There was significant heterogeneity in the results (χ2 = 13.78, p < .05). This could 
partly be explained by the small correlation reported by Haeck et al12.. 
 
Two studies25,32 used the EASI to measure AD severity in relation to QoL.  Both studies found 
statistically significant relationships between QoL and disease severity (ps < .05); QoL was perceived 
as being poorer with increasing disease severity, with personal relationships being related to a lesser 
extent to disease severity than other domains. . 
 
Nine studies13,17,18,19,22,23,24,34,35 explored relationships between patient-assessed disease severity and 
DLQI scores and reported statistically significant medium to large sized correlations whereby an 
increase in disease severity was associated with a decrease in QoL.. Two studies37,38 explored 
gender differences and found a significant positive correlation between patient-assessed disease 
severity and DLQI score (p < .001) and between visible regions and DLQI score (p = .001) for women, 
however neither of these correlations were observed in men.  
 
Two studies33,39 assessed severity using the Rajka & Langeland scoring system which measures 
clinical course, severity, and extent of AD. Both studies found statistically significant correlations 
between disease severity and QoL. Highest correlations found were between disease severity and 
symptoms and feelings; higher disease severity was related to worsening symptoms and feelings as a 




Ten studies used the SF-36 to measure QoL; six of these looked at the relationship between SF-36 
scores and disease severity17,19,24,25,32,33,40,41 . Five studies found significant correlations between 
disease severity and the SF-36, with increased severity associated with poorer QoL. However one 
study25 found no significant correlations between any SF-36 subscales and clinically measured 
disease severity (EASI). The correlations between the SF-36 and disease severity across the six 
studies were small to large-sized. The mean physical dimension scores appeared to be less impaired 
in AD patients compared to the mean mental component scores of the scale17,24,32,3342,43  .  
 
Quality of life in patients with AD compared to healthy controls or other patient groups 
A total of 15 studies compared adults with AD QoL to that of healthy controls.  Ten studies used 
generic QoL scales such as the SF-36 to enable comparison across groups19,23,24,25,33,35,40,41,43,44 ., 
three studies used dermatology specific QoL scales to make comparisons22,26,45 and three 
studies35,37,46 used both generic and dermatology specific scales.  Overall QoL was significantly 
poorer in those with AD compared to healthy controls and, domains such as mental health and social 
functioning were affected to a greater extent in AD patients17,22,29,35 . In a recent study by Misery et al46 
scores on the mental dimension of the SF-12 were lower in AD patients with visible area involvement 
compared to those without (p<0.001).  
 
Two studies compared QoL between vitiligo and AD patients34,45 and found significantly lower QoL in 
the AD groups compared to the vitiligo groups (ps<0.001). Four studies compared QoL between 
psoriasis and AD patients9,19,34,41. Two of these studies found that AD patients had significantly lower 
QoL than patients with psoriasis9,34 whereas Lunderberg et al.19 found significant differences in the 
physical and mental functioning domains; with AD patients scored better than patients with psoriasis. 
Eckert et al41 found no significant differences in QoL ratings in patients with psoriasis or AD. Grob et 
al9 also compared AD with chronic urticaria and found that AD patients were more affected by skin 
discomfort than chronic urticaria patients.  They also had lower scores in relation to ‘treatment 







This systematic review examined the impact of AD on QoL in adults. The DLQI and the SF36 were 
the most frequently used scales to measure QoL in patients with AD, and studies in this review looked 
at QoL in relation to disease severity, other chronic skin conditions, or healthy controls. The 
qualitative synthesis of results and meta-analysis show that there is a consistent relationship between 
increasing AD severity and poorer QoL in adults, and adult patients with AD have poorer QoL than 
healthy groups.  Findings are more equivocal for comparisons with other chronic skin conditions. 
 
Qol and disease severity 
Nineteen of the 20 studies that measured QoL in relation to disease severity found increased disease 
severity was significantly related to poorer QoL. This finding is consistent with reviews looking at QoL 
in children with AD8,47. Almost all adult patients had mild to moderate AD in the studies included in this 
review. Interestingly, in paediatric studies where more patients had moderate to severe AD, QoL 
correlated less well with disease severity than the adult patients with mild to moderate AD in this 
review48,49. The consistent finding that disease severity was related to QoL underscores not only the 
importance of offering both dermatological and psychological treatment to patients, but also the need 
to incorporate QoL screening tools in dermatology. Nonetheless, AD is a complex condition and QoL 
cannot solely be explained by severity of the disease as most studies reported low to medium 
correlations between the two variables. One factor that may influence QoL and may explain 
differences between studies is time of recruitment whereby patients could be experiencing a flare-up 
during recruitment, thus affecting QoL scores; this is especially the case if participants were recruited 
during dermatology visits.  
 
QOL and patients with AD compared to other healthy controls 
All studies that compared QoL in AD patients to healthy controls found significantly lower QoL in AD 
patients. However, four studies used the DLQI measure to explore this difference; the DLQI is a 
dermatology specific questionnaire with questions that are not suitable for use in a sample of the 
general population. In such cases, generic QoL measures such as the SF-36 should be employed. 
When using the SF-36, better physical QoL was reported by studies in this review compared to 
mental QoL. This is in line with a systematic review carried out looking at QoL in psoriasis patients50. 
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The SF-36 is probably not sensitive enough to measure the physical limitations of AD due to its 
generic nature; questions relating to walking abilities for example are unlikely to be relevant to this 
group.   
 
QOL and patients with AD compared to other chronic skin conditions 
Studies comparing QoL to other chronic skin conditions had mixed results, but for those comparing 
vitiligo and AD patients, significantly lower QoL was seen for AD. This may be because vitiligo is not 
accompanied by symptoms such as itching, inflammation, and sleeplessness. Symptoms such as 
pruritus have more of an impact on QoL than visual aspects; indeed, this review found that the area of 
QoL most affected was symptoms surrounding AD. Studies reporting better physical and mental 
functioning scores in patients with AD compared to those with psoriasis and poorer scores in patients 
with AD regarding skin discomfort compared to urticaria suggests that pruritus is the dominant factor 
that interferes with everyday life. Further, the contrast between lower scores related to ‘treatment 
induced restrictions’ in patients with AD and better scores in patients with chronic urticaria suggest 
that topical treatments can be highly restrictive to patients. Indeed, alternative/complementary 
therapies for AD, such as Chinese herbal therapy have become increasingly popular51,52,53 
 
Demographic characteristics of patients 
Many of the participants in the included studies were female.  Partly this reflects health care 
utilization, whereby women use more health services and an estimated 67% of women worldwide 
make all medical choices in society54; in this case, most of the participants were out-patients in 
dermatology clinics. Only one study looking primarily at gender differences in QoL and AD and found 
no significant correlation between disease severity and QoL in males but a significant positive 
correlation was present in females. Thus, the extent to which the AD severity is correlated with QoL in 
in relation to females rather than males deserves further research attention. Lesions located in visible 
areas have been found to affect women more than men37 possibly because women may have a 
higher ideal of culturally determined physical appearance than men so more attention is given to the 
skin.  Gender differences have been found in other allergic conditions with females presenting more 






Limitations of the studies in this review 
The heterogeneity in tools used to measure disease severity made it impossible to pool results across 
all included studies. The SCORAD and EASI are generally preferred by researchers over patient-
assessed severity or visual analogue scales as they are validated measures of disease severity. 
However, they do not cover all issues affected in AD patients, for example, SCORAD only measures 
disease severity over the preceding three days, therefore long-term severity effects on QoL cannot be 
inferred. Nevertheless, studies that included both patient-assessed severity and objective measures 
found relatively strong correlations between the two, indicating that patients can self-assess their 
disease severity accurately.  
 
All studies included in this review used cross-sectional methods to assess QoL in relation to disease 
severity. Results using this methodology should be interpreted with caution as it’s impossible to 
determine cause and effect. Future studies should utilise prospective designs and collect more 
longitudinal data to strengthen predictive power of psychological and clinical variables of QoL.  AD is 
generally better during the summer and worse in winter58. Only one study specified the season.  
 
Although the quality appraisal for the studies showed that the majority had good to excellent ratings, 
many suffered from methodological weaknesses, such as the use of small sample sizes, or the use of 
non-validated measures. Other issues included absence of statistical testing and incomplete 
presentation of QoL data such as descriptive statistics. In addition, some studies used dermatology 
specific questionnaires to determine QoL in healthy controls.   
 
Conclusions and directions for future research  
This study is the first systematic review and meta-analysis conducted on adults and demonstrates 
that AD influences all aspects of the lives of adult sufferers. Results support findings from previous 
research on similar skin conditions50,60 and in children7,8,47.  The present review points to several 
areas for future research. In the present review, overall scores were difficult to interpret because of 
the variability of scores and the absence of formal reference values or norm scores, or the absence of 
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formal comparisons with population norms. More research with validated psychometric scales is 
needed to generate a consistent body of knowledge of overall QoL of patients with AD. Furthermore, 
application of both generic and disease- or dermatology-specific quality-of-life questionnaire which 
cover the full range of quality-of-life issues are needed. 
 
Second, data on the relationship between specific AD characteristics and QoL suggest that itch, sleep 
disturbances, and exacerbations in facial and genital body areas34 could be relevant predictors of 
quality of life, as reported by a few studies in this review,13,34,45. A deeper insight into these 
relationships is important because of consequences for disease-severity measurement in quality-of-
life research; indeed, a more qualitative approach would help uncover some of these issues. 
 
Researchers in dermatology are encouraged to utilise validated and clinically relevant QoL measures 
for patients that provide accurate measurement of quality of life and allow for subsequent comparison 
of results across studies. Factors such as sleep disturbances and pruritus should be included when 
determining QoL and future studies should also further explore gender differences in QoL in adults 
with AD; only a few studies in this review considered these factors. Longitudinal study designs are 
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Table 1. Study characteristics 
Authors Country N Participants Measures used  Outcomes measured Outcomes measured 





Arima et al (2018) Japan 638 Mean age- 38.67 years, 52.37% female. 
45.45% rated severity as 
moderate/severe, 54.54% rated severity 




SF-36 QoL comparisons 
between patient groups 
and healthy controls 
AD patients reported significantly reduced HRQoL 
relative to matched non-AD controls (p<0.001) for 
mental and physical domains of the SF-36.  
Baron et al (2006)
  
UK 63 Mean age – 34 years, Mean duration of 
AD- 15.2 years, 26 men and 37 women  
SCORAD DLQI Relationship between 
disease severity and QoL  
The mean DLQI reduced over all three visits from 9.5 to 
8.8 at T2 to 7 at T3. The DLQI was significantly 
correlated with SCORAD at T1 (r= 0.389, p <0.01) and at 
T2 (r=0.321, p < 0.01) but not at T3. Mean SCORAD 
reduced by 52% from T1 to T2 (F 2,62 =37.9, <0.001) but 




Beikert et al 
(2014) 
Germany 384 384 AD patients (mean age 42, range- 
18-92, 69.8% female). Patients with AD 




DLQI Relationship between 
disease severity and 
QoL; Comparisons 
between AD patients 
and patients with other 
conditions. 
The mean DLQI total score in AD was 8.5, compared to 
7.0 in Vitiligo and 6.7 in psoriasis and 4.3 in rosacea. 
Impairment of QoL measured by DLQI correlated 
positively with the affected body surface area (r=0.46, 
p<0.001). Characteristic AD symptoms such as skin 
dryness, pruritus, and sleep disturbances also correlated 
significantly with the DLQI total score (rs=0.34 to 0.53, 
p<0.001). 
Chen et al (2012) Taiwan 
 
1132 The participants were categorized in to 3 
groups: 1) AD (n=90), 2) non-atopic hand 
eczema (n=205), 3) control group with 
no aforementioned skin conditions 
(n=837), average age- 30.5 years, 100% 
female. 
- SF-36 QoL comparisons 
between patient groups 
and healthy controls; 
Comparisons between 
AD patients and patients 
with other conditions. 
QoL was significantly lower for patients with AD 
compared to controls in 5 out of 8 domains including 
social functioning, bodily pain, vitality, mental health 
and general health (ps <0.05). No significant difference 
was found between the AD group and the non-atopic 
eczema group in all domains of QoL investigated. 
Chrostowska-Plak 
et al (2013) 
Poland 89 59 females and 30 males. Mean age- 
31.6 years.  Mean disease duration- 22.8 
years.   
SCORAD DLQI Relationship between 
disease severity and 
QoL. 
There was a significant correlation between pruritus and 
HRQoL (r= 0.5, p < 0.001) DLQI also correlated with 
periods without itching indicating that patients with 
longer itching-free periods had better HRQoL (r= 0.23, 
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p<0.05) There was a significant correlation between the 
severity of the disease (using SCORAD) and HRQOL 
(r=0.65, p < 0.001) 
Coghi et al (2007) Brazil 75 Patients were diagnosed and treated as 
isolated AD by the attending clinician; 
65.33% were females, mean age -26.28 





disease severity and QoL 
QoL and disease control were found to be related but 
with low scores both in DLQI (r = 0.26) and in SF-36 (r = 
0.2) but with greater correlation for SF-36 mental 
components. Both correlations were significant (p < 
0.001).  
Eckert et al (2017) USA 349 Mean age- 46.1 years; 68.3% women; 




SF-36 QoL comparisons 
between patient groups 
and healthy controls; 
Comparisons between 
AD patients and patients 
with other conditions. 
AD patients reported lsignificantly reduced HRQoL 
relative to matched non-AD controls for both mental 
and physical domains of the SF-36 (P<0.001 & p=0.004 
respectively). Compared with psoriasis, AD had a similar 
impact on HRQoL.  
Finlay (1996) UK 92 43 males and 49 females; average age 




DLQI Comparisons between 
AD patients and patients 
with other conditions.  
The mean DLQI index was 18 with subsections relating 
to ‘symptoms and feelings’ and ‘treatment effects’ 
scoring highest. Disease comparison utility questions 
demonstrated that patients consider diabetes and 
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hypertension would be better than having eczema 
whereas bronchitis would be worse than having eczema. 
Fivenson et al 
(2002) 
USA 107 Cohort- 298; 107 adults; mean age of 











disease severity and 
QoL, QoL comparisons 
between patient groups 
and healthy controls. 
46% of adults had mild disease, 11% adults had severe 
disease. In terms of provider assessed severity, 51% 
adults had mild disease. The mean DLQI score was 6.6 
for adults with a range of 0 to 27. The mean score for 
DLQI increased with increasing disease severity for all 
but two questions. For the SF-36, statistically significant 
differences were detected between the study group and 
the US population norms for vitality, social functioning, 
and mental health. Patient-assessed severity had a 
stronger association with DLQI (r = 0.57, p = 0.0001) 
than provider-assessed severity (r = 0.27, p = 0.0036).  
Grob et al (2005) France 
  
1356 An investigator had to recruit clusters of 
three patients, one with chronic 
urticarial (CU), one with psoriasis (PSO) 
and one with AD, matched by sex and 







AD patients and patients 
with other conditions.  
After adjustment for confounders, HRQoL dimensions 
were differently affected in the three diseases. The 
‘physical discomfort’ dimension was more degraded in 
AD and CU than in PSO (p < 0.001) and ‘leisure activities 
more in PSO than in CU (p < 0.001). No aspect of HRQoL 
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was rated by the physicians as 
minimal/moderate/severe/very severe 
was spared in AD. The mean overall VQ-Dermato index 
was significantly lower in CU (M= 36.93) and in PSO (M= 
38.88) than in AD (M= 44.62, p < 0.001). 




54 Average age of the patients was 37.3. At 
inclusion, the average objective SCORAD 
was 43 indicating severe AD, average 
DLQI was 14.6 indicating a large effect 
on QoL. 
SCORAD,  DLQI Relationship between 
disease severity and QoL 
At t=0, there was a small non-significant correlation 
between the DLQI and objective SCORAD, ‘rule of nine’ 
or serum TARC level. At t=6 the objective SCORAD, 
serum TARC and the ‘rule of nines’ scores showed 
moderate and significant correlations with the DLQI (r = 
0.34, p = 0.02; r = 0.31, p = 0.03; r = 0.49, p <0.001). An 
individual’s improvement in disease activity (SCORAD, 
SASSAD and ‘rule of nines’) with 10 points was 
associated with an improvement in DLQI.  
Higaki et al (2004) Japan 162 162 patients with AD ranged in age from 
17-77 years: the mean age was 29 years; 
55% were female. 17 had mild, 107 had 









disease severity and QoL 
Each of the three scale scores (symptoms, emotions and 
functioning) of the patients with AD were significantly 
higher than those of patients with isolated lesions. 
Patients with severe AD showed significantly higher 
scores in the three scales, as well as the Global Scale 





significant positive correlation between the severity and 
each of the three scale scores (r’s= 0.32 to 0.45, p < 
0.001).  
Holm et al (2004) Denmark 112 Mean duration of AD of 28.6 years. 
Females (n=88) and males (n=24); mean 




DLQI  Relationship between 
disease severity and 
QoL, Differences in QoL 
between men and 
women with AD 
For women, there was a significant positive correlation 
between disease severity ad DLQI score (KW test, 15.9; 
p < 0.001) and also between DLQI score and visible 
regions affected by disease (KW test, 14.2; p = 0.001); 
these correlations were not observed in men. No 
significant differences between men and women were 
noted for age, disease duration, overall disease severity 
or QoL as assesse using the DLQI. 
Holm et al (2006) Denmark 101 101 atopic eczema patients, 66 adults 









disease severity and 
QoL, QoL comparisons 
between patient groups 
and healthy controls. 
Patients with AE had significantly lower QoL (p<0.05) 
than healthy controls (median DLQI score 5 in AD 
patients vs. 0 in controls) and the general population. 
DLQI, pruritus and patents and investigator overall 
assessment of eczema severity were significantly (p < 
0.0001) and positively correlated with SCORAD, while 
the generic questionnaire showed only poor correlation.  
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Holm et al (2016) Denmark 191 Mean age-  31.32 years, 59.2% females SCORAD DLQI Relationship between 
disease severity and QoL 
Significant relationship between disease severity and 
HRQoL ( r=0.42, P<0.001), with increase disease severity 
significantly associated with worsening HRQoL.  There 
was also a significant relationship between DLQI and 
self-rated health (r=-0.37, p<0.001).  
Kiebert et al 
(2002) 
USA 239 Mean age- 36 years, 79% female; 18.2 
years mean duration of disease, 46% 
mild severity, 41% moderate severity, 







disease severity and 
QoL; QoL comparisons 
between patient groups 
and healthy controls. 
SF-36 scores showed a significant decrease with 
increasing disease severity.  DLQI scores correlated well 
with patients ratings of disease severity. The SF-36 
scores correlated significantly with DLQI scores. The SF-
36 scores of patients with AD were significantly lower 
(indicative of more impairment) than those of the 
general population. The mental component score of the 
SF-36 was significantly correlated with patient severity 
rating (r=-0.41, p<0.001), the physical component was 
not. 
Kim et al (2012) Korea 415  Subjects were divided in to three 
groups; infants, children and adults ((75 
SCORAD DLQI Relationship between 
disease severity and 
QoL. 
The total mean DLQI score was 10.7. No significant 
differences in gender and age were observed. Adults 
with atopic disease including AD with concomitant 
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males and 72 females). Mean age of 
adults= 25.8 years. 
asthma, allergic rhinitis or allergic conjunctivitis had 
higher total scores than those with AD alone. Both the 
Rajka & Langeland eczema severity score (r=0.261, 
p<0.05) and SCORAD index correlated significantly with 
all the total QoL scores (r=0.432, p < 0.001). 
Kong et al (2016) Korea 50 22 men and 28 women, mean age 26.4 
years. 
SCORAD DLQI Relationship between 
disease severity and QoL 
Significant relationship between disease severity and 
HRQoL ( r=0.237, P<0.001), with increase disease 
severity significantly associated with worsening HRQoL. 
There was also a significant association between sleep 
disturbance and QoL (r=0.388, p=0.04), with increase 
sleep disruption associated with worsening QoL.  
Kwak et al (2017) Korea 157 Mean age- 35.2 years; 51.8% Males; 
11,756 non-AD controls (mean age- 45.3 
years; 49.3% male)  
- EQVAS QoL comparisons 
between patient groups 
and healthy controls 
Adults with AD had lower HRQoL (p=0.013) and more 
stress (p=0.002) than those with AD. Even when 
controlling for demographic characteristics, HRQoL of 
adults with AD was lower than adults without AD. 
Lee et al (2018)  Korea 677 Mean age 36.1 years; 47.8% females; 






between patient groups 
and healthy controls 
EQ-VAS scores were significantly higher in patients with 
AD than in those without AD (p=0.004). A higher rate of 
pain/discomfort, and anxiety/depression was found on 
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the EQ-5D in AD patients compared to controls (p=0.003 
and p<0.001, respectively).  
Linnet & Jemec 
(1999) 
Denmark 54 23 women (mean age=27.5), 9 men 
(mean age=30.3); average duration of 
condition=26.1 years. Aged 18-60 years. 
SCORAD DLQI Relationship between 
disease severity and 
QoL; QoL comparisons 
between patients groups 
and healthy controls. 
AD patients- significantly lower dermatological life 
quality (Z= 5.1, p<0.001) and higher state (Z= 2.14, 
p<0.032) and trait (Z= 3.49, p<0.001) anxiety compared 
to the control group. Significant positive correlation 
between SCORAD and DLQI (r= 0.54, p<0.002). 
Lundberg et al 
(2000) 
Sweden  366 The average duration of AD was 25.83 
years and the mean age of AD patients 
was 34.79 years old; 92% were male. 
The average duration of psoriasis was 
18.39 years and the mean age of 
psoriasis patients was 49.87 years old; 







disease severity and 
QoL; QoL comparisons 
between patients groups 
and healthy controls; 
Comparisons between 
AD patients and patients 
with other conditions. 
DLQI scores showed poorer HRQoL for patients with AD 
compared to psoriatic patients but this was not 
significant when controlling for confounding factors. No 
significant difference on the SF-36 between patients 
with AD and patients with psoriasis. There was a 
decreasing DLQI score for patients of higher ages; 
improved HRQoL. Spearman’s correlation coefficients 
showed that all SF-36 dimensions were significantly 
correlated with all measures of disease activity (r= 0.182 
to 0.526), the DLQI correlations with VAS were also 
significant (r=0.005 to 0.595). 
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Maksimovic et al 
(2012) 
Serbia 130 Adults- 56.1% female, mean age 34.18 
years, mean age of onset of disease -
13.95 years, mean duration of disease- 




disease severity and 
QoL, QoL comparisons 
between patient groups 
and healthy controls. 
The DLQI scores corresponded well with disease 
severity; increased disease severity was associated with 
greater impairment in HRQoL (r=0.14 to 0.47 for all 
domains of the DLQI). In adults, significant differences 
were only found between DLQI scores for mild and 
severe AD. The highest correlations were seen between 
symptoms and feelings and daily activities (r = 0.75, p < 
0.01), symptoms and feelings and work/school (r = 0.53, 
p < 0.01) and leisure and work/school (r = 0.59, p < 
0.01). Patients with AD had inferior social functioning 
and mental health scores compared with the general 
population. 
Mikolajczyk et al 
(2017) 
Poland  59 36 women and 23 men with AD; aged 18 
to 46 years; mean age- 26.9 years; mean 
disease duration- 15.1 years 
- DLQI Gender differences in 
QoL; impact of illness 
duration on QoL 
No significant differences between women and men for 
DLQI scores (p>0.05); significant correlations between 
QoL and health evaluation and body areas satisfaction 
(r=-0.48), appearance orientation (r=0.31).  
264 
 




266 34.2% patients were males and 65.8% 
were females. The mean age was 32.7 
years and mean duration was 19.3 years. 
1,6% had mild AD, 42.9% had moderate 







 QoL comparisons 
between patient groups 
and healthy controls. 
The mean DLQI score was 8.8 and the physical and 
mental composite 12 scores were 50.7 and 39.5 
respectively. Analyses according to SCORAD showed 
DLQI scores 6.8 (SD=4.4) and 10.2 (SD=5.6) for moderate 
and severe AD groups (p<0.0001).  
Misery et al 
(2018) 
France 1024 58.3% female; 27.6% mild AD, 40.4% 




Differences in QoL by 
visible area involvement  
Patients with visible area involvement were found to 
have lower QoL than those without (p<0.0001), EQ-5D 
(p<0.05), and the mental score of the SF-12 (p<0.0001). 
No differences in physical score of SF-12.  
Mozaffari et al 
(2007)  
Iran 184 75% AD adults were female, 57.2% 
control group adults were female. Mean 
age of AD adults was 38.25 and mean 
duration of disease was 20.6 years, 9.5% 
had mild AD, 12% had moderate AD, and 




DLQI Relationship between 
disease severity and 
QoL, QoL comparisons 
between patient groups 
and healthy controls. 
Significant differences between DLQI mean scores in AD 
group (M=20.5 SD=4.7) and control group (M=1.15, 
SD=0.85) mean score (p < 0.001). Scores of each 
question were significantly higher in the AD group than 
in the control group (p<0.001). Correlation between 
DLQI and AD severity was significantly positive (r=0.88, p 
< 0.001).  
Noh et al (2013) Korea 180 27 males (45%), 33 females (55%) with 
AD, mean age 32.4 years. Mean age of 
EASI DLQI QoL comparisons 
between patient groups 
AD patients- significantly higher scores for all 5 
questionnaire items compared with normal controls 
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Vitiligo patients was 35.1 (31 males and 
29 females), mean age of normal 
controls was 31.9 (25 males and 35 
females). 
and healthy controls; 
Comparisons between 
AD patients and patients 
with other conditions.  
(p<0.001). In the comparison between the AD and 
Vitiligo groups, AD patients reported lower QoL (β= 
0.752, t=11.522, p < 0.001) 
Sanchez-Perez et 
al (2012) 
Spain 323 Adults mean age was 32.3 years and 
58.7% were women; over half of adults 
(55.8%) were aged between 18 and 30 
years. Concomitant disease was 
observed in 40% of adults. 
EASI, patient 
assessed 
severity   
DLQI Relationship between 
disease severity and QoL 
Significant differences in QoL observed according to 
investigator assessed severity (mild disease – M=5.5, 
SD=5.3; Moderate disease- M=7.5, SD=4.8; severe 
disease- M=12, SD=5; p < 0.05). Pruritus caused 
everyday problems related to sleep and sexual function. 
The presence and intensity of pruritus was very closely 
related to HRQoL, with a high correlation coefficient 
between overall itch severity scale (ISS) score and 
overall DLQI score (0.72).  
Silverberg et al 
(2018)  
USA 602 53.6% female and 71.9% White, with 
mean age of 52 years. AD severity was 
measured using self-reported global 
severity- 53.1% mild, 38.8% moderate, 






disease severity and 
QoL; Comparisons 
between AD patients 
SF-12 mental health sub-scores for moderate AD were 
lower than all other disorders (e.g. diabetes, asthma, 
anxiety/depression, heart disease) and for severe AD, 
dramatically lower than all other disorders. Little 
difference between physical health scores across 
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and patients with other 
conditions. 
disorders. Moderate and severe AD (using PO-SCORAD, 
PEOM and global severity) were significantly associated 
with DLQI (ps<0.0001).  
Torrelo et al 
(2013) 
Spain 282  48.2% were male and mean age of the 
adults was 33.06 years. 79.4% had 
moderate AD and 19.9% had severe AD. 





DLQI Differences between 
groups for disease 
severity.  
Statistically significant impact on the daily lives of 
patients receiving maintenance therapy. However 
patients with moderate AD had higher levels of 
emotional, physical and social well-being compared to 
those with severe AD (p < 0.05). 
Wittkowski et al 
(2004) 
England 125 23 males, 102 females; aged 18 to 66 
(mean age of 37.2 years).  The mean 




DLQI Relationship between 
disease severity and QoL 
Disease severity was significantly correlated with QoL (r 
= 0.49, p < 0.01), perceptions of stigma (r = -0.28, p < 
0.01) and depression (r = 0.18, p < 0.05). 46.7% of the 
variance in DLQI scores (p<0.001) was explained by 
depression and disease severity. Disease severity 






Table 2 Questionnaires used by studies reporting correlations or mean differences across 
















Arima, Gupta, Gadkari, Hiragun, Kono, 
Katayama, & Eckert(2018) 
 ****   
Baron, Morris, Dye, Fielding, & Goulden 
(2006) 
**   ** 
Beikert, Langenbruch, Radtke, Kornek, 
Purwins, & Augustin (2014) 
***  ***  
Chen, Wu, Li, Ko, Yu, & Chen et al., (2012)  *** ***  
Chrostowska-Plak, Reich, & Szepietowski 
(2012) 
**    
Coghi, Bortoletto, Sampaio, Junior, & Aoki 
(2007) 
*   * 
Eckert, Gupta,  Amand, Gadkari., & 
Mahajan (2016) 
 **** ****  
Finlay (1996)   ***  
Fivenson, Arnold, Kaniecki, Cohen, Frech, & 
Finlay (2002) 
*** ***   
Grob, Revuz, Ortonne, Auqueir, & Lorette 
(2005) 
  ****  
Haeck, Berge, Velsen, Bruin-Weller, 
Bruijnzeel-Koomen, & Knol (2011) 
**    
Higaki, Kawamoto, Kamo, Ueda, Arikawa, & 
Kawashima (2004) 
****   **** 
Holm, Agner, Clausen, & Thomsen, (2016) **    
Holm, Esmann, & Jemec (2004) ***   *** 
Holm, Wulf, Stegmann, & Jemec (2006) *** **  •• 
Kiebert, Sorensen, Revicki, Fagan, Doyle, 
Cohen & Fivenson (2002) 
*** ***   
Kim, Li, Seo, Jo, Yim, Kim, et al (2012) **    
Kong, Han, Lee, & Son (2016) **    
Kwak & Kim (2017)  ****   
Lee, Lee, Lee, Lee, Lee, & Park. (2018)  ****   
Linnet & Jemec (1999) ** **   
Lundberg, Johannesson, Silverdahl, 
Hermansson & Lindberg (2000) 
*** *** ***  
Maksimovic, Jankovic, Marinkovic, 
Sekulovic, Zivkivic, & Spiric (2012) 
*   * 
Mikołajczyk, Rzepa, Król, & Żaba, (2017).    *** 
Misery, Finlay, Martin, Bousetta, Nguyen, 
Myon, et al (2007) 
     ** 
Misery, Seneschal, Ezzedine, Heas,  
Merhand, Reguiai, & Taieb, (2017) 
   ** 
Mozaffari, Pourpak, Pourseyed, Farhoodi, 
Aghasmohammadi, & Movahadi et al 
(2007) 
*** ***   
Noh, Kim, Park, Hann, & Oh (2013)  * *  
Sanchez-Perez, Dauden-Tello, Mora, & 
Surinyac (2012) 
***   *** 
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Silverberg,  Gelfand, Margolis, 
Boguniewicz, Fonacier, Grayson, & 
Fuxench. (2018) 
**  **  
Torrelo, Ortiz, Alomar,Ros, Pedrosa, & 
Cuervo (2013) 
   *** 
Wittkowski, Richards, Griffiths, & Main 
(2003) 
***   *** 
NOTE: *- studies measuring DLQI in relation to EASI, **studies measuring DLQI in relation to SCORAD, 
***Studies measuring DLQI using another measure of severity or no severity measure, ****studies using 
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9.4 Appendix 4 participant information sheet 
 
 
Study Title: Quality of Life in Adults with Atopic Dermatitis  
 
INFORMATION SHEET FOR PARTICIPANTS 
 
 
My name is Gurkiran Birdi and I am a PhD student at Aston University, supervised by 
Dr Rebecca Knibb, we are running a study looking at how Atopic Dermatitis affects the 
quality of life of adults.  We are inviting you to take part in this study.   
 
Before you decide if you would like to take part, it is important for you to understand 
why the research is being done and what it will involve. Please take time to read the 
following information carefully.  If anything is not clear and you would like some more 
information you can get in touch with me on the above number or email address.  
Please take your time to decide whether or not you wish to take part. 
 
The purpose of the study: 
 
Atopic Dermatitis seems to be on the increase in adults, yet there is not much research 
that looks at how it affects peoples’ lives. We would like to interview adults who have 
Atopic Dermatitis to find out how it has affected them.  Interviews are being conducted 
by Gurkiran Kaur Birdi as part of her PhD in Psychology.  
 
Why have I been chosen and what would I need to do? 
 
You have been asked to take part in the study because you have Atopic Dermatitis.  If 
you would like to take part we would like to interview you about how Atopic Dermatitis 
has affected your life.  The interviews can take place at Aston University or another 
quiet location of your choosing.  We can also do interviews over the telephone or by 
Skype.  We will tape the interviews and will ask you if you are happy for us to use your 
words when we write about the study (with your name removed). In total this will take 
about 45 minutes to an hour. 
 




No, it is up to you to decide whether or not to take part. If you decide to take part you 
will be asked to keep this information sheet and to sign a consent form, which says you 
are happy to take part in an interview. If you change your mind and wish to stop the 
interview at any point, you may do so and withdraw (stop taking part) from the study 
without giving a reason.  
 
If after taking part in the interview you wish to withdraw your data from being used, you 
can do so at any time without giving a reason, but please be aware that your data may 
have already been anonymised, analysed or published.  If you do decide to withdraw 
your data just contact us and we will destroy all the information you gave us.  
 
What are the benefits of taking part? 
 
We hope that this study will help health care professionals develop ways in which you 
can be supported to manage your Atopic Dermatitis better and subsequently improve 
your quality of life and coping mechanisms.  
 
Will I be reimbursed for my time? 
 
In return for your help you will receive £10 in Love to Shop vouchers.  
 
What are the disadvantages of taking part? 
 
There are no disadvantages or risks to taking part but you might feel a little upset 
talking about your Atopic Dermatitis.  If you decide during the interview that you want to 
stop or take a break, you can do this at any time. 
 
What will I need to do if I decide to take part? 
 
If you would like to take part, please get in touch with Gurkiran Birdi via email on 
birdigk@aston.ac.uk or by phone on 0121 204 3402. We will then get in touch with you 
to arrange an interview.   
 
 





Will the information I give in this study be kept confidential? 
 
Yes, all information collected from you for the study will be kept strictly confidential.  
That means that no one outside of the research team will see any of the information 
you give us.  Each person taking part in the study will be given a code or study number 
that we will use when looking at what they have said in the interview.  Information will 
be kept in a locked filing cabinet and on a password protected computer at Aston 
University for 6 years and then it will be destroyed. The procedures for handling, 
processing, storage and destruction of the questionnaire data collected during the 
study are compliant with the Data Protection Act 1998.   
 
If you tell us something which we feel is putting you at risk we may need to talk to you 




What will happen to the results of the study? 
      
We will write a report of the study, which will be published.  The information we collect 
will also be written up as part of a PhD in Psychology being conducted by Gurkiran 
Birdi.  We can send you a copy of the report if you would like.  Your name will not be in 
anything we publish. 
 
What if there is a problem? 
 
If you have any concerns or complaints about anything to do with this study, please 
speak to the research team and we will do our best to answer your questions.  You can 
ring Dr Rebecca Knibb on 0121 204 3402 or email her on r.knibb@aston.ac.uk.  If she 
cannot help you and you still have any worries about the way in which the study has 
been conducted, then you should contact the Director of Governance of the University 
Research Ethics Committee, Mr John Walter, at j.g.walter@aston.ac.uk or telephone 
0121 204 4665. 
 
Who has reviewed the study? 
 
This study has been looked by the School of Life and Health Sciences Ethics 
Committee at Aston University.  These are a group of people who check research to 
make sure that it protects the safety, rights, wellbeing and dignity of anyone who takes 




Can I get more information? 
 
If you are interested in taking part in this study but would like some more information 
before you decide, please talk to Dr Rebecca Knibb or email us.  If you would like to talk 
to an independent person about taking part in this study or about research in general in 
Psychology at Aston University please contact the Director of the Aston Research 
Centre for Children’s and Young People’s Health, Professor Helen Pattison, on 
h.pattison@aston.ac.uk.   
 
 







Dr Rebecca Knibb 
Chief Investigator and PhD supervisor 
 
















9.5 Appendix 5 Consent form  
 
 
    
Study Title: Quality of Life in Adults with Atopic Dermatitis 




I agree to participate in this research study looking at how Atopic Dermatitis has affected 
my quality of life 
 
I have read the study information (version 1) and know who to contact should I have any 
questions about my participation in the study.  
 
I understand that my participation in the study is voluntary, and that I am free to withdraw 
at any time.  I do not have to give any reasons or explanations for doing so.  I have been 
provided with details of who I should contact if I wish to withdraw. 
 
I agree for my interview to be recorded and understand that it will be kept confidential 
and saved using an assigned participant number. 
 
I agree for direct quotes to be used from the interview and understand that any quotes 
will be anonymised and my name will not be used in any publications from this research. 
 
I understand that all data I provide will be kept confidential and stored securely on a 
password protected computer.  Any hard copies of data will be stored in a locked filing 
cabinet. 
 
_____________________          __________________________         
______________ 
Name of Participant            Signature             
Date__________________________           _________________________ 
     ______________ 
Researcher              Signature        Date 
  
Please initial each 
box to indicate you 
have read the 
statement: 
Ethics Approval Number_____________  
 




9.6 Appendix 6 Interview schedule  
Question Rationale for asking the question Prompts 
 
Could you give me 




Start with a question that will ease 
them into the interview 
Encourage the participant to start 
talking about their AD 
Uncover how their diagnosis came 
about and how long they have 
suffered with AD. 
 
When were you first 
diagnosed with AD? 
How long have you 
suffered from AD? 
Are you aware of the 
triggers of your AD? 
How severe is your 
AD? 
 
How has AD 
impacted your daily 
life? 
 
Investigate the impact that AD has 
on a day to day basis 
Does it affect what they do/where 
they go/how they behave 
The activities that they feel they 
unable to take part in a result of their 
condition.  
 
How is life different now 
to how it would ideally 
be? 
How does your AD 
affect your day to day 
life with regards to 
money? Do you feel 
looking after your 
condition is a burden in 
financial ways? 
 
How would you 
describe yourself 
as a person in 
relation to your 
AD? 
 
Understand whether Atopic 
dermatitis affects the way they 
identify themselves 
Do they see their AD as a part of 
them – is this in a good way or a 
bad way 
Does the AD affect their lives in a 
big way? 




would you associate 
with yourself? 
 
Has AD made a 
difference to how 
you view yourself? 
 
Look into emotional well-being – 
how do they feel towards 
themselves. 
 
How would you view 
yourself differently if 
you did not have the 
condition compared to 
having it 
 
How do you think 
the people around 
 





you/close to you 
view your AD? 
How did your friends 
and family react to your 
AD? 
 
How often do you 
feel concerned 
about your AD? 
Why? 
 
Understand the emotional difficulties 
they may face towards AD 
 
How often does AD 
cross your mind? 




Tell me how you 
find dealing with 
AD on a day to day 
basis? 
 
May uncover information 
surrounding their physical and 
environmental QoL 
 
Understand whether it takes up a 
large part of their day 
How has AD affected their 




What do you do to 
cope with and 
manage your AD? 
How do you feel 
about this? 
 
What are the lengths that they go to 
to control their AD 
How much of their day does this 
take up 
 
Have you made any 
adjustments to your life 
as a result of AD? 
 




See whether they believe they can 
cope with their condition in the 
future 
How they plan to do this 
What would you like to 
do in your future? 
How do you view 
yourself in 5 or 10 years 
time? 
What do you hope to 
have achieved in 5 or 












9.7 Appendix 7 Socio-demographic questionnaire 
1. Have you been clinically diagnosed with Atopic Dermatitis/Eczema?   
          Yes  
          No  
2. Who made this diagnosis? Please tick the box that applies   
           GP  
           Nurse practitioner or physician’s assistant   
           Dermatologist  
           Paediatrician   
           Other    
If you answered ‘Other’, please 
state_____________________________________________  
3. At what age were you first diagnosed with Atopic Dermatitis? 
______________________  
4. What medication(s) have you been prescribed for your Atopic Dermatitis? 
_____________________________________________________________________
____  
5. Are you currently being treated by a dermatologist?   
          Yes   
          No   
6. How often do you have follow-up visits for your Atopic Dermatitis?   
          More than once a month  
          More than once every three months   
          Once every three months  
          Once every six months  
          Once a year or less   
7. Have you ever had doctor-diagnosed: (choose all that apply)   
          Asthma  
          Seasonal Allergies or Hayfever  
          Food Allergies  
          None of the above   
8. Did your mother, father, siblings or child ever have Atopic Dermatitis?   
          Yes  



















































Study Title: Quality of Life and Mental Health in Adults with Atopic   Dermatitis 
compared to Healthy People  
INFORMATION SHEET FOR PARTICIPANTS 
My name is Gurkiran Birdi and I am a PhD student at Aston University, supervised by Dr 
Rebecca Knibb.  We are running a study looking at how clinically diagnosed atopic 
dermatitis affects the quality of life and mental health of adults compared to healthy 
controls. We are inviting you to take part in this study. 
You are eligible to take part in this study if you have:  
• Clinically diagnosed atopic dermatitis with no other long-term conditions apart 
from co-morbid conditions such as hay fever, asthma and allergies 
• You do not have atopic dermatitis or any other long-term conditions and are 
otherwise healthy 
Before you decide if you would like to take part, it is important for you to understand why 
the research is being done and what it will involve. Please take time to read the following 
information carefully.  If anything is not clear and you would like some more information 
you can get in touch with me on the above number or email address.  Please take your 
time to decide if you wish to take part. 
The purpose of the study: 
Atopic dermatitis seems to be on the increase in adults, yet there is not much research 
that looks at how it affects peoples’ lives. We are conducting a study exploring how stress, 
quality of life, depression, and anxiety is linked with atopic dermatitis. We are also 
comparing quality of life and mental health in adults with atopic dermatitis to adults without 
atopic dermatitis who are otherwise healthy and do not have any long term/chronic health 
conditions.   
Why have I been chosen and what would I need to do? 
You have been asked to take part in the study because you either go to the dermatology 
clinic at Queen Elizabeth Hospital or have seen an advert for this study.  
If you consent to taking part in this study, we will ask you to complete a consent form 
and some questionnaires that should take no longer than about 30 minutes. The 
questionnaires ask about your quality of life, levels of stress, anxiety and depression. If 
you are reading this online, you can find the questionnaires by clicking the bottom of the 
page.  If you have been given this information in clinic or sent this information sheet and 
questionnaires by post, please fill in the questionnaires and post them back to us.  If you 
want us to send the questionnaires to you by post, just get in touch with us and we can 
send them to you. You can also complete the questionnaires with the help of Gurkiran 
Birdi, the PhD researcher.  
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Do I have to take part? 
No - taking part in this study is voluntary and if you decide to take part you can withdraw 
at any time during completion of the questionnaires without giving a reason. 
You do not need to give us your name when taking part in this study, it is completely 
anonymous.  
However, after you have completed your questionnaires and sent the answers to us, we 
will not be able to withdraw your data from the study.   
What are the benefits of taking part? 
We hope that this study may help health care professionals develop ways in which 
patients can be supported to manage their atopic dermatitis better and subsequently 
improve their quality of life. 
What are the disadvantages or risks of taking part? 
You may feel upset answering questions about anxiety or depression, or questions about 
how your condition has affected you if you are a patient.  You may stop answering 
questions at any time you wish and either take a break or decide you do not want to take 
part anymore.  
What will I need to do if I decide to take part?  
If you are reading this online, clicking to the next page will take you to a consent form.  
You will need to fill this in to tell us that you are happy to take part.  You then just need 
to fill in the questionnaires.   
If you have been sent this information sheet and questionnaires by post or they have 
been given to you in clinic, you can find the consent forms with the questionnaires.  You 
will need to fill these in and post them back to us.  Or you can find everything online at 
xxxx. 
INFORMATION ABOUT THE CONDUCT OF THE STUDY 
Will the information I give in this study be kept confidential? 
Yes, all information collected from you for the study will be kept strictly confidential. That 
means that no one outside of the research team will see any of the information you give 
us.  You do not need to give us your name so we will not know the information has 
come from you.   
After you have completed your questionnaires and sent the answers to us, we will not 
be able to withdraw your data from the study, as the data collected from you will be 
anonymous and will not have your contact information on it. 
Information collected during this study will be kept in a locked filing cabinet and on a 
password protected computer at Aston University until the study is complete. The 
procedures for handling, processing, storage and destruction of the questionnaire data 
collected during the study are compliant with the General Data Protection Act (2018). 
Who is organising this study and acting as data controller for the study? 
Aston University is the sponsor for this study based in the United Kingdom. We will be 
using information from you in order to undertake this study and will act as the data 
controller for this study. This means that we are responsible for looking after your 
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information and using it properly. Aston University will keep identifiable information about 
you for 6 years after the study has finished. 
Your rights to access, change or move your information are limited, as we need to 
manage your information in specific ways in order for the research to be reliable and 
accurate. If you withdraw from the study, we will keep the information about you that we 
have already obtained. To safeguard your rights, we will use the minimum personally-
identifiable information possible. 
You can find out more about how we use your information at 
www.aston.ac.uk/dataprotection or by contacting our Data Protection Officer at 
dp_officer@aston.ac.uk.  
As a university we use personally-identifiable information to conduct research to improve 
health, care and services. As a publicly-funded organisation, we have to ensure that it is 
in the public interest when we use personally-identifiable information from people who 
have agreed to take part in research.  This means that when you agree to take part in a 
research study, we will use your data in the ways needed to conduct and analyse the 
research study.  
Health and care research should serve the public interest, which means that we have to 
demonstrate that our research serves the interests of society as a whole. We do this by 
following the UK Policy Framework for Health and Social Care Research. 
If you wish to raise a complaint on how we have handled your personal data, you can 
contact our Data Protection Officer who will investigate the matter. If you are not satisfied 
with our response or believe we are processing your personal data in a way that is not 
lawful you can complain to the Information Commissioner’s Office (ICO).  
Our Data Protection Officer is Victoria Mee and you can contact them at: 
dp_officer@aston.ac.uk.  
University Hospitals Birmingham NHS Foundation Trust will collect information from you 
and your medical records for this research study in accordance with our instructions.  
University Hospitals Birmingham NHS Foundation Trust will use your name, and contact 
details to contact you about the research study, and make sure that relevant information 
about the study is recorded for your care, and to oversee the quality of the study. 
Individuals from Aston University and regulatory organisations may look at your medical 
and research records to check the accuracy of the research study. University Hospitals 
Birmingham NHS Foundation Trust will pass these details to Aston University along with 
the information collected from you. The only people in Aston University who will have 
access to information that identifies you will be people who need to contact you to 
arrange and undertake research visits or audit the data collection process. The people 
who analyse the information will not be able to identify you and will not be able to find 
out your name, or contact details.   
What will happen to the results of the study? 
We will write a report of the study, which will be published.  The information we collect 
will also be written up as part of a PhD in Psychology being conducted by Gurkiran Birdi. 
We can send you a summary of the results if you would like them.  Your name will not 
be in anything we publish. 
What if there is a problem? 
284 
 
If you have any concerns or complaints about anything to do with this study, please 
speak to the research team (details below) and we will do our best to answer your 
questions.  You can ring Dr Rebecca Knibb on 0121 204 3402 or email her on 
r.knibb@aston.ac.uk. If she cannot help you and you still have any worries about the 
way in which the study has been conducted, then you should contact Aston University’s 
Director of Governance, Mr John Walter, at j.g.walter@aston.ac.uk or telephone 0121 
204 4665.  
Who has reviewed the study? 
This study has been looked by xxx NHS research ethics committee.  These are a group 
of people who check research to make sure that it protects the safety, rights, wellbeing 
and dignity of anyone who takes part. They have given it a favourable opinion. 
Can I get more information? 
If you are interested in taking part in this study but would like some more information 
before you decide, please contact one of the research team members (details at the end 
of this sheet). If you would like to talk to an independent person about taking part in this 
study or about research in general in Psychology at Aston University please contact the 
Director of the Applied Health Research Group, Dr Claire Farrow, on 
c.farrow@aston.ac.uk If you would like independent advice on any aspect of this study, 
you can also contact the PALS (Patient Advice and Liaison Service) at the Queen 
Elizabeth Hospital ( , e-mail: PALS@uhb.nhs.uk)  .  If after taking part 
in this study you are worried about your health please make an appointment to see your 
G.P.  If you have atopic dermatitis and are worried about that, please see your G.P. or 








Dr Ser-Ling Chua 




Dr Rebecca Knibb 



















Study Title: Quality of Life and Mental Health in Adults with Atopic 
Dermatitis compared to Healthy People 
 




PLEASE CLICK EACH STATEMENT TO SHOW THAT YOU HAVE READ AND 
AGREE WITH IT.  YOU MUST CLICK ON EACH STATEMENT BEFORE YOU ARE 
ABLE TO ACCESS THE QUESTIONNAIRES 
 
I have read the study information (version x dated x) and know who to contact should 
I have any questions about my participation in the study. 
 
I understand that my participation in the study is voluntary, and that I am free to 
withdraw at any time during completion of the questionnaires.  I do not have to give 
any reasons or explanations for doing so.  I have been provided with details of who 
I should contact if I wish to withdraw. 
  
I understand that this study will have no impact on my usual medical care.  
 
I understand that all data I provide will be kept confidential and stored securely at 
Aston University on a password protected database. Any paperwork completed 
including my consent forms and questionnaire measures will be stored in a locked 
filing cabinet or on a password protected computer. Only the research team will have 
access to this. 
 
I understand that these results may be disseminated through conferences 
and/or published articles. I understand that my data will remain anonymous at 
all times. 
 
I agree to participate in this research study looking at the impact of atopic 








9.11 Appendix 11  Socio-demographic questionnaire  
Age ____________   Gender ____________    Ethnicity ______________ Occupation 
_____________ 
Where did you see the advert for this study? __________________ 
1. Have you been diagnosed with atopic dermatitis/eczema?  
          Yes 
          No 
2. Do you have any long-term skin condition(s) that is currently active and being 
treated?  
          Yes 
          No 
If yes, please state __________________________ 
3. Do you currently have any other long term/chronic physical health condition(s) such 
as diabetes, arthritis, cancer, stroke, coronary heart disease, and heart failure? 
          Yes 
          No 
If yes, please state __________________________ 
   
If you have answered yes to any of the above, you are not eligible to continue 

















9.12 Appendix 12 STROBE checklist  







Relevant text from 
manuscript 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
  
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
  
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
  
Objectives 3 State specific objectives, including any prespecified hypotheses   
Methods  
Study design 4 Present key elements of study design early in the paper   
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Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
  
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods 
of case ascertainment and control selection. Give the rationale for the choice 
of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
  
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the 




Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 




8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods 
if there is more than one group 
  
Bias 9 Describe any efforts to address potential sources of bias   
Study size 10 Explain how the study size was arrived at   





11 Explain how quantitative variables were handled in the analyses. If applicable, 




12 (a) Describe all statistical methods, including those used to control for 
confounding 
  
(b) Describe any methods used to examine subgroups and interactions   
(c) Explain how missing data were addressed   
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls 
was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account 
of sampling strategy 
  




Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
  
(b) Give reasons for non-participation at each stage   
(c) Consider use of a flow diagram   
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, social) 
and information on exposures and potential confounders 
  
(b) Indicate number of participants with missing data for each variable of interest   
(c) Cohort study—Summarise follow-up time (eg, average and total amount)   
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over 
time 
  
Case-control study—Report numbers in each exposure category, or summary 




Continued on next page   
Cross-sectional study—Report numbers of outcome events or summary 
measures 
  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence interval). Make clear which confounders 
were adjusted for and why they were included 
  
(b) Report category boundaries when continuous variables were categorized   
(c) If relevant, consider translating estimates of relative risk into absolute risk for 








Key results 18 Summarise key results with reference to study objectives   
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
  
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
  
Generalisability 21 Discuss the generalisability (external validity) of the study results   
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
  
 












9.14 Appendix 14 Consent form  
 
The relationship between psychological stress and disease severity in adults 
with atopic dermatitis: a feasibility study 
Consent Form 
Name of Chief Investigator: Gurkiran Birdi 
Please initial boxes 
1.  I confirm that I have read and understand the Participant Information 
Sheet (V1, 07/11/18) for the above study. I have had the opportunity 




2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my 
legal rights being affected. 
 
 
3.  If I decide that I do not want to take part in the study at any point in 
the 3 month duration, I am happy for my data collected up to that 
date to be included in analysis.  
 
 
4.  I agree to my personal data and data relating to me collected during 








6.  I agree to my personal data being processed for the purposes of 
inviting me to participate in future research projects. I understand 
that I may opt out of receiving these invitations at any time.  
  
 
7.  I am happy for the researcher to send me text message reminders 
about the study.  
 
 
8.  I am happy to be contacted at the end of this study to see if I would 
like to take part in an interview. 
 
 




_________________________ ________________ ___________________ 
Name of participant Date Signature 
 
 
_________________________ ________________ ___________________ 
Name of Person receiving Date Signature 
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9.15 Appendix 15 Socio-demographic questionnaire 
 
Age ____________   Gender ____________    Ethnicity ______________ Occupation 
_____________ 
Where did you see the advert for this study? __________________ 
1. Have you been diagnosed with atopic dermatitis/eczema?  
          Yes 
          No 
[For online surveys, if participants answer “yes”, they will be directed to questions 4 
onwards, if they answer “no” to the above, they will be directed to questions 2 and 3).  
2. Do you have any long-term skin condition(s) that is currently active and being 
treated?  
          Yes 
          No 
If yes, please state __________________________ 
3. Do you currently have any other long term/chronic physical health condition(s) such 
as diabetes, arthritis, cancer, stroke, coronary heart disease, and heart failure? 
          Yes 
          No 
If yes, please state __________________________ 
   
If you have answered yes to questions 2 or 3, you are not eligible to continue 
with the study. We appreciate your interest and time. 
 
4. Have you been clinically diagnosed with atopic dermatitis/eczema?  
          Yes 
          No 
 
If you have answered no to the above question, you are not eligible to continue 







5 . Do you currently have any other long term/chronic physical health condition(s) such 
as diabetes, arthritis, cancer, stroke, coronary heart disease, and heart failure?  
Please note that this does not include co-morbid conditions such as asthma, hay-fever 
or food allergies, which commonly occur alongside atopic dermatitis 
          Yes 
          No 
If yes, please state __________________________ 
If you have answered yes to the above question, you are not eligible to continue 
with this study. We appreciate your interest and time. 
 
6. Who made this diagnosis? Please tick the box that applies  
           GP 
           Dermatologist 
           Paediatrician  
           Other   
7. At what age were you first diagnosed with atopic dermatitis? 
______________________ 
8. What medication(s) have you been prescribed for your atopic dermatitis? 
_____________________________________________________________________
____ 
9. Are you being managed or followed up in clinic by a dermatologist?  
          Yes  
          No  
If yes, please answer question 6, otherwise please proceed to question 7. 
10. How often do you have follow-up visits for your atopic dermatitis?  
          More than once a month 
          More than once every three months  
          Once every three months 
          Once every six months 
          Once a year or less  
11. Has a doctor ever diagnosed the following? (choose all that apply)  
          Asthma 
          Seasonal Allergies or Hay fever 











          None of the above  
12. Did your mother, father, siblings or children ever have Atopic Dermatitis?  


































9.16 Appendix 16 daily diary 
Please complete daily before retiring for sleep 
Please spend five minutes telling us how you felt today. 
Date ____________________ 
Please circle your answer 
Did anyone give you a “hard time” or make life difficult for you 
today? 
0(no)  1 (a little)  2 (a lot)  
Did you feel angry or annoyed today? 0 (no)  1 (a little) 2 (a lot) 
Did you feel trapped in an uncomfortable situation that you wanted 
to get out of? 
0 (no)  1 (a little) 2 (a lot) 
Did you express feelings of anger or annoyance to anyone today? 0 (no)  1 (a little) 2 (a lot) 
Did you find yourself in a situation, today, when you had to defend 
yourself? 
0 (no)  1 (a little) 2 (a lot ) 
Did you experience a feeling of defeat or frustration today? 0 (no)  1 (a little) 2 (a lot) 
Did you feel rebuffed or hurt by someone today? 0 (no)  1 (a little) 2 (a lot) 
Did you feel tense or anxious today? 0 (no)  1 (a little) 2 (a lot ) 
Did you feel lonely or isolated? 0 (no)  1 (a little) 2 (a lot) 
Did you seek a period of isolation and solitude away from other 
people? 
0 (no)  1 (a little) 2 (a lot) 
Has there been anything on your mind today - something you’ve 
been thinking about a lot? 
0 (no)  1 (a little) 2 (a lot) 
Did you at any time feel depressed? 0 (no)  1 (a little) 2 (a lot) 
Did you feel that other people were intruding into your privacy? 0 (no)  1 (a little) 2 (a lot) 
Did you have a feeling you wanted to seek help from someone in 
solving some of your problems? 
0 (no)  1 (a little) 2 (a lot) 
 
Did you have a flare -up that started today?  Yes______ No_______ 
How severe is your atopic dermatitis today?  0 (mild)               1(moderate)             
2(severe) 
How well did you sleep last night?                    0 (slept well)       1 (somewhat)          2 
(not at all)  
Did you experience a particularly stressful situation today? Yes______ No_______ 















9.17 Appendix 17 participant information sheet 
 
 
The relationship between psychological stress and disease severity in adults 
with atopic dermatitis: a feasibility study  




We would like to invite you to take part in a research study. 
 
Before you decide if you would like to participate, take time to read the following 
information carefully and, if you wish, discuss it with others such as your family, friends 
or colleagues.  
 
Please ask a member of the research team, whose contact details can be found at the 
end of this information sheet, if there is anything that is not clear or if you would like 
more information before you make your decision. 
 
 
What is the purpose of the study? 
 
Atopic Dermatitis seems to be on the increase in adults, yet there is not much research 
that looks at how it affects peoples’ lives. We would like adults with clinically diagnosed 
atopic dermatitis to complete daily diaries for one month and weekly questionnaires 
about psychological stress and atopic dermatitis for 3 months. This study is being 
conducted by Gurkiran Kaur Birdi as part of her PhD in Psychology.  
 
Why have I been chosen? 
  
You are being invited to take part in this study because: 
• You have seen an advert for this study on a support group page on Facebook, 
social media platforms Facebook/Twitter or an advert at Aston University 
• You are an adult with clinically diagnosed atopic dermatitis  




What will happen to me if I take part? 
 
You will be sent study materials via post or you will be able to complete diaries via a 
secure web-link on Qualtrics if you decide to take part in the study. These materials will 
comprise a diary to complete every night for 4 weeks- this should only take you 5 
minutes every night. You will also be asked to complete questionnaires at the start of 
the study and once a week (ideally towards the end of the week) for the 3 month 
duration of the study.  You will be sent reminders on a study-specific group on 
Facebook or via text messages if you consent to this. At the end of the study, you will 
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be asked to post the study pack to Aston University using a pre-paid envelope if the 
materials were posted to you. After you have participated in the study, we will ask if 
you would like to take part in an interview to gather your thoughts about taking part in 
the study.  You do not have to take part in this interview if you do not wish to. 
 
Do I have to take part? 
 
No. It is up to you to decide whether or not you wish to take part.  
 
If you do decide to participate, you will be asked to sign and date a consent form. You 
would still be free to withdraw from the study at any time without giving a reason. If you 
decide to withdraw from the study during the three month period, you can consent to 
data already collected forming a part of the study.  
 
Will my taking part in this study be kept confidential? 
 
Yes. A code will be attached to all the data you provide to maintain confidentiality.  
 
Your personal data (name telephone number, contact details and address) will only be 
used if the researchers need to send you the study pack to your postal address and/or 
send you text message reminders. Analysis of your data will be undertaken using 
coded data. Your personal data will be destroyed following completion of recruitment.  
 
The data we collect will be stored in a secure document store (paper records) or 
electronically on a secure encrypted mobile device, password protected computer 
server or secure cloud storage device. 
 
To ensure the quality of the research, Aston University may need to access your data 
to check that the data has been recorded accurately. If this is required, your personal 
data will be treated as confidential by the individuals accessing your data. 
 
 
What are the possible benefits of taking part? 
 
While there are no direct benefits to you of taking part in this study, the data gained will 
help health care professionals develop ways in which patients can be supported to 
manage their atopic dermatitis better and the mental impact of the condition better.  
 
 
What are the possible risks and burdens of taking part? 
 
You may feel upset answering questions about anxiety or depression, or questions about 
how your condition has affected you.  You may stop answering questions at any time 
you wish and either take a break or decide you do not want to take part anymore. As this 
study has a total duration of three months, time commitment may be a burden, however, 
we anticipate that it will take no longer than 5 minutes to complete diaries every night, 
and no longer than 15 minutes to complete questionnaires at the end of each week.  
What will happen to the results of the study? 
 
The results of this study may be published in scientific journals and/or presented at 





A lay summary of the results of the study will be available for participants when the 
study has been completed and the researchers will ask if you would like to receive a 
copy. 
The results of the study will also be used in Gurkiran Birdi’s PhD thesis.  
 
Expenses and payments 
 
You will receive £20 Love to Shop vouchers for your time in the study 
 
Who is funding the research? 
 
The study is being funded by Aston University  
 
Who is organising this study and acting as data controller for the study? 
 
Aston University is organising this study and acting as data controller for the study.  
You can find out more about how we use your information in Appendix A. 
Who has reviewed the study? 
 
This study has been reviewed and received a favourable opinion from the School of 
Life and Health Sciences Ethics Committee at Aston University. 
 
 
What if I have a concern about my participation in the study? 
 
If you have any concerns about your participation in this study, please speak to the 
research team and they will do their best to answer your questions.  Contact details 
can be found at the end of this information sheet.  
 
If the research team are unable to address your concerns or you wish to make a 
complaint about how the study is being conducted you should contact the Aston 
University Director of Governance, Mr. John Walter, j.g.walter@aston.ac.uk or 










Dr Rebecca Knibb 
Chief Investigator and PhD supervisor 
Email: r.knibb@aston.ac.uk 
Tel:  
Dr Micheal Larkin 




Tel: 0121 204 3112 
 
 
Aston University takes its obligations under data and privacy law seriously and 
complies with the General Data Protection Regulation (“GDPR”) and the Data 
Protection Act 2018 (“DPA”).   
Aston University is the sponsor for this study based in the United Kingdom. We will be 
using information from you in order to undertake this study.  Aston University will 
process your personal data in order to register you as a participant and to manage 
your participation in the study.  It will process your personal data on the grounds that it 
is necessary for the performance of a task carried out in the public interest (GDPR 
Article 6(1)(e).  Aston University may process special categories of data about you 
which includes details about your health.  Aston University will process this data on the 
grounds that it is necessary for statistical or research purposes (GDPR Article 9(2)(j)).  
. Aston University will keep identifiable information about you for 6 years after the study 
has finished. 
Your rights to access, change or move your information are limited, as we need to 
manage your information in specific ways in order for the research to be reliable and 
accurate. If you withdraw from the study, we will keep the information about you that 
we have already obtained. To safeguard your rights, we will use the minimum 
personally identifiable information possible. 
You can find out more about how we use your information at 
www.aston.ac.uk/dataprotection or by contacting our Data Protection Officer at 
dp_officer@aston.ac.uk.  
If you wish to raise a complaint on how we have handled your personal data, you can 
contact our Data Protection Officer who will investigate the matter. If you are not 
satisfied with our response or believe we are processing your personal data in a way 










9.18 Appendix 18 Cross-lagged panel models  
Stress and disease severity 
 
Stress and depression  
 




9.19 Appendix 19  Cross-lagged panel model  
 
 
 
